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CHEMINFORMATIC AND MECHANISTIC STUDY OF  
DRUG SUBCELLULAR TRANSPORT/DISTRIBUTION 
 
The subcellular transport and distribution behavior determines both the 
pharmacological effect on the cellular level and the drug exposure at a tissue, 
organ and whole body level. Despite of the rapid evolution in experimental and 
computational approaches for studying the subcellular transport of small 
molecules, a thorough understanding and reliable experimental analysis of 
cellular pharmacokinetic behavior remain challenging. Mechanism-based 
computational models are promising tools for testing hypothesis, exploring 
mechanism and guiding experiment design and data analysis in pharmacokinetic 
and system biology studies. The primary goal of this work is to propose a 
hypothesis-driven, simulation-guided strategy for drug subcellular transport and 
distribution studies. The current knowledge of organelle targeting features of 
small molecules was analyzed in terms of its relevance to developing 
computational models for analyzing subcellular pharmacokinetic behavior. A non-
invasive insert system was designed to characterize small molecules’ 
intercellular transport kinetics, and a mechanism-based passive diffusion model 
was adapted to facilitate the design and analysis of subcellular distribution and 
intercellular transport experiments. This study pointed out many opportunities to 
advance effective screening for drug candidates with desirable distribution and 
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transport behavior at a subcellular and systemic level. These opportunities 
include: 1) the development of quantitative experimental platform for the real-time 
tracking and analysis of non-fluorescent molecules in multiple subcellular 
compartments; 2) the elaboration of hypothesis-driven, mechanistic modeling 
techniques emphasizing a better understanding of the non-steady-state 
intracellular accumulation behavior and limited intercellular diffusivity; 3) the 
promotion of simulation-guided experimental design strategy; and 4) the 









The systemic pharmacokinetics and pharmacodynamics of small molecules are 
determined by subcellular transport phenomena. Although approaches used to 
study the subcellular distribution of small molecules have gradually evolved over 
the past several decades, experimental analysis and accurate prediction of 
cellular pharmacokinetics behavior remain a challenge. In this review, we 
surveyed the progress of subcellular distribution research since the 1960s, with a 
focus on the advantages, disadvantages and limitations of the various 
experimental techniques and computational predictive tools. Critical review of the 
existing body of knowledge pointed to many opportunities to advance the rational 
design of organelle-targeted chemical agents. These opportunities include: 1) 
development of quantitative, non-fluorescence-based, whole cell methods and 
techniques to measure the subcellular distribution of chemical agents in multiple 
compartments; 2) exploratory experimentation with non-specific transport probes 
that have not been enriched with putative, organelle-targeting features; 3) 
elaboration of hypothesis-driven, mechanistic and modeling-based approaches to 
guide experiments aimed at elucidating subcellular distribution and transport; and 
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4) introduction of revolutionary conceptual approaches borrowed from the field of 
synthetic biology combined with cutting edge experimental strategies. Specific 
aims were proposed for state-of-the-art subcellular transport studies which aimed 
at understanding the formation of new organelles in response to drug therapy, 
exploring the role of chemically-synthetic organelles as intracellular drug depots 
and developing subcellular pharmacokinetics models to guide the rationale 
design of organelle targeting super drugs. 
 
Keywords: drug transport; pharmacokinetics; biodistribution; drug targeting; 

















Despite of the rapid development in combinatorial chemistry and high 
content screening assays for synthesizing and testing of large numbers of new 
chemical agents, the discovery of drug candidates with favorable 
pharmacokinetics (PK) and pharmacodynamics (PD) properties has remained a 
challenge in drug discovery process. Nowadays, the pharmaceutical industry is 
facing the „productivity crisis‟ featured by increasing R&D cost and decreasing 
number of marketing approvals [1], during which 75% of the cost of drug 
development turned out to be on failures in Phase II/III clinical trials and any 
attempted recoveries after regulatory rejection [2, 3]. Therefore, to meet the 
growing demand for more drugs [4, 5] and to increase rate of approval, the ability 
to accurately predict the absorption, distribution, metabolism, excretion, and 
toxicity (ADMET) profile of new chemical agents is highly desirable. 
On the cellular level, the entire set of processes of absorption / uptake, 
distribution, metabolism and elimination within one single cell, as referred to as 
the subcellular transport and distribution, controls not only the benefit / toxic 
effect on a cellular level but also drug exposure at a tissue, organ and whole 
body level. This is because many drugs require entrance into specific subcellular 
organelles to reach their targets, or they have side effects associated with 
unwanted accumulation in non-target sites within cells. For example, although 
the concentration of many weak base anticancer agents remains high in drug-
resistant cell lines, the efficacy of the drugs are often compromised due to 
sequestration of weak bases in acidic intracellular organelles rather than the 
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intracellular sites of action [6-10]. In osteoporosis therapy, the lysosomal cysteine 
protease inhibitor with physicochemical properties that facilitate lysosomal 
trapping also exhibit significantly higher in vitro and in vivo potencies than its 
derivatives with less preferable molecule properties [11]. 
On that ground, novel drug targeting strategies to improve compound 
efficiency in reaching specific organelles have been sought to increase a 
molecule‟s potency and decrease undesired side effects. For example, small 
molecules are being targeted to mitochondria by conjugating these molecules to 
cell-penetrating, lipophilic peptides, oligoguanidinium, or triphenylphosphonium 
moieties [12-17]. To fulfill this organelle targeting drug design strategy, there 
have been many efforts aiming at characterizing the physiological properties of 
the most important intracellular organelles and identifying key physicochemical 
features that determine the accumulation of exogenous chemical agents inside 
these organelles [18-21]. More importantly, the mechanisms driving the 
distribution kinetic of chemical agents within the cell and the dynamic cellular 
response to these chemical agents are being revealed with the aid of new 
experimental strategies and conceptual approaches.  
To put the state-of-the-art of subcellular transport research in perspective, 
we reviewed the historical progress of subcellular biodistribution research, 
focusing on the evolution of experimental, theoretical and conceptual approaches 
used to analyze the organelle-targeting features of small molecule chemical 
agents. The advantages, disadvantages and limitations of the various 
experimental techniques and computational predictive tools were discussed. 
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Specific aims were proposed for pioneering subcellular transport studies which 
aimed at understanding cellular response to drug therapy, exploring the role of 
chemically-synthetic organelles as intracellular drug depots, and characterizing 
and analyzing the comprehensive pharmacokinetics behavior at a cellular level. 
 
Pharmacological effects as evidence for specific organelle accumulation   
Eukaryotic cells have highly organized subcellular compartments with 
distinct structural and functional features. Current knowledge of the physiological 
properties and general principles of target delivery into major subcellular 
organelles were summarized (Table 1.1). Pharmacological effects, i.e. changes 
in these features, especially changes in organelle morphology (swelling, rupture, 
shrinkage, etc.) upon drug treatment have been used in a large number of 
studies as the evidence for compound localization in specific organelles. 
Surveying the literature, a large number of subcellular localization reports were 
based on evidence that the chemicals induced changes in the structure or 
function of specific organelles [22].   
Prior to the widespread adaption of cell-based uptake and transport assays 
in small molecule drug development, morphological changes were commonly 
used as evidence for organelle accumulation. From the 1960s to the 1980s, 
similar numbers of studies were based on observations with light microscopy, 
fluorescence microscopy and transmission electron microscopy [23-25].  Light 
microscopy was the preferred tool in detecting expansion in the endolysosomal 
compartment, visible as a massive, cytoplasmic vacuolation phenomenon.  With 
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transmission electron microscopy, morphological changes of the major 
organelles could be observed directly, with or without the aid of specific organelle 
tracers.  In the early 1980s, fluorescence microscopy became increasingly 
applied to the detection of organelle swelling and shrinkage using fluorescent 
probes.  In the endolysosomal compartment, the observed morphological 
changes have been shown to reflect the accumulation of weakly basic 
compounds inside these organelles, or the inhibitory effects of cations on the 
activity of lysosomal proteins [26, 27].   
Morphological changes in lysosomes and mitochondria often coincided with 
changes in membrane potential, pH gradients or membrane permeability [28-32]. 
Under some circumstances such changes resulted in the release of a resident, 
organelle-specific enzyme into the cytosol or into the extracellular compartment. 
Thus the detection of fluctuation in voltage or pH gradients, or the detection of 
released organelle components, was used as evidence for accumulation of 
exogenous small molecules in specific organelles, from the 1970s [33-36] and 
continuing to this day [37-40]. 
Also since the 1970s, analytical measurements using thin layer 
chromatography and HPLC to detect alterations in organelle composition, 
including changes in lipid content, protein concentrations and metabolic changes, 
have been used as evidence to infer accumulation of small molecules in specific 
organelles [41-43]. For example, significant increases of phospholipids in the 
renal cortex of gentamicin- or netilmicin-treated rats [44] were ascribed to 
impaired lysosomal degradation of phospholipids due to inhibition of lysosomal 
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phospholipase C by accumulation of said molecules in lysosomes. Ammonia, 
amiodarone and some other compounds that interfere with degradation of 
proteins or phospholipids in lysosomes [45-47] were also associated with 
inhibition of lysosomal proteases and phospholipases due to the accumulation of 
these weakly basic compounds in the lysosomes, resulting in intra-lysosomal pH 
changes with consequent effects on lysosomal enzyme activities [48-52].   
Nevertheless, claims that a molecule “accumulates in” an organelle based 
on a change in organelle structure (or function) are circumstantial and prone to 
misinterpretation and experimental artifacts.  For example, in the case of toxic 
compounds, inhibition of organelle function may not require direct interaction, or 
accumulation within a specific organelle. For instance, apoptosis signal 
transduction pathways lead to mitochondrial membrane permeabilization, loss of 
mitochondrial membrane potential and the release of cytochorome c from the 
mitochondria, as well as nonspecific effects on other organelles. Therefore, 
induced changes in mitochondrial volume, membrane potential, or permeability 
do not necessarily reflect a direct interaction with mitochondria. The same is true 
for other organelles [53]. 
 
Chemical analysis as evidence for specific organelle accumulation  
Pharmacokinetics gradually became part of drug development from the 
1960s through the 1980s. However, only since the 1990s, there has been an 
increasing recognition of the importance of cellular pharmacokinetics as a 
determinant of systemic pharmacokinetics. In the process, quantitative 
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measurement of chemical uptake in vivo or in vitro became increasingly 
important as direct evidence supporting the actual localization of a molecule in a 
specific subcellular compartment. Irrespective of the experimental strategy, 
analytical measurements were increasingly applied in cellular uptake or 
distribution studies, providing direct evidence for accumulation in specific 
organelles. However, only a relative small fraction of the molecules whose 
intracellular localization has been reported in the scientific literature is supported 
by such evidence [22]. 
In uptake experiments, researchers measure drug mass in intact cells or in 
isolated organelle after in vitro or in vivo administration of the compound. In some 
cases, a known, organelle-targeting compound was used to compete for the 
interaction or otherwise inhibit the organelle-specific accumulation mechanism. 
For instance, in a report of the subcellular localization sites of weakly basic 
molecules, the reduced cellular uptake after the disruption of trans-membrane pH 
gradients was used as evidence for endolysosomal accumulation [54, 55]. Less 
commonly, ion-selective electrodes have been used to study the uptake of 
positively charged, lipophilic compounds in isolated mitochondria [56-58]. Binding 
to resident organelle-specific components including protein, lipids or nucleic 
acids has also been measured as direct evidence to demonstrate organelle or 
cytosolic accumulation [59-62].  
Starting in the 1990s, there was an increase in the number of investigations 
looking at the qualitative or semi-qualitative (relative) distribution of a compound 
in all subcellular compartments, simultaneously, featuring analytical 
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measurements following cell fractionation [22]. In cell fractionation studies, the 
basic experimental strategy has been to isolate the various organelles by 
differential centrifugation [63], followed by measurements of the absolute amount 
of a compound in each organelle fraction [64-66] and/or comparing that amount 
relative to the total accumulation of the compound in the cell [67-69]. Reliable 
separation of distinct subcellular organelles is critical to the evaluation of 
subcellular distribution profile. While enzyme activity of organelle specific marker 
proteins in each fraction can be readily determined, for effective separation of 
subcellular compartments requires little overlap in marker enzyme activities 
between the fractions. Then the fractions can be subjected to chemical analysis 
of organelle associated compound accumulation by means of spectrophotometry 
[70], HPLC [71-73], LC/MS [74], and most commonly, by scintillation counting of 
radiolabeled compounds [75-78].  
Many significant advances in distribution studies were achieved through the 
development of cell fractionation techniques. Organelle separation and analysis 
techniques such as immunoisolation, fluorescence activated sorting and 
electromigration analysis was developed. However their use in subcellular 
distribution studies remains infrequent, possibly because they are technically 
demanding. For organelle immunoisolation, cell homogenates were exposed to 
organelle-specific antibodies attached to solid supports and the cell fractions of 
interest were concentrated by binding to antibody [79-81]. Fluorescent activated 
cell sorting was applied to separate multiple intracellular organelles stained with 
membrane dyes or labeled with fluorescent antibodies to organelle membrane 
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proteins [82-85]. Since around the early 2000s‟ electrophoresis has been used to 
separate different subcellular organelle fractions from cell homogenate [86-94]. 
Most recently, magnetic chromatography methods were developed to isolate and 
enrich lysosomes from cells that internalize iron-containing particles [95-97].  
As a caveat, organelle isolation procedures are not necessarily free from 
experimental artifacts: organelle isolation procedures can disrupt such 
interactions [58]. During the lengthy procedures to attain higher purity and 
adequate amount for further analysis, organelle damage and compound leakage 
from one or more subcellular organelles are inevitable and difficult to control [63]. 
While whole cell fractionation analysis followed by analytical measurement has 
advantages over experiments that probe a specific compound-organelle 
interaction. However, fractionation analysis is very labor intensive.  
 
Whole cell based microscopic imaging studies as evidence for intracellular 
localization. 
Whole cell based microscopic imaging studies using intrinsically fluorescent 
or fluorescently-tagged molecules accounted the most number of scientific 
articles reporting a molecule‟s subcellular localization [22] and have been most 
common over the past decade.  Less commonly, electron microscopy combined 
with immunocytochemical methods were used to obtain high resolution 
information of intracellular distribution of small molecular weight compounds that 
precipitated out at their sites of accumulation [98, 99] or that were tagged with a 
specific immune-epitope [22, 100, 101].  
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Compared to pharmacological and chemical analyses which are tedious and 
prone to artifacts, microscopic imaging has generally been preferred as an 
efficient and reliable method to obtain real-time intracellular distribution data.  
Microscopic visualization of fluorescent or fluorescently-tagged molecules 
provided the evidence for establishing subcellular localization, in the majority of 
published, subcellular localization studies [22]. While the intracellular 
accumulation sites of fluorescent compounds can be determined directly based 
on the characteristic morphology of stained compartments [102-108], the use of 
resident, reference fluorescent markers [109-113] has enabled determination of 
subcellular distribution by analysis of co-localization patterns. Following 
advances in location proteomics [114-118], machine vision-based quantitative 
image analysis has been used to establish the degree of co-localization between 
compounds of interest with an organelle-specific reference marker [119-121]. 
Furthermore, large combinatorial libraries of fluorescent probes and automated 
high content screening instruments have facilitated analysis of chemical motifs 
associated with specific intracellular distribution patterns [120-122]. For 
compounds with fluorescent property but interfered with cellular auto-
fluorescence, the fluorescence resonance energy transfer-based approach has 
been designed to study the trafficking and distribution of xenobiotics with proper 
conjugation [123].  
Fluorescence based imaging techniques offer many advantages over other 
detection methods, evidence for subcellular localization based on fluorescence-
based studies is generally criticized due to well-known artifacts.  For example, 
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environmental factors such as binding status [124], ionic strength [125], solvent 
polarity [126-128], pH [129-131] and temperature [132-134] can affect a 
molecule‟s fluorescence intensity, or peak excitation and emission wavelengths. 
If the fluorescence intensity is dependent on environmental factors, conclusions 
on subcellular distribution pattern might not be entirely accurate or complete as 
molecules may not be fluorescent in every compartment they localize to[135].  
For non-fluorescent molecules to be detectable under fluorescent microscopy, a 
fluorescent tag needs to be conjugated to the compound.  This tag can alter the 
distribution of the original compound.  Thus, claims about the subcellular 
localization of a tagged compound are only valid in the context of the entire small 
molecule-fluorescent probe conjugate. 
Over the past decade, more sensitive and general mass spectroscopy 
imaging methods, such as the confocal Raman microscopy and secondary ion 
mass spectroscopy, have also emerged to monitor the distribution of non-
fluorescent compounds in cells [136]. To date, a few pioneering studies based on 
these techniques have been reported in intracellular mapping of xenobiotics [22, 
137, 138].  Nevertheless, significant breakthroughs are being achieved in this 
area. For example, the major challenge in conventional Raman imaging is how to 
amplify and quantify the weak resonance signal in live cell environment. The 
application of coherent anti-stokes Raman scattering has led to improvement in 
signal detection and has been applied in tracking the intracellular distribution of 
endogenous lipids, virus RNA and organelle transport [139-141].  
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Yet another recent advance was the application of secondary ion mass 
spectrometry (SIMS) in analyzing subcellular localization sites of chemical agents. 
SIMS is the most sensitive analysis technique traditionally used in material 
sciences to analyze the elemental, isotopic or molecular composition of thin films 
[142-144]. Beginning the late 1990s‟ SIMS has seen new applications in 
quantifying the phospholipids composition in biological membranes [145] and 
mapping the distribution of isotope labeled chemical agents after in vitro or in 
vivo dosing [146-149]. Though still in its infancy, SIMS is garnering attention in 
subcellular distribution studies because of its high sensitivity and outstanding 
resolution. 
 
Computational models to frame quantitative hypotheses and analyze 
subcellular distribution patterns.  
Since the 2000s, cheminformatics and computational modeling-based 
approaches have become essential to drug discovery and development. In 
parallel, cheminformatics and computational approaches are increasingly being 
used to generate and test hypothesis about the intracellular distribution and 
transport behavior as well as the chemical-organelle interactions in particular 
subcellular organelles [18-20, 120, 150-152]. However, evaluation of 
computational models is inherently dependent on the quantity and quality of 
subcellular localization measurements. In the next few sections that follow, we 
will discuss the features and applications of common types of mathematical 
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models that have been developed to predict subcellular distribution and transport 
behavior. 
 
Empirical and semi-empirical models 
Computational models for predicting the subcellular PK/PD behaviors can be 
classified into two categories: the statistically-based, empirical or semi-empirical 
models and the mechanism-based physiological models. Typical statistical 
models use experimental observations of small molecule subcellular localization 
as a training dataset. With calculated physicochemical properties as input 
parameters, regression, multivariate statistical analysis or classification strategies 
can be applied to make qualitative (yes/no) or quantitative (how much) 
descriptions of the compound distribution pattern in the training set. If the fit 
between the model and the training set is acceptable, the model can be applied 
to a different test set of molecules with overlapping physicochemical properties, 
to make predictions about the molecules‟ localization. In cheminformatics 
research, this is referred to as a quantitative structural-activity relationship 
(QSAR) study [153].  
QSAR models have been widely used in and seen commercialized products 
for the prediction of different ADMET properties, including the prediction of 
physicochemical and topological parameters [154-156], oral bioavailability [157-
159] and toxicity, carcinogenicity, skin sensitization and so on [160-162]. In 
predicting the steady state subcellular distribution pattern, several published 
articles have been published to analyze compound intracellular accumulation 
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sites using decision trees and other regression based QSAR tools [18-20, 163-
167]. QSAR models could also be combined with time exposure data to simulate 
the kinetics of distribution in different subcellular compartments [119, 152, 167-
170]. In these models a multi-compartment model was built based on first order 
elimination and the time course, concentration or activity data from test 
compounds was used to optimize the adjustable parameters in the original model. 
The resultant model with optimized parameters could be applied in evaluation of 
efficacy and risk assessment for newly synthesized chemical agents.  
The success of QSAR-based models depends largely on the accurate 
calculation of molecular properties and the quality of input data. Ideally the 
observations used for predictive QSAR models should be derived from the same 
experiments, based on the same mechanism of study, assessed with the same 
criteria, and performed with similar methods so as to avoid intra-laboratory 
variations in the manner the measurements are made and the way the 
observation is defined. QSAR models also benefit from large data sets of 
compounds. Therefore, QSAR models based on scant published data obtained 
with different methods and experimental approaches are more descriptive than 
predictive.  
 
Mechanism-based physiologically-relevant models 
Mechanism-based physiologically-relevant models for predicting subcellular 
localization take into account not only the molecular parameters of the chemical 
agents but also the physiological properties of subcellular organelles of interest. 
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The pH-partition theory and the ion-trapping mechanism have been proposed as 
basis of the earliest and simplest mechanism based model to estimate the steady 
state accumulation in single subcellular organelle type, as driven by trans-
membrane electrical potentials and pH gradient across phospholipid bilayer. 
According to the pH-partition theory, lipophilic cations accumulate in the 
mitochondria due the negative mitochondria membrane potential, and the 
behavior could be predicted by the Nernst equation [171-173]. According to the 
ion-trapping theory [48], when a phospholipid bilayer separates two 
compartments of different pH levels or electrical potential, the basic membrane 
permeant lipophilic molecules become protonated and charged preferentially in 
the acidic compartment. Because of the lowered membrane permeability of the 
charged form of the molecule, the molecule becomes concentrated in the acidic 
compartment [174-176]. 
More recently, complex mathematical models have been developed to 
predict the subcellular distribution and transport behavior among all intracellular 
compartments. These models usually incorporate a number of general 
mechanisms including mass balance, Fick‟s law of diffusion, pH–partitioning 
theory and ion-trapping. For example, physiologically-based models were 
developed to calculate the uptake of electrolytes into plant cells [177], the 
intracellular accumulation and organelle distribution of molecules in cells 
suspended in homogeneous extracellular drug concentration [178], or in 
epithelial cells exposed to transcellular drug concentration gradient [179].  Using 
combinations of input values, simulations can be performed to mimic the kinetics 
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of small molecules distribution in lysosomes, mitochondria and cytosol of millions 
of virtual molecules differing in molecular properties [21]. To demonstrate the 
potential of this approach, a predictive, multi-scale, cell-based model was 
constructed to simulate the distribution properties of pulmonary drugs in different 
cell types and anatomical regions of the lung [180].  
 Translated to the in vivo realm, mechanism base models could be extend to 
incorporate some less general mechanisms involved in specific biological 
process (e.g. active transport, binding and metabolism) [181-185]. Unsurprisingly, 
the validation of more physiologically related models will require detailed 
experimental measurements and kinetic analysis of small molecule distribution at 
multiple scales, in a manner that exceeds the capabilities of state of the art 
experimental approaches by many orders of magnitude. 
 
Conclusion 
Thus far, we have presented a comprehensive survey of the past and 
present state of the art of subcellular transport knowledge, focused on the 
evolution of experimental approaches and methods. Our understanding of small 
molecule distribution inside cells has been shaped (and is being reshaped) by 
the application and limitations associated of each one of these approaches and 
methods, and the invention of new ones (Table 1.2). Analytical measurements 
following precise cell fractionation can be considered the most quantitative and 
convincing evidence for claims of preferential accumulation of chemical agents in 
specific subcellular compartments. However, fractionation studies are low 
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throughput and labor intensive. Accordingly, live cell-based imaging with 
fluorescence microscopes has become the most common method for 
documenting the subcellular distribution of small molecule chemical agents [22].  
The application of fluorescence-based techniques in subcellular distribution 
studies has had two major consequences on the current state of knowledge in 
this field: 1) much of what is presently known about the subcellular localization 
properties of small molecules is biased towards fluorescent compounds, with 
either intrinsic fluorescence or fluorescent molecular tags; and 2) the majority of 
compounds with reported subcellular localizations are either highly specific, 
organelle-targeting transport probes or their subcellular distribution has been 
analyzed only in the context of a specific organelle.  Thus, the development of 
methods to quantify the distribution pattern of non-fluorescent, non-targeted 
molecules at the whole cell level will be necessary to expand our current 
understanding of the subcellular distribution properties of small molecules.  
For this reason, in addition to whole cell experimental analysis methods, 
physiologically-based modeling efforts aimed at predicting cellular 
pharmacokinetics are contributing positively towards formulating a hypothesis-
driven framework for experimental, quantitative analysis of cellular biodistribution 
phenomena. Although still at its inception phase, whole-cell, mechanism-based 
computational modeling is a promising tool in terms of providing quantitative 
hypotheses for guiding the design of experiments aimed at furthering 
understanding of subcellular distribution and transport phenomena, without 
focusing on a particular location.  
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In the future, combinations of experimental methods will be used to study 
cells loaded with concentrated solutions of small molecules, which should 
facilitate analyses and provide new insights into the interaction of cells with 
exogenous chemical agents. For example, by combining computational modeling, 
Raman confocal microscopy, fluorescence microscopy, electron microscopy and 
chemical analysis [138], we found that incubating cells with concentrated 
chloroquine solutions (such as those found in the urine of patients undergoing 
chloroquine therapy) drives the formation of intralysosomal drug-membrane 
complexes that bind to other weakly basic molecules (Figure 1.1) [138]. With 
clofazimine, combining biochemical, microscopy and molecular imaging 
techniques, revealed that continuous exposure of cells to supersaturated drug 
solutions resulted in the synthesis of intracellular, autophagosome-like drug 
inclusions, new organelle-like cytoplasmic structures formed by condensed drug-
membrane aggregates derived from mitochondria and possibly other organelles 
[186]. While such drug-membrane complexes may form and accumulate inside 
cells, such complexes may also form at the plasma membrane and can be shed 
by cells into the extracellular medium [187].   
To conclude, continued investigation of subcellular transport phenomena will 
lead to fundamental insights into the chemistry of life, and the ability to predict 
and optimize the subcellular transport and biodistribution properties of small 
molecules at the cellular level is seen as a stepping stone towards predicting and 
optimizing systemic pharmacokinetics and pharmacodynamics. Although an 
accurate, quantitative assessment of the microscopic distribution of small 
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molecules inside cells remains a challenge, we envision that progress in this field 
with the development of an increasingly sophisticated combination of methods 
and analytical techniques will serve as a stepping stone towards developing new 
drug delivery strategies and therapeutic modalities.  
 
Specific aims 
As aforementioned, knowledge about the relationships between the 
molecular properties and subcellular distribution of exogenous chemical agents 
leads to greater understanding of their biological effects and serves as a basis for 
the rational design of “supertargeted” chemical agents to specific sites of action 
within cells [188]. While there have been many efforts in identifying specific 
molecular properties and physiological conditions that are associated with 
predictable subcellular distribution patterns and bioavailability [189-192], such 
efforts have been limited to a relatively small group of chemical agents.  A 
comprehensive cheminformatic analysis of the physicochemical and subcellular 
distribution properties of a diverse set of small molecules would be valuable and 
may lead to more general insights that are important to prioritize future research 
efforts in this area. 
Previously in our lab, a mechanism-based computational model of cell 
pharmacokinetics was developed to guide experimental design and analysis of 
the subcellular distribution and transport properties of small molecules across cell 
monolayer [193]. This model has seen successful application in predicting the 
transcellular permeability of small molecules across cell monolayer [194]. Using 
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the weakly dibasic drug chloroquine as a test compound, the model was capable 
of capturing the transcellular transport kinetics for the first four hours of drug 
treatment [194]. We envision that such physiologically based models would also 
be a useful tool in guiding experimental design for intracellular accumulation and 
intercellular transport studies.  
The aim of this project is to assess the status of current knowledge of the 
subcellular pharmacokinetics of small molecules, and to develop a fast and cost 
effective computational tool to facilitate the experimental design and analysis of 
small molecules‟ subcellular distribution behavior, especially the intracellular 
distribution and intercellular transport. Four specific aims of this project are as 
follows:  
1. To explore the extent to which current knowledge about the 
organelle-targeting features of small molecules may be applicable towards 
controlling the accumulation and distribution of exogenous chemical 
agents inside cells, and to evaluate the feasibility of developing a 
statistically based empirical model in predicting subcellular accumulation 
sites. In this study, molecules with known subcellular localization properties as 
reported in the scientific literature will be compiled into a single data set and 
compared to reference data sets from the DrugBank database or the PubChem 
database to identify potential physicochemical properties that are associated with 
subcellular targeting phenotype. Specific trends in the distribution of molecular 
properties as associated with reported subcellular localization sites will be 
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discussed in relation to the development of empirical structure-localization 
relationship models for predicting steady state subcellular distribution profile.  
2. To evaluate the performance of a cell-based, physiologically relevant 
mathematic model in predicting subcellular distribution pattern by 
cheminformatic analysis of virtual libraries of small drug-like molecules. In 
this part of the study, mathematic models of single cells will be used to simulate 
the steady state intracellular distribution pattern of ninety-nine lysosomotropic 
small molecules in a leukocyte in homogeneous extracellular drug concentration 
or an epithelial cell facing an apical-to-basolateral drug concentration gradient. 
The simulated subcellular accumulation sites will be compared to literature 
reports and the relationship between the physicochemical properties and the 
associated cellular distribution profiles will be studied. 
3. To demonstrate the flexibility and application of mechanism based 
models in hypothesis testing using chloroquine as a model compound. 
Chloroquine is a weak base drug with extensively intracellular accumulation 
which could not be explained by the traditional pH-portioning theory and ion 
trapping mechanisms. In this study, we proposed an alternative hypothesis to 
explain chloroquine accumulation: that drug-induced phospholipidosis 
corresponds to an inducible, weak base disposition system. We will perform 
detailed quantitative analysis of chloroquine cellular pharmacokinetics in 
epithelial cells and modify our cell-bases simulator to establish the impact of 
phospholipidosis on the cellular pharmacokinetics of chloroquine.  
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4. To apply the mechanism-based cell simulator to analyze the inter-
cellular transport of small molecules within cell monolayers. In this study, a 
novel design featuring impermeable membrane support with geometric pore 
arrays will be proposed. The time course of inter-cellular transport of small 
molecules will be analyzed with a cell-based mathematic model. Fluorescence 
microscopy will be used to capture the kinetics of transport of different chemical 
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Figure 1.1. MDCK cells treated with 50 M chloroquine concentration for 4 
hours prior to staining with Lysotracker Green (yellow, lysosomes), 
Mitotracker Red (blue, mitochondria) and Hoechst (red, nuclei). Cells 
exposed to high concentrations of chloroquine undergo profound changes in 
endolysosomal membrane organization. Continuous accumulation of chloroquine 
leads to the formation of spherical, multilamellar drug-membrane complexes that 
visibly bind to Lysotracker Green within the lumen of the expanded lysosomes 






The Subcellular Distribution of Small Molecules:  




To explore the extent to which current knowledge about the organelle-targeting 
features of small molecules may be applicable towards controlling the 
accumulation and distribution of exogenous chemical agents inside cells, and to 
evaluate the feasibility of developing a statistically based empirical model in 
predicting subcellular accumulation sites, molecules with known subcellular 
localization properties (as reported in the scientific literature) were compiled into 
a single data set. This data set was compared to a reference data set of 
approved drug molecules derived from the DrugBank database, and to a 
reference data set of random organic molecules derived from the PubChem 
database. Cheminformatic analysis revealed that molecules with reported 
subcellular localizations were comparably diverse. However, the calculated 
physicochemical properties of molecules reported to accumulate in different 
organelles were markedly overlapping.  In relation to the reference sets of Drug 
Bank and Pubchem molecules, molecules with reported subcellular localizations 
were biased towards larger, more complex chemical structures possessing 
44 
 
multiple ionizable functional groups and higher lipophilicity. Stratifying molecules 
based on molecular weight revealed that many physicochemical properties 
trends associated with specific organelles were reversed in smaller vs. larger 
molecules.  Most likely, these reversed trends are due to the different transport 
mechanisms determining the subcellular localization of molecules of different 
sizes.  Molecular weight can be dramatically altered by tagging molecules with 
fluorophores or by incorporating organelle targeting motifs. Generally, current 
body of knowledge in compounds with subcellular distribution information is not 
suitable for developing predictive empirical models. In order to better explore 
structure-localization relationships, subcellular targeting strategies would benefit 
from analysis of the biodistribution effects resulting from variations in the size of 
the molecules. 
 
Keywords: drug transport; pharmacokinetics; biodistribution; drug targeting; 




To develop small molecule chemical agents that accumulate at specific sites 
within cells, one would need to address not only bioavailability and tissue 
distribution issues at a systemic level, but also focus on delivery and targeting 
strategies at the subcellular level. In this context, knowledge about the 
relationships between the physicochemical properties and subcellular distribution 
of exogenous chemical agents could lead to greater understanding of their 
biological effects and could serve as a basis for the rational design of chemical 
agents “supertargeted” to specific sites of action within cells [1]. As such, 
supertargeted collections of chemical agents could serve as a starting point for 
developing more potent and less toxic drug leads, focusing on molecules that 
concentrate at intended sites of action while avoiding unwanted interactions with 
unintended targets. 
The scientific literature supports the notion that many small molecule 
chemical agents tend to accumulate in specific organelles. The localization is 
usually supported by evidence including physical interaction with organelle 
components, resulting changes in organelle structure and function, or it may be 
visualized microscopically when a molecule has a specific optical signature. At a 
microscopic level, tissue distribution profiles depend on drug molecules crossing 
cellular membranes. During this process, drug molecules may also accumulate in 
various subcellular organelles, or bind to components such as lipids, proteins, 
DNA, RNA that localize to different intracellular or extracellular compartments. 
Specific properties of small molecules (pKa, logP, molecular size, formal charges, 
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hydrogen bond forming capacity, etc.) have been associated with predictable 
differences in systemic bioavailability and tissue distribution [2-5]. Indeed, a 
comprehensive cheminformatic meta-analysis of the physicochemical and 
subcellular distribution properties of small molecules as reported in the scientific 
literature could lead to interesting insights and would be important to prioritize 
future research efforts in this area. 
Here, to help assess the status of current knowledge about the distribution 
of small molecules inside cells and its application to develop predictive empirical 
models for subcellular drug targeting and delivery, we compiled a data set of 
small molecules with reported subcellular localization features. In turn, a meta-
analysis was performed to reveal how chemical structure and physicochemical 
properties are associated with the subcellular transport and biodistribution 
properties of exogenous chemical agents inside cells.  
 
Methods 
Data collection. Manual, text-based searches were undertaken using 
PubMed, Web of Sciences, MEDLINE and a commercial catalogue of fluorescent 
probes (Molecular Probes Catalog, Invitrogen Inc) using standard MESH terms 
(i.e., lysosome, mitochondria, nucleus, cell membrane / plasma membrane / 
cytoplasmic membrane, endoplasmic reticulum, Golgi apparatus / Golgi complex, 
subcellular, intracellular, accumulation, distribution) to identify small molecules 
exhibiting organelle-specific intracellular localization patterns. This initial pool of 
references was expanded by searching for articles written by the same authors, 
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articles citing or cited by these articles, as well as articles describing studies 
perforomed on related compounds as identified by searching chemical substance 
names (e.g. styryls, amines, etc.). For molecules that were found in review 
articles or catalogues, the chemical name (and synonyms) were used as key 
words to search PubMed and Google Scholar for original research articles 
describing experimental evidence documenting their subcellular localization.  
Database construction. Each molecule was incorporated into a database 
of 967 unique compounds with subcellular localization information about their 
chemical structure and distribution profile (Table 2.1, Appendix A-H). Claims for a 
specific subcellular distribution pattern were established based on the authors’ 
interpretation of the data. For example: “compound X targets organelle Y”; 
“compound X (strongly / mainly / predominantly / selectively) localized in 
organelle Y” [6-10]; “compound X exhibited a organelle Y localization” [8, 11]; 
“compound X mostly concentrating in organelle Y” [12, 13]; “method Z showed 
significant enrichment of compound X in organelle Y” [14]; “strong organelle Y 
accumulation was observed for compound X” [15]; “compound X (preferentially) 
accumulated in organelle Y” [16-18]; “Z percentage of compound X was 
associated with organelle Y” [19]; “subcellular distribution of compound X1 was 
almost identical with the distribution of compound X2” [20]; “organelle Y 
accounted for approximately Z percentage of the total distribution” [21-23]. The 
experimental methods used to support the claims were documented (Table 2.2). 
Each entry was linked to the main reference source about the compound’s 
subcellular localization. Compound chemical structures were sketched in MOE 
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(Molecular Operating Environment, Chemical Computing Group Inc., Montreal, 
Canada) using the Molecule Builder, then reduced to single connected 
components (i.e., without counter-ions) with MOE Wash algorithm, and then 
converted to Simplified Molecular Input Line Entry Specification (SMILES) strings. 
Localization categories. For integrative analysis, we manually grouped the 
chemical agents into one of seven major categories, based on their reported site 
of accumulation (Appendix A-H). Functional considerations led us to consider 
lysosomes and endosomes as a single endolysosomal compartment because the 
molecular components of endosomes and lysosomes generally overlap in 
different cell lines, possessing an acidic lumen pH and readily exchanging 
contents. Molecules accumulating in the endoplasmic membrane (ER) and Golgi 
apparatus were also grouped together since these two organelles share similar 
protein markers and exchange content (localization to the Golgi and ER is 
generally reported together, because these two organelles are also difficult to 
distinguish using fluorescence microscopy).   
Database comparisons. For comparison purposes, a random sample of 
1000 compounds was downloaded from DrugBank [24, 25] which represents a 
collection of drugs that have been approved by the FDA (Appendix I). Similarly, a 
random sample of 982 compounds was downloaded from PubChem which 
represents an arbitrary sample of small organic compounds (Appendix J). The 
two reference datasets did not have overlapping molecules. ChemAxon and 
MOE were used to calculate molecular descriptors of the major micro-species at 
pH 7.4 for each compound in the subcellular localization dataset, or the 
49 
 
PubChem and DrugBank reference sets. Z-score was computed to compare the 
mean descriptor value of molecules in the database to PubChem or DrugBank 








 , where X1 and 
X0 are the mean descriptor value of two subgroups (i.e. the subcellular 
localization dataset vs PubChem or DrugBank datasets; the lower vs. higher 
molecular weight compounds; or, the targeting vs non-targeting compounds);  s1
2 
and s0
2 are the sample variances of the corresponding populations; and,  n1 and 
n0 are the number of molecules in the corresponding populations. A positive or 
negative Z-score with an absolute value greater than 3.1 indicates X1 is 
significantly greater or less then X0 (p-value < 0.001). The histograms of 
molecular descriptors of the compounds in both datasets were plotted and 
overlaid for visual comparison. Statistical analyses were performed with Python 
2.5 (www.python.org). 
Discriminant analysis. Linear discriminant analysis (LDA) was used to 
elucidate how the seven molecular descriptors that showed greatest association 
with individual subcellular localization categories (molecular weight, a_don, 
b_rotR, dipole, glob, logP_ow, and formal charge at pH7.4) were related to the 
reported localization of compounds at the four major sites (lysosomes, 
mitochondria, nuclei and plasma membrane). The LDA was restricted to those 
compounds with complete property data and that localized exclusively to one of 
these four sites. Five of the seven properties (weight, a_don, b_rotR, dipole, glob) 
were non-negative and skewed, so they were logarithmically transformed using 
the function log2(x+1). LDA was applied separately to compounds < 500 Daltons 
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(n = 437) and > 500 Daltons (n = 332). Scatter plots of the points according to the 
first two discriminant directions were constructed and the points were labeled 
according to each subcellular localization category. 
Chemical diversity analysis. The chemical structures were input into MOE 
to generate a Simplified Molecular Input Line Entry Specification (SMILES) 
strings. Next, the MACCS Structure Keys (Molecular ACCess System, a library of 
166 generic chemical substructure features) was used to generate a binary 
fingerprint of each molecule, based on which MACCS substructure feature is 
present or absent in each molecule (as captured by the SMILES strings). To 
calculate the Tanimoto coefficient for each pair of compounds, the total number 
of features shared by each pair of molecules and the number of common, 
overlapping features present in both molecules are used, according to the 
equation:  
 
       
 , where N1 + N2 represent the total number of unique 
features (bits) in the pair of molecules and C represents the number of unique 
features (bits) shared in common by the fingerprints of both molecules. Two 
molecules were considered as structurally similar if the Tc value was greater than 
0.85. Average Tc of each sub-group of the subcellular localization dataset was 
calculated as the average of Tc values between all possible pairs of molecules 
present in each localization category.  
 
Results 
The physicochemical properties of compounds with reported subcellular 
localization features were compared with the corresponding properties of 
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reference compounds obtained from two public repositories of small molecule 
information (PubChem and DrugBank databases [24, 25]; Figure 2.1 and Figure 
2.2). Relative to a random PubChem data set (Figure 2.1, line), compounds with 
reported localization properties (Figure 2.1, grey) were larger (e.g. higher 
molecular weight), possessed a broader charge distribution at physiological pH 
7.4, and were more lipophilic (higher logP_ow). Compounds with reported 
localization properties also contained more hydrogen bond donors (a_don), more 
rotatable bonds (b_rotR, fraction of rotatable bonds) and were flatter (glob, or 
globularity, with a value of 1 indicating a perfect sphere and 0 indicating a one- or 
two- dimensional object) (Figure 2.1). Values for atom count, bond count, shape, 
volume and surface area-related descriptors of all localization categories were 
also greater than those of the reference PubChem compounds (histograms not 
shown).  
Chemical agents with reported subcellular localization were also larger, 
more hydrophobic and contained more positive charges at physiological pH as 
compared to small molecule drugs currently on the market, represented by the 
DrugBank data set (Figure 2.2). When compared with DrugBank compounds [24, 
25], compounds with reported subcellular localization possessed a more positive 
charge distribution at pH 7.4, higher logP values and higher molecular weight 
(Figure 2.2), although hydrogen donor count (a_don), rotatable bond fraction 
(b_rotR) and globularity (glob) were similar. Interestingly, while 84.7% and 71.6% 
DrugBank compounds conformed to Lipinski’s Rule of Five or Oprea’s Rule of 
Lead-likelihood, only 52.8% and 41.4% of compounds with known subcellular 
52 
 
localization features conformed to the Rule of 5 [2] and the Rule of Lead-
likelihood [26] (Table 2.3). Most of the violations of drug-likeliness or lead-
likeliness tests were due to higher molecular weight and higher logP_ow of 
compounds with reported localization (data not shown). The majority of violations 
observed for compounds reported to localize at the plasma membrane, ER/Golgi, 
and cytosol.  
Many compounds with reported subcellular localization were conjugated to a 
specific targeting motif or fluorophore, to enhance organelle-specific 
accumulation or to facilitate the detection of the compounds inside cells [9, 18]. 
Such conjugation is accompanied by an increase in molecular weight, which 
could impact the mechanisms of transport and accumulation inside cells. 
Therefore, to assess the effect of molecular weight on localization, compounds 
with subcellular localization information were stratified into lower and higher 
molecular weight groups using a molecular weight of 500 Dalton as a threshold. 
Compounds < 500 Daltons are more “drug-like” or “lead-like” based on Lipinski’s 
Rule of 5 or Oprea’s Rule of Lead-likeness, and generally lack extraneous 
fluorophore tags or delivery vectors.  Molecules with lower molecular weight 
(Figure 2.3, grey filled line) contained less hydrogen bond donors, smaller dipole 
moments, lower fractions of rotatable bonds, and were less lipophilic and less 
globular than molecules with higher molecular weight (Figure 2.3, solid line).  
Exploring the pH-dependent ionization states of molecules with reported 
subcellular localization, the overall formal charge increased from negative to 
positive as pH decreased, as expected from the protonation of the ionizing 
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centers within each molecule. This trend was apparent in both low (Figure 2.4, 
grey filled line) and high (Figure 2.4, solid line) molecular weight compounds.  
Nevertheless, in most cases and especially under extreme pH conditions, higher 
molecular weight molecules showed a much broader distribution of formal 
charges than lower molecular weight compounds, reflecting the prevalence of 
multiple ionization centers in higher molecular weight compounds. 
Other molecular properties of low and high molecular weight compounds 
were different, depending on the reported subcellular localizations (Table 2.4). 
Compared to larger compounds >500 Daltons, smaller compounds with reported 
endo-lysosomal localization were more positively charged at physiological pH, 
were smaller (lower molecular weight) and more spherical (higher glob). The 
smaller compounds with reported mitochondrial localization contained lower 
dipole moment (dipole). The smaller compounds with reported nuclear 
localization contained a lower fraction of rotatable bonds (b_rotR) and were 
flatter (lower glob). The smaller compounds with reported plasma membrane 
localizations were larger than non-localizing compounds but contained fewer 
hydrogen bond donors and were less spherical in shape.  
Remarkably, for larger compounds within a given localization class, many 
trends observed between physicochemical properties and subcellular 
localizations appear reversed, when compared to the trends observed for smaller 
compounds (Table 2.4). This was especially striking in the case of molecular 
weight:  lower molecular weight was associated with lysosomal localization for 
compounds <500 Daltons, while larger molecular weight was associated with 
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lysosomal localization for compounds >500 Daltons. In addition, higher molecular 
weight was associated with mitochondrial, nuclear and plasma membrane 
localization for compounds <500 Daltons, while lower molecular weight was 
associated with mitochondrial and plasma membrane localization for 
compounds >500 Daltons.  Similar molecular weight-dependent trend reversals 
were observed for other physicochemical properties in every localization 
category (Table 2.4).  
Linear discriminant analysis was applied to find linear combinations of 
features which separate compounds with different reported subcellular 
localization sites in the endo-lysosomes, mitochondria, nucleus and plasma 
membrane, amongst the lower and higher molecular weight subsets (Figure 2.5). 
For compounds <500 Daltons (Figure 2.5, left plot), only a small portion of 
molecules with reported endo-lysosomal localization could be distinguished from 
the rest by the first and second combination of molecular properties (LDA 1 and 
LDA 2). These endo-lysosomal compounds possessed lower molecular weight 
and lower lipophilicity (data not shown). However, these compounds were all 
derived from a single experimental report focusing on the pharmacological 
effects of closely related alkylamines [27]. For compounds >500 Daltons (Figure 
2.5, right plot), molecules reported to localize to different subcellular 
compartments exhibited highly overlapping physicochemical properties. 
Lastly, we confirmed that based on their chemical structure, molecules with 
reported subcellular localization features were reasonably diverse, irrespective of 
their organelle-targeting properties. The average Tanimoto coefficient (Tc) value 
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is 0.350 for molecules with reported localization, which was close to the average 
Tc values of random PubChem (0.282) and DrugBank (0.292) datasets. The 
group of molecules with reported lysosomal localization had the lowest average 
Tc of 0.325 while the group of reported ER/Golgi localization had the highest 
average Tc of 0.438. No molecule in the database was similar to more than 24 
(2.5%) molecules in the entire dataset for Tc> 0.85. Within each category, there 
were variations in terms of the similarity of the molecules to each other (Figure 
2.6), with molecules localizing to mitochondria and lysosomes being most diverse, 
and molecules localizing to the ER/Golgi and plasma membrane being least 
diverse. This trend could reflect an intrinsic tendency for molecules possessing 
specific structural features to accumulate in the ER/Golgi and plasma membrane 
compartments, although it was also possible that this reported localization may 
also be biased by systematic chemical synthesis efforts of molecules 
incorporating specific organelle-targeting motifs. 
 
Discussion 
Knowing the bioaccumulation and biodistribution patterns of exogenous 
chemical agents inside cells could be useful to develop subcellular drug targeting 
and delivery approaches for increasing drug efficacy and decreasing toxicity.  In 
this study, we have evaluated the relationship between the chemical structure of 
small molecules and the subcellular distribution patterns, based on published 
reports compiled from the scientific literature. In an accompanying review article, 
we have reviewed the evolution of the methods that have been used for 
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performing subcellular distribution studies. Our major conclusion is that 
understanding of small molecule distribution inside cells has been biased by the 
experimental strategies that have been used for studying subcellular distribution, 
which have largely ignored the effect of molecular weight on the observed 
structure-localization relationships.  
Today, fluorescence imaging constitutes the most common method used to 
establish the subcellular distribution of organelle-targeted small molecules.  For 
this purpose, molecules are tagged with fluorescent probes and are studied 
because of their specific, organelle-targeting properties. Perhaps for this reason, 
molecules with known subcellular localization properties appeared to be more 
complex, larger, possessed many ionizable centers, and were more lipophilic as 
compared with references sets of molecules representing drugs currently on the 
market, or random samples of PubChem compounds without subcellular 
localization information.  
As presented in the accompanying review article, there are many more 
reports of molecules that localize to a single organelle, as compared to reports of 
molecules that localize to multiple organelles. Perhaps this is because it is easier 
to focus analysis on localization to single organelles, but it could also be because 
most molecules that have been studied in terms of their localization are analyzed 
because of their specific targeting property. To target a single organelle, complex 
chemical structures with multiple functional groups may allow for strong and 
specific interactions with resident organelle components.  Our results indicate 
that multiple ionizing centers are associated with larger compounds reported to 
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accumulate in specific organelles. While multiple ionization centers may underlie 
highly specific, organelle-targeting properties, high lipophilicity would be a 
necessary prerequisite for these molecules to penetrate inside cells. Our results 
also confirm that higher lipophilicity is a characteristic of compounds that have 
been reported to accumulate in specific organelles. 
Molecular weight is an important parameter affecting transport properties 
and drug-likelihood [2, 26, 28] because of its direct inverse effect on diffusivity 
and plasma membrane permeability [29]. Using 500 Daltons as a threshold, 
molecular properties associated with specific subcellular compartments were 
identified and different trends of molecular properties distribution were observed 
for molecules lesser or greater than 500 Daltons. The differences in the observed 
trends emphasize the importance of molecular weight as a key property 
determining the transport mechanisms and molecular interactions affecting 
subcellular distribution.   
In retrospect, the effect of molecular weight on the other physicochemical 
properties affecting localization may have been expected based on what is 
known about the molecular and cellular mechanisms responsible for organelle 
targeting and retention. For example, in the case of endolysosomal localization, 
the smallest molecules enter the cells and accumulate in lysosomes by passive 
diffusion while being retained by pH-dependent ion trapping. However, large, 
charged molecules enter the cells and accumulate in endolysosomes by 
pinocytosis or endocytosis, while being retained there by virtue of being 
intrinsically membrane impermeant.  Similarly, flat, rigid, hydrophobic, small 
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molecules accumulate in the nucleus by directly traversing the membranes of the 
nuclear envelope while being retained there by intercalating between the bases 
of DNA. However, larger, more globular, less membrane-permeant molecules 
possessing multiple positive charges may preferentially accumulate in the 
nucleus by entering through the nuclear pores while being retained there by 
forming electrostatic ion complexes with the phosphate backbone of DNA.  Only 
in the case of the plasma membrane were our results consistent with a single 
common mechanism affecting localization: lipophilic partitioning of hydrophobic 
molecules possessing lipid-like characteristics.  
Based on this meta-analysis, the ability to derive chemical-structure 
localization relationships of small molecules could benefit from more focused, 
quantitative structure-localization relationship studies performed on molecules 
possessing closely-related chemical structures, taking into account how transport 
mechanisms are molecular size-dependent. In addition, experimental analysis of 
nonspecific subcellular distribution patterns of compounds lacking targeting 
motifs should be a priority. High throughput chemical analytical techniques 
including chemical imaging modalities that do not rely on a fluorescence signal, 
such as Raman confocal microscopy, could improve understanding of the 
subcellular transport and distribution properties without the need of fluorescent 
tags for detection. Today, physiologically-based models consider logP, pKa and 
charge as key input parameters to formulate quantitative pharmacokinetic 
hypothesis. Our results argue for the importance of research aimed at elucidating 
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the effect of molecular weight (and related molecular size-dependent properties) 

























1. G.R. Rosania. Supertargeted chemistry: identifying relationships between 
molecular structures and their sub-cellular distribution. Curr Top Med 
Chem. 3:659-685 (2003). 
2. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney. Experimental 
and computational approaches to estimate solubility and permeability in 
drug discovery and development settings. Adv Drug Deliv Rev. 46:3-26 
(2001). 
3. M.R. Feng. Assessment of blood-brain barrier penetration: in silico, in vitro 
and in vivo. Curr Drug Metab. 3:647-657 (2002). 
4. T. Rodgers, D. Leahy, and M. Rowland. Physiologically based 
pharmacokinetic modeling 1: predicting the tissue distribution of moderate-
to-strong bases. J Pharm Sci. 94:1259-1276 (2005). 
5. T. Rodgers and M. Rowland. Physiologically based pharmacokinetic 
modelling 2: predicting the tissue distribution of acids, very weak bases, 
neutrals and zwitterions. J Pharm Sci. 95:1238-1257 (2006). 
6. J.P. Berry, G. Lespinats, F. Escaig, P. Boumati, S. Tlouzeau, and J.F. 
Cavellier. Intracellular localization of drugs in cultured tumor cells by ion 
microscopy and image processing. Histochemistry. 93:397-400 (1990). 
7. T.P. Best, B.S. Edelson, N.G. Nickols, and P.B. Dervan. Nuclear 
localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell 
culture. Proc Natl Acad Sci U S A. 100:12063-12068 (2003). 
8. A.C. Croce, G. Bottiroli, R. Supino, E. Favini, V. Zuco, and F. Zunino. 
Subcellular localization of the camptothecin analogues, topotecan and 
gimatecan. Biochem Pharmacol. 67:1035-1045 (2004). 
9. J. Fernandez-Carneado, M. Van Gool, V. Martos, S. Castel, P. Prados, J. 
de Mendoza, and E. Giralt. Highly efficient, nonpeptidic oligoguanidinium 
vectors that selectively internalize into mitochondria. J Am Chem Soc. 
127:869-874 (2005). 
10. M.F. Ross, T.A. Prime, I. Abakumova, A.M. James, C.M. Porteous, R.A. 
Smith, and M.P. Murphy. Rapid and extensive uptake and activation of 
hydrophobic triphenylphosphonium cations within cells. Biochem J. 
411:633-645 (2008). 
11. K.L. Horton, K.M. Stewart, S.B. Fonseca, Q. Guo, and S.O. Kelley. 
Mitochondria-penetrating peptides. Chem Biol. 15:375-382 (2008). 
12. P. Villa, D. Sassella, M. Corada, and I. Bartosek. Toxicity, uptake, and 
subcellular distribution in rat hepatocytes of roxithromycin, a new 
semisynthetic macrolide, and erythromycin base. Antimicrob Agents 
Chemother. 32:1541-1546 (1988). 
61 
 
13. W. Li, X.M. Yuan, S. Ivanova, K.J. Tracey, J.W. Eaton, and U.T. Brunk. 3-
Aminopropanal, formed during cerebral ischaemia, is a potent 
lysosomotropic neurotoxin. Biochem J. 371:429-436 (2003). 
14. H. Glaumann, A.M. Motakefi, and H. Jansson. Intracellular distribution and 
effect of the antimalarial drug mefloquine on lysosomes of rat liver. Liver. 
12:183-190 (1992). 
15. R.B. Lichtner, A. Rotgeri, T. Bunte, B. Buchmann, J. Hoffmann, W. 
Schwede, W. Skuballa, and U. Klar. Subcellular distribution of epothilones 
in human tumor cells. Proc Natl Acad Sci U S A. 98:11743-11748 (2001). 
16. G. Cramb. Selective lysosomal uptake and accumulation of the beta-
adrenergic antagonist propranolol in cultured and isolated cell systems. 
Biochem Pharmacol. 35:1365-1372 (1986). 
17. A. Lansiaux, F. Tanious, Z. Mishal, L. Dassonneville, A. Kumar, C.E. 
Stephens, Q. Hu, W.D. Wilson, D.W. Boykin, and C. Bailly. Distribution of 
furamidine analogues in tumor cells: targeting of the nucleus or 
mitochondria depending on the amidine substitution. Cancer Res. 
62:7219-7229 (2002). 
18. R.J. Burns, R.A. Smith, and M.P. Murphy. Synthesis and characterization 
of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted 
to the mitochondrial matrix. Arch Biochem Biophys. 322:60-68 (1995). 
19. P.J. Houghton, J. Sosinski, J.H. Thakar, G.B. Boder, and G.B. Grindey. 
Characterization of the intracellular distribution and binding in human 
adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-
chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor 
diarylsulfonylurea sulofenur. Biochem Pharmacol. 49:661-668 (1995). 
20. J.E. Pettersen and M. Aas. Subcellular localization of hexadecanedioic 
acid activation in human liver. J Lipid Res. 15:551-556 (1974). 
21. K. Yokogawa, E. Nakashima, J. Ishizaki, H. Maeda, T. Nagano, and F. 
Ichimura. Relationships in the structure-tissue distribution of basic drugs in 
the rabbit. Pharm Res. 7:691-696 (1990). 
22. K. Yokogawa, E. Nakashima, J. Ishizaki, M. Hasegawa, H. Kido, and F. 
Ichimura. Brain regional pharmacokinetics of biperiden in rats. Biopharm 
Drug Dispos. 13:131-140 (1992). 
23. J. Ishizaki, K. Yokogawa, F. Ichimura, and S. Ohkuma. Uptake of 
imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J 
Pharmacol Exp Ther. 294:1088-1098 (2000). 
24. D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. 
Stothard, Z. Chang, and J. Woolsey. DrugBank: a comprehensive 




25. D.S. Wishart, C. Knox, A.C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. 
Gautam, and M. Hassanali. DrugBank: a knowledgebase for drugs, drug 
actions and drug targets. Nucleic Acids Res. 36:D901-906 (2008). 
26. T.I. Oprea. Property distribution of drug-related chemical databases. J 
Comput Aided Mol Des. 14:251-264 (2000). 
27. P.O. Seglen and P.B. Gordon. Effects of lysosomotropic monoamines, 
diamines, amino alcohols, and other amino compounds on protein 
degradation and protein synthesis in isolated rat hepatocytes. Mol Pharm. 
18:468-475 (1980). 
28. O. Ursu and T.I. Oprea. Model-free drug-likeness from fragments. J Chem 
Inf Model. 50:1387-1394 (2010). 
29. S. Balaz. Modeling kinetics of subcellular disposition of chemicals. Chem 





























Endo-lysosomes 226 23.37 96 
Mitochondria 259 26.78 136 
Nucleus 123 12.72 67 
Plasma membrane 162 16.75 75 
ER/Galgi 37 3.83 26 
Cytosol 59 6.10 59 
Multiple 
localizations 
101 10.44 71 



































Count Percentage (%) 
Pharmacological 
effects 





 Cell fractionation 54 5.58 
Microscopic imaging Fluorescence 633 65.46 
 
Histochemistry 9 0.93 
 Others 6 0.62 
Not mentioned  25 2.59 


































Table 2.3. Drug-likeness based on Lipinski’s Rule of Five and lead-likeness 
based on Oprea’s Rules of compounds with reported subcellular 
localizations. The number of drug-likely or lead-likely compounds in each 
location was calculated with MOE and divided by the total number of molecules 
in each location to calculate the percentage pass rate. The reference set of 





Count Percentage Count Percentage 
Endo-
lysosomes 
149 65.93 134 59.29 
Mitochondria 170 66.15 134 51.74 
Nuclei 68 55.28 47 38.52 
Plasma 
membrane 
40 24.69 31 19.14 
ER/Gogli 9 24.32 3 8.11 
Cytosol 19 32.20 16 27.12 
Multiple 49 48.51 35 34.65 
Total 528 52.80 400 41.37 







Table 2.4. Physicochemical property trends of small molecules stratified 
into lower (<500 Daltons) and higher (>500 Daltons) molecular weight 
categories, and associated with various subcellular localizations. Z-scores 
were used to compare differences in molecular properties of localizing vs. non-
localizing molecules. Z-scores with an absolute value greater than 3.1 were 
highlighted in bold, indicating a significant trend associated with a specific 
localization. Z-scores with absolutes value greater than 3.1 and with a different 
sign from the Z-score of molecular weight were underscored. Z-scores for 
molecular descriptors that exhibited consistent (same sign) and significant 
differences between localizing vs. non-localizing compounds in both lower and 
higher MW groups were shaded in grey. Chemicals with reported ER/Golgi and 








difference of targeting from non-targeting  
small molecules (Z-scores) 

























difference of targeting from non-targeting  
large molecules (Z-scores) 























Figure 2.1. Descriptor distributions of molecules with reported subcellular 
localization (filled gray area) and a random PubChem sample (solid line). Z-
scores with an asterisk indicate a significant difference between the mean values 
of a descriptor in the group of compounds with reported localization and the 
reference PubChem dataset (p-value < 0.001). a_don: Hydrogen bond donor 
count. b_rotR: The fraction of rotatable bonds. glob: Globularity, a value of 1 
indicates a perfect sphere while a value of 0 indicates a two- or one-dimensional 
object. logP_ow: Log of the octanol/water partition coefficient. weight: Molecular 





















Figure 2.2. Descriptor distributions of molecules with reported subcellular 
localization (filled gray area) and random DrugBank dataset (solid line). Z-
scores with an asterisk indicate a significant difference between the mean values 
of a descriptor in the group of compounds with reported localization and the 
reference DrugBank sample (p-value < 0.001). a_don: Hydrogen bond donor 
count. b_rotR: The fraction of rotatable bonds. glob: Globularity, with a value of 1 
indicating a perfect sphere and a value of 0 indicating a two- or one-dimensional 
object. logP_ow: Log of the octanol/water partition coefficient. weight: Molecular 























Figure 2.3. Descriptor distributions of lower molecular weight (filled gray 
area; <500 Daltons) and higher molecular weight (solid line; > 500 Daltons) 
molecules with reported subcellular localization. Z-scores with an asterisk 
indicate a significant difference between the mean values of the descriptor in the 
lower and higher molecular weight groups (p-value < 0.001). a_don: Hydrogen 
bond donor count. b_rotR: The fraction of rotatable bonds. dipole moment: Dipole 
moment calculated from the partial charges of the molecule. glob: Globularity, 
with value of 1 indicating a perfect sphere and a value of 0 indicating a two- or 






















Figure 2.4. Calculated, formal charge distributions of lower molecular 
weight (filled gray area; <500 Daltons) and higher molecular weight (solid 
line; >500 Daltons) compounds with reported subcellular localization, at 





Figure 2.5. Linear discriminant analysis of low (<500 Daltons) and high 
(>500 Daltons) molecular weight compounds with reported subcellular 
localizations.  The axes of the plot represent linear combinations of seven 
molecular properties, identified using linear discriminant analysis to maximize the 
separation amongst the localization classes. LDA1 and LDA2 corresponded to 
the two, dominant linear combinations, with the "between class" variance 
accounting for 37% and 11% of the total variance, respectively.  Additional 
discriminant factors (not shown) explained less than 3% of the total variance. The 

























Figure 2.6. The major subcellular localization categories are represented by 
diverse subsets of molecules. In the plot, the x-axis indicates the percentage 
similarity threshold and the y-axis indicates the percentage of population in the 
group that falls between the similarity thresholds. With a Tc threshold of 0.85, 
above 65% percent of the compounds in each localization category were similar 
to no more than 2.5% of the subset, indicating highly diverse compounds 
representing each category. The relatively high percentage (21%) of PM 
molecules that are similar to 2.5% to 5% other molecules in PM group indicates 
that PM molecules are least diverse (Key: Lyso = lysosomes; Mito = 
Mitochondria; Nuc = nuclei; PM = plasma membrane; EG = Endoplasmic 











Simulation-based Analysis of Organelle-Targeted Molecules: 
Lysosomotropic Monobasic Amines 
 
Abstract 
To facilitate exploratory cheminformatic analysis of virtual libraries of small drug-
like molecules, mathematical models of single cells were built from equations 
capturing the transport of small molecules across membranes. Physicochemical 
properties of small molecules were used as input to calculate the kinetics of 
intracellular drug distribution. Here, with mathematical equations and biological 
parameters adjusted so as to mimic a leukocyte in the blood, simulations were 
performed to calculate steady-state accumulation of small molecules in 
lysosomes, mitochondria, and cytosol of this target cell, in the presence of a 
homogenous extracellular drug concentration. Similarly, with equations and 
parameters set to mimic an intestinal epithelial cell, simulations were also 
performed to calculate steady state concentrations and transcellular permeability 
in this non-target cell, in the presence of an apical-to-basolateral drug 
concentration gradient. With a reference set of ninety-nine lysosomotropic small 
molecules, simulation results help map out relationships between the chemical 
diversity of the molecules, their calculated intracellular distributions and their 
associated cellular phenotypes. 
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Weakly basic molecules possessing one or more amine groups have been 
reported to highly accumulate in lysosomes and other membrane-bound acidic 
organelles because of the proposed ion trapping mechanism [1-3]. Amines 
generally have a pKa value in the physiological pH range. Accordingly, they exist 
as a combination of ionized (protonated) and neutral (unprotonated) species.    
Because the pH of lysosomes is one or more units lower than the pH of the 
cytosol, the thermodynamic equilibrium between neutral and ionized species 
shifts towards the protonated, ionized state. Conversely, because the pH of the 
cytosol is higher, the thermodynamic equilibrium between neutral and ionized 
species shifts towards the neutral, unprotonated state.  Since charged molecules 
are less membrane-permeant, the protonated species becomes trapped inside 
the membrane bound compartments, relative to the neutral species. Within an 
acidic lysosome, the concentration of the neutral, membrane-permeant species is 
less than its concentration in the more basic cytosol.  This leads to a 
concentration gradient of the neutral form of the molecule across the lysosomal 
membrane, further driving the uptake of the neutral species of the molecule into 
the acidic organelle.   
In medicinal chemistry, the ability to modify the chemical structure of small 
molecules so as to tailor lysosomotropic behavior may be important for 
decreasing unwanted side effects, as much as it may be important for increasing 
efficacy. For many monobasic amines that target extracellular domains of cell 
surface receptors and ion channels, lysosomal accumulation can be considered 
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a secondary effect of the physicochemical properties of the molecule [4-8].   
Previously, many monobasic amines have been experimentally analyzed in cell-
based assays, in terms of their ability to accumulate in lysosomes [6, 9-12].  In 
response to ion trapping, cells exposed to monobasic amines swell and become 
replete with large vacuoles [6, 9, 10, 13-15].  With a phase contrast microscope, 
swollen lysosomes can be easily discerned and scored.  Furthermore, as 
monobasic amines accumulate in lysosomes, they can increase the pH of the 
organelle through a buffering effect, or by shuttling protons out of the lysosome, 
across the lysosomal membranes [16]. Therefore, such molecules “compete” 
with each other for lysosomal accumulation, providing another way to assay for 
lysosomotropic behavior [16, 17].  A third way to assay lysosomotropic behavior 
is by labeling lysosomes of cells with fluorescent probes (e.g. Lysotracker® dyes) 
[17].  As lysosomes expand in response to accumulation of lysosomotropic 
agents, they accumulate increasing amounts of the Lysotracker® dye and the 
cells become brightly labeled.  By virtue of these effects on live cells, many 
monobasic amines have been positively identified as “lysosomotropic”.   
Nevertheless, different studies analyzing lysosomotropic monobasic amines 
have also identified molecules that deviate from the norm. Furthermore, there is 
a broad range of concentrations at which vacuolation becomes apparent, 
spanning several orders of magnitude [10, 18-20]. In addition, there are 
monobasic amines that do not exhibit any vacuolation-inducing behavior [6, 9, 10, 
13, 14, 21], and do not compete with the lysosomal uptake of other 
lysosomotropic probes [6, 16], or that are cytotoxic [21].  Most importantly, some 
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lysosomotropic molecules have been reported to accumulate in other organelles, 
such as mitochondria [22]. Alprenolol, chlorpromazine, fluoxetine, propranolol, 
and diltiazem are just but some of the FDA approved drugs in this category [6, 16, 
22, 23], that have been classified as being both lysosomotropic and 
mitochondriotropic by different investigators.  In addition, certain monobasic 
amines may accumulate in lysosomes to a much greater extent than ion trapping 
mechanisms would predict [20]. 
These apparent discrepancies in terms of the lysosomotropic behavior 
prompted us to begin exploring the relationship between the phenotypic effects of 
monobasic amines, and their subcellular distribution in lysosomes vs. other 
organelles. We decided to use a cell-based molecular transport simulator [24, 25] 
to begin exploring the different possible behaviors of monobasic amines inside 
cells based on the ion trapping mechanism, paying special attention to their 
accumulation in lysosomes, cytosol and mitochondria. In this manner, the 
simulations are not meant to “predict” the actual concentration and distribution of 
the molecules inside the cells, but rather to assess the possible variations in 
intracellular transport behaviors, based solely on the biophysical principles 
underlying the ion trapping mechanism.  Because the ability to optimize the 
subcellular transport of small molecules could have practical applications in drug 
development, we also deemed it important to calculate the distribution of 
molecules inside non-target cells mediating drug transport in the presence of a 
transcellular concentration gradient.  In fact, although direct experimental 
measurement of subcellular concentration in the presence of a transcellular 
79 
 
concentration gradient would be difficult, this may be the condition that is most 
relevant for drug uptake and transport throughout the different tissues of the body.   
 
Methods 
Modeling the cellular pharmacokinetics of target cells in suspension: 
The T-Model. For subcellular compartments delimited by membranes, passive 
transport of small molecules in and out of these compartments is determined by 
the interaction of the molecules with the membrane, the concentration gradient of 
molecules across the membrane, the local microenvironment on either side of 
the membrane, and the transmembrane electrical potential [24, 25].  Drug-
membrane interactions are largely dependent on the physicochemical properties 
of small molecules (such as pKa and lipophilicity) and the environmental 
condition (such as local pH values and membrane potentials).  Based on the 
biophysics of membrane transport, mass transfer of drug molecules between 
different organelles in a cell surrounded by a homogeneous extracellular drug 
concentration has been modeled mathematically [25] (Figure 3.1 A).  Accordingly, 
three coupled ordinary differential equations describe the concentration change 
with time in each subcellular / cellular compartment:   
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                                            (3)  
where C indicates the concentration, J indicates the fluxes, A and V indicate 
membrane surface and volume respectively. The subscripts o,c,l, and m indicate 
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extracellular compartment, cytosol, lysosomes, and mitochondria respectively. 
The directions of fluxes are the orders of the subscripts, e.g. mcJ ,  indicates the 
flux from cytosol to mitochondria.  Calculations for fluxes between each pair of 
compartments were similar as described before [25]. The ordinary differential 
equations were numerically solved (Appendix K) [24].  
An important feature of this model is that at steady state, the drug 
concentration in the cytosol is only dependent on the drug concentration outside 
the cell, the plasma membrane permeability properties, and the ionic conditions 
of the cytosol and the extracellular medium.  Similarly, the drug concentration 
inside any given organelle is only dependent on the drug concentration in the 
cytosol, the permeability properties of the membrane delimiting the organelle, the 
ionic conditions of the cytosol, and the inner lumen of the organelle.  
Consequently, one can use the same equations to calculate steady state 
concentration or mass of drugs in lysosomes or mitochondria (and other 
organelles) simply by adjusting the pH of the organelle, the transmembrane 
electrical potential, and the organelle volume, surface area, and lipid fraction.  
For mitochondria, the inner lumen pH was set at 8 [25] and the membrane 
potential was set at -150 mV [26].  Mitochondria were considered as spheres with 
1 µm radius. For lysosomes, the inner lumen pH was set at 5 [1, 27-29] and the 
membrane potential was set at +10 mV [30].  Leukocytes were modeled as 
spherical objects of 10 µm diameter.  Plasma membrane potential was set at -60 
mV [31] .  Extracellular pH was set at 7.4 (blood).  Cytosolic pH was set at 7.0 
[32].  Since we are more interested in the drug aqueous concentration in cytosol 
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the lipid fraction equal to 0 was used in calculation.  Other models parameters 
were adapted from the literature [25].  Hereafter, this cellular pharmacokinetic 
model applicable to free floating cells in suspension (e.g. leukocytes in the 
circulation) will be dubbed Trapp‟s Model or „T-Model‟.   
Modeling cellular pharmacokinetics of non-target, polarized epithelial 
cells: The R-Model. For modeling drug transport across polarized epithelial cells 
[24], the cell surface area is divided into apical and basolateral membrane 
domains (Figure 3.1 B). Similarly, the extracellular space is divided into apical 
and basolateral extracellular compartments.  Accordingly, drug uptake into the 
cell is represented by mass transfer of drug molecules from the apical 
extracellular medium into the cytosol, across the apical membrane.  Drug efflux 
from the cells is represented by mass transfer from the cytosol to the basolateral 
medium, across the basolateral membrane.  Because the apical membrane is 
normally covered with microvilli, the apical membrane surface area (Aa) can be 
adjusted independently from the basolateral membrane (Ab). Similarly, the 
extracellular pH of the apical (pHa) and basolateral compartments (pHb), and 
transmembrane electrical potentials across apical and basolateral membranes 
(Ea and Eb )  can be independently adjusted, so as to mimic the local 
microenvironment of the epithelial cells.   
A cellular pharmacokinetic model for intracellular concentration and passive 
transcellular permeability calculation was developed as described previously [24, 
33].  Mass transport across the boundary of each compartment can be described 
by equations 4 to 7:  
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The subscripts a and b indicate „apical‟ and „basolateral‟ respectively. Other 
symbols and subscripts mean the same as in the T-model.    As in the T-model, 
the inner lumen pH of mitochondria was set at 8 [25] and the mitochondrial 
membrane potential was set at -150 mV [26].  For lysosomes, the inner lumen pH 
was set at 5 [1, 27-29] and the membrane potential was set at +10 mV [30].  
Epithelial cells were modeled as cuboidal objects of 10 µm length. Again since 
we are more interested in the drug aqueous concentration in cytosol the lipid 
fraction was set to 0.   All other model parameters used in calculation were 
obtained from the literature [24], and can be found in Appendix K.  To maintain 
sink condition in the basolateral compartment, we set the volume of the 
basolateral compartment (Vb) equal to the human blood volume (4.7 L).   
From simulating cytosol to basolateral flux of molecules in an intestinal 
epithelial cell, the membrane permeability of the intestinal epithelial cell 
monolayer can be calculated with the following equation [24]: 
     
   
                                   
 (8) 
where Peff is the effective permeability, Ca is the initial concentration in the apical 
compartment and is considered to be constant, dmb/dt is the change in drug 
mass in the basolateral compartment per unit time, and Aaa is the apparent cross 
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sectional area of the cell, which would approximately correspond to the total area 
of the surface over which drug transport is occurring divided by the number of 
cells that are effectively transporting drug. Henceforth, this cellular 
pharmacokinetic model that applies in non-target epithelial cells will be dubbed 
Rosania‟s Model or „R-Model‟.   
Simulating organelle-targeting and transcellular permeability with R- 
and T-models. To simulate the intracellular distribution of monovalent weakly 
basic molecules possessing amine functionality, all different combinations of 
octanol : water partition coefficients of the neutral form of the molecule (logPn); 
octanol : water partition coefficients of the ionized form of the molecule (logPd); 
and pKa were used as input. LogPn and logPd spanned a range from -5 to +5, 
with logPd constrained to a value less than or equal to logPn.  pKa spanned a 
range from 0 to 14. pKa, logPn, and logPd were varied in 0.2 unit increments [24]. 
The molecular charge (z) was set equal to 1, which means the simulated whole 
physicochemical space is specific for monovalent amine-containing molecules. 
With R- and T-Model, drug concentrations in different compartments were 
calculated over time, until concentrations reached steady state (normally, at 106 
seconds after beginning of the simulation). For R-Model simulations, initial apical 
drug concentration was set at 1 mM, and basolateral drug concentration was set 
at 0 mM. For T-model simulations, extracellular drug concentration was set at 1 
mM, and kept constant. Accordingly, for each combination of pKa, logPn, and 
logPd  used as input, there are seven calculated results: CcytoR, CmitoR, ClysoR (the 
steady-state cytosolic, mitochondrial and lysosomal concentration calculated with 
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the R-model); Peff (the steady-state effective permeability calculated with the R-
Model); and CcytoT, CmitoT, and ClysoT (the steady-state cytosolic, mitochondrial 
and lysosomal concentrations calculated with the T-Model) . 
A reference set of monobasic amines with associated lysosomotropic 
behaviors. Focusing on lysosomal targeting, ninety-nine monobasic amines 
(Table 1) were found by searching PubMed abstracts and titles for articles 
containing the word “lysosome”, “lysosomal”, or “lysosomotropic”; from other 
articles referenced by these articles; and from current review articles describing 
the lysosomal accumulation of weakly basic molecules [1]. There are more 
lysosomotropic amine-conatining molecules besides molecules included in our 
table (for example, zwitterions or dibasic amines).  However since R- and T-
Models have been validated mostlywith molecules possessing one ionizable 
functional grouop, lysosomotropic amines with more than one ionizable 
functionality were not included.  To calculate the pKa (at 310.15K), logPn and 
logPd for each molecule, we used ChemAxon (http://www.chemaxon.com). A 
liposomal approximation [24, 34] was applied for logPn and logPd based on the 
values obtained from ChemAxon. Intracellular concentrations were calculated for 
those ninety-nine molecules at steady state with the T-model and R-model. 
Transcellular permeability was calculated for the ninety-nine molecules at steady 
state with the R-model. 
Interactive visualization of simulation results. Visualization of simulation 
results was performed with the Miner3D software package (Dimension 5, Ltd., 
Slovakia, EU).  Simulation results were graphed as 3D scatter plots, with logPn, 
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logPd and pKa plotted on the three coordinate axes, and the calculated steady 
state concentration or permeability determining the color and intensity of the 
points.  For linking simulation results with the reference set of lysosomotropic 
molecules, we used the pKa,  logPn and logPd  values obtained after liposomal 
approximations [24]. 
To plot different chemical spaces we set a threshold concentration value to 
define accumulation in a specific subcellular compartment.  For intracellular 
concentration, the threshold lysosomal accumulation for lysosomotropic 
molecules was ClysoT  ≥ 2 mM ( i.e. tw0-fold greater than extracellular 
concentration). The thresholds for selective lysosomal accumulation were ClysoT 
≥ 2 mM; ClysoT /CmitoT  ≥ 2 ; and ClysoT /CcytoT  ≥ 2. The threshold for 
mitochondrial accumulation was CmitoT ≥ 2 mM. The thresholds for selective 
mitochondrial accumulation were CmitoT ≥ 2 mM; CmitoT /ClysoT ≥2; and CmitoT 
/CcytoT ≥2. The threshold for cytosolic accumulation was CcytoT ≥ 2 mM. The 
thresholds for selective cytosolic accumulation were CcytoT ≥  2 mM; CcytoT /CmitoT 
≥ 2; and CcytoT /CmitoT ≥ 2. The reason for using the 2-fold concentration value as 
a threshold is because it gave the highest percentage of correct classification 
and low false positive prediction for the reference set of lysosomotropic 
molecules (as detailed in the Results section).  
As recommended by the FDA, the permeability value of metoprolol was 
used as a threshold to distinguish high vs. low permeability molecules [24]. 
Previously we calculated permeability for metoprolol , using the pKa and logPn 
obtained from experimental measurements , to be equal to 35 ×10-6 cm/sec [24].  
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In the present study, we used this value as a threshold to distinguish high vs. low 
permeability molecules.  In addition, we arbitrarily set a value of 1×10-6 cm/sec as 
a cut-off number to distinguish low from negligible permeability molecules.  
Accordingly, three permeability classes were defined as: negligible (Peff < 1×10
-6 
cm/sec); low (1 ≤ Peff < 35 ×10
-6 cm/sec); and high (Peff ≥ 35 ×10
-6 cm/sec).   
 
Results 
Defining a lysosomal accumulation threshold for lysosomotropic 
molecules. We began by exploring the physicochemical property space 
occupied by monobasic amines, in relation to the reference set of molecules 
obtained from published research articles (Table 3.1).  Three different lysosomal 
concentration values (2 mM, 4 mM and 8 mM) were tested in terms of their ability 
to discriminate lysosomotropic vs. non-lysosomotropic compounds (Figure 3.2). 
For compounds with ≥ 2 mM accumulation in lysosomes (Figure 3.2 A-D), eight 
of the reference compounds were below the accumulation threshold (Figure 3.2 
A and B), while 91 were above the threshold (Figure 3.2 C and D).  For 
compounds with ≥ 4 mM accumulation in lysosomes (Figure 3.2 E-H), twelve of 
the reference compounds were below the accumulation threshold (Figure 3.2 E, 
F), while 87 were above the threshold (Figure 3.2 G, H).  For compounds with a ≥ 
8 mM accumulation in lysosomes (Figure 3.2 I-L), 56 lie below the accumulation 
threshold (Figure 3.2 I, J) while 43 are above (Figure 3.2 K, L).    
We established that a lysosomal accumulation threshold of 2 mM is best 
suited to distinguishing lysosomotropic from non-lysosomotropic molecules, since 
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it gave the highest correct classification and lowest false positive error in terms of 
matching simulation results with the experimentally-observed, lysosomotropic 
behaviors. Accordingly, for a lysosomal accumulation threshold of 2mM, of the 
eight molecules that were below the accumulation threshold, five (62.5%) have 
been positively identified as non-lysosomotropic.  Conversely, of the 91 above 
the threshold, 8 (8.8%) non-lysosomotropic molecules have been false positively 
classified as lysosomotropic.  For a lysosomal accumulation threshold of 4 mM, 
of the twelve below the threshold, five (41.7%) have been identified as non-
lysosomotropic. Conversely, of the 87 above threshold, 8 (9.2%) non-
lysosomotropic molecules have been false positively classified as lysosomotropic. 
For a lysosomal accumulation threshold of 8 mM, of the 56 below the threshold, 
9 have been positively identified as non-lysosomotropic (16.1%).  Conversely, of 
the 43 above the threshold, 4 (9.3%) non-lysosomotropic molecules have been 
false positively classified as lysosomotropic.  
The reference set appears highly clustered in relation to the available 
lysosomotropic, physicochemical property space. Exploring the relationship 
between the physicochemical properties of the reference set of molecules 
obtained from the literature, with that of the theoretical physicochemical property 
space occupied by molecules that accumulate in lysosomes at the different 
threshold values, we observed that most of the reference molecules tend to be 
clustered in very specific region of “lysosomotropic space”.  In fact, 
physicochemical property space occupied by molecules that accumulate in 
lysosomes at ≥ 2 mM (Figure 3.2 B) appears largely similar to the space of 
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molecules that accumulate at ≥ 4 mM (Figure 3.2 F) and at ≥ 8 mM (Figure 3.2 J). 
It was surprising that most lysosomotropic molecules in the reference set were 
calculated to have a lysosomal accumulation between 2 and 8-fold over the 
extracellular medium, although the largest portion of the calculated 
physicochemical property space that can be occupied by monobasic amines 
corresponds to > 8-fold lysosomal accumulation. 
Using simulation results to define the expected transport classes for 
monovalent weak bases.  Using a 2-fold or greater concentration of drug over 
the extracellular medium to distinguish high vs. low lysosomal, mitochondrial and 
cytosolic concentration, and by incorporating high vs. low permeability 
classification obtained with the R-model, a total of 16 classes of molecules can 
be  defined a priori (Table 3.1).  By mapping the reference set of molecules to 
these 16 different classes, we find that some classes of molecules are well-
represented by a number of molecules, while other classes of molecules are not 
represented at all (Table 3.1). However, according the simulation results, several 
of these a priori classifications are deemed to be “non-existent” by virtue of our 
being unable to find a combination of physicochemical properties consistent with 
the corresponding class of molecules in simulations.  
Simulation results point to general trends in lysosomotropic behaviors. 
For the reference set of molecules, we observed that the calculated intracellular 
accumulation in non-target cells (R-Model) is much lower than the corresponding 
accumulation in target cells (T-model) (Table 3.1).  We also observed lysosomal 
accumulation occurring for a broad range of transcellular permeability values 
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(Table 3.1).  Unexpectedly, for most lysosomotropic molecules, we also observed 
mitochondrial concentration tending to be much greater than lysosomal or 
cytosolic concentration, suggesting that lysosomotropic behavior is not 
exclusively related to selective accumulation in lysosomes.  Lastly, we observed 
that none of the lysosomotropic molecules in the reference set are able to 
accumulate in cytosol to a greater extent than they accumulate in mitochondria or 
in lysosomes (Table 3.1).  In fact, plotting the physicochemical property space of 
such molecules yielded an empty space (data not shown), indicating that the lack 
of such type of molecules in the reference set is not because of sampling biases, 
but rather it is expected based on the calculated cellular pharmacokinetic 
properties of monovalent weak bases.  
Calculating the physicochemical space occupied by selectively 
lysosomotropic molecules. Selectively lysosomotropic molecules were defined 
as those that accumulate in lysosomes to a 2-fold (or greater) level over the 
extracellular medium, cytosol, and mitochondria.  Out of the 91 reference 
lysosomotropic molecules (Figure 3.3 A, out of circle), only seventeen (Figure 
3.3B, D green circle) appear to be selective in terms of lysosomal accumulation.  
These 17 molecules (Figure 3.3 B) appear clustered at the middle pKa value of 
the reference set of molecules comparing with non-lysosomotropic molecules 
(Figure 3.3 A, in green circle) and non-selectively lysosomotropic molecules.  
Plotting the theoretical physicochemical property space occupied by selectively 
lysosomotropic molecules related to the reference molecules reveals that the 
reference molecules that accumulate in lysosomes are highly clustered (Figure 
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3.3 C) in the middle pKa and high logPd values.  This can also be observed in the 
corresponding plot of non-selectively lysosomotropic and non-lysosomotropic 
physicochemical property space (Figure 3.3 D).   
Analyzing the effect of transcellular permeability on selective 
lysosomal accumulation. Next, we analyzed the relationship between selective 
lysosomal accumulation in target cells, and transcellular permeability in non-
target cells, to determine if the ability to develop selective lysosomotropic agents 
may be constrained by desirably high transcellular permeability characteristics 
important for intestinal drug absorption and systemic tissue penetration (Figure 
3.4).  As a reference, the permeability of metoprolol (Peff = 35×10
-6 cm/sec) was 
used to distinguish high permeability from low permeability drugs. Accordingly, 
three permeability categories were defined: Negligible Permeability (Peff < 1×10
-6 
cm/sec; Figure 3.4 A and B); Low Permeability (1 ≤ Peff < 35×10
-6 cm/sec; Figure 
3.4 C and D); and High Permeability (Peff ≥35×10
-6 cm/sec, Figure 3.4 E and F).   
With increasing permeability, the simulation results indicate that 
physicochemical space occupied by selective lysosomotropic molecules shifts 
towards lower pKa values and higher logPd values. The position of selective 
lysosomotropic chemical space in relation to the reference set of non-selective 
lysosomotropic or non- lysosomotropic molecules can be clearly seen, for 
molecules with Peff < 1×10
-6 cm/sec (Figure 3.4 A); 1 ≤ Peff < 35×10
-6 cm/sec 
(Figure 3.4 B); and Peff ≥ 35×10
-6 cm/sec (Figure 3.4 C).  Accordingly, there is 
only one selectively-lysosomotropic reference molecule with Peff < 1×10
-6 cm/sec 
(Figure 3.4 B; green arrow); five with 1≤ Peff<35×10-6 cm/sec (Figure 3.4 D; 
91 
 
green arrow); and eleven with Peff ≥ 35×10
-6 cm/sec (Figure 3.4 F; green arrow). 
Thus, high permeability and selective lysosomal accumulation are not mutually 
exclusive. Nevertheless, we observed that the selective lysosomotropic reference 
molecules with neglibile low and high permeability are tightly clustered in a small 
region of chemical space, at mid pKa and high logPd values. 
Demarcating the physicochemical property space of extracellular 
targeted molecules. Extracellular-targeted molecules can be defined as those 
whose intracellular accumulation at steady state is less than the extracellular 
concentration [24]. For drug development, such a class of molecules is important 
as many drug targets are extracellular. Accordingly, we analyzed simulation 
results to determine if there were molecules with low intracellular accumulation 
and high permeability, which would be desirable for the pharmaceutical design of 
orally absorbed drugs (Figure 3.5). By maximizing permeability and minimizing 
intracellular accumulation, (using Peff  ≥ 35×10
-6 cm/sec, Ccyto < 1mM, Cmito < 1mM, 
and Clyso < 1mM as thresholds in both in the R and T models), we find five  
molecules falling into this class (Figure 3.5 A-C; green circle): pyrimidine, 
benzocaine, β-naphthylamine, 8-aminoquinoline, and the anti-epileptic drug 
candidate AF-CX1325XX. These are monobasic amines with pKa < 4.5. 
Molecules with pKa > 4.5 (the physicochemical property space shown in Figure 
3.5 C) exhibit intracellular accumulation in lysosomes, cytosol or mitochondria to 
levels above those found in the extracellular medium.  Figure 3.5 B shows the 
physicochemical space of molecules with high permeability and low intracellular 
accumulation. Figure 3.5C shows the physicochemical space of molecules with 
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high intracellular accumulation regardless of permeability.  Again we can see that 
molecules with low intracellular accumulation have a pKa < 4.5 and with high 
intracellular accumulation have a pKa > 4.5. 
Many reported lysosomotropic molecules are calculated to accumulate 
in mitochondria. For the majority of the reportedly lysosomotropic monobasic 
amines in the reference set, our calculations predict that they should accumulate 
in mitochondria more than they accumulate in lysosomes. In total, 56 of the 91 
lysosomotropic molecules in the reference set accumulate in mitochondria at 2-
fold or greater levels than they accumulate in lysosomes, cytosol, or the 
extracellular medium (Figure 3.6 A; Table 3.1, selectively mitochondrotropic 
compounds underlined). These molecules have a pKa of 8.2 or greater, a logPn of 
1.5 or greater, and span a wide range of transcellular permeability values – from 
impermeant to very highly permeant. In addition, eighteen lysosomotropic 
molecules also exhibit mitochondrial and high cytosolic accumulation, at 
concentrations comparable to the concentrations at which they accumulate in 
lysosomes (Figure 3.6 B; Table 3.1). Again, these molecules span a broad range 
of transcellular permeability values, from impermeant to highly permeant.   
Plotting the theoretical physicochemical property space occupied by 
lysosomotropic molecules with selective mitochondrial accumulation reveals that 
the molecules in the reference set are clustered in this realm of physicochemical 
property space (Figure 3.6 C). Similarly, plotting the physicochemical property 
space occupied by lysosomotropic molecules that also accumulate in cytosol and 
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mitochondria reveals that the molecules are clustered in this realm of chemical 
space.  
Calculated effect of pH in apical compartment on permeability and 
biodistribution. The accumulation of monobasic amines in lysosomes is largely 
dependent on the difference in pH of between lysosome and extracellular 
medium (data not shown). While the pH of the medium bathing the target cells is 
expected to be rather constant, the pH surrounding an intestinal epithelial cell is 
expected to vary along the intestinal tract [35].  To test if this variation would lead 
to major differences in the observed trends, we decided to test the extent to 
which the calculated chemical space occupied by selectively lysosomotropic 
molecules was affected by variation in the apical pH of non-target cells (Figure 
3.7). We note that for selectively lysosomotropic molecules with negligible 
(Figure 3.7 A), low (Figure 3.7 B), and high (Figure 3.7 C) permeability, the 
theoretical physicochemical property space occupied by selectively 
lysosomotropic molecules is similar, and the reference molecules that fall into 
that region of chemical space tend to be the same.  Similarly, other regions of 
physicochemical property space occupied with molecules of different 
permeability tend to be similar, with variations in the apical pH of the intestinal 
epithelial cell in a pH range of 4.5 to 6.8 (data not shown).   
 
Discussion 
Modeling the cellular pharmacokinetics of monobasic amines. Over the 
past few years, mathematical models of cellular pharmacokinetics have been 
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developed, based on coupled sets of differential equations capturing the 
transmembrane diffusion of small molecules.  Previously, these models have 
been used to simulate the intracellular distribution of lipophilic cations in tumor 
cells [25], and the distribution and passage of small molecules across intestinal 
epithelial cells [24].  For a monovalent weakly acidic or weakly basic small 
molecule drug, three input physical-chemical properties are used to simulate 
cellular drug transport and distribution: the logarithms of the lipid/water partition 
coefficient of the neutral form of the molecule (logPn) and ionized form (logPd), 
and the negative logarithm of the dissociation constant of the ionizable group 
(pKa). For monovalent weak bases, the transcellular permeability values 
calculated with this approach were comparable with measured human intestinal 
permeability and Caco-2 permeability, yielding good predictions [24]. Similarly, 
the corresponding mathematical models were able to predict mitochondrial 
accumulation of lipophilic cationic substances in tumor cells [22, 25].  
For analyzing the lysosomotropic behavior of monovalent weak bases 
possessing an amine functionality, we adapted these two mathematical models 
to simulate the cellular pharmacokinetic behavior of target cells exposed to a 
homogeneous extracellular drug concentration, and non-target cells mediating 
drug absorption in the presence of an apical-to-basolateral concentration 
gradient. The results we obtained establish a baseline, expected concentration of 
small drug-like molecules in mitochondria, lysosomes and cytosol of target cells, 
as well as permeability in non-target cells. With a reference set of small 
molecules, the simulations permit exploration of the relationship between 
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physicochemical properties of the molecules, their calculated intracellular 
distributions and transport behavior, and the observed cellular phenotypes.   
Simulation-based analysis and classification of lysosomotropic 
behavior. By analyzing the intracellular distribution and transcellular transport 
characteristics of a reference set of molecules, together with more general 
physicochemical space plots covering all possible combinations of pKa, logPn and 
logPd, sixteen a priori classes of lysosomotropic behavior for monobasic amines 
were defined (Table 3.1). However, we noted that several of these classes are 
deemed to be non-existent by the simulations –meaning that there is no 
combination of pKa, logPn and logPd that will yield a molecule in such a class. For 
other classes, it was not possible to find a molecule in the reference set of 
lysosomotropic molecules whose calculated properties would lie within the 
physicochemical property space defining the hypothetical class of molecules. 
This is certainly the case for positively-identified, non-lysosomotropic molecules. 
These results argue for expanding the reference set of monovalent, weakly basic 
molecules, so as to represent all possible classes of intracellular transport 
behaviors.  
An equally important observation from the simulation resides in the tight 
clustering of the reference molecules in constrained regions of physicochemical 
property space, in relation to the simulated physicochemical property space that 
is actually available for molecules in the different lysosomotropic and 
permeability categories.  Thus, the diversity of lysosomotropic behaviors 
represented by the reference set of molecules is rather limited. Indeed, the 
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simulations indicate that expanding the reference set of molecules to unexplored 
regions of physicochemical property space could be used to find molecules that 
better represent the different types of cellular pharmacokinetic behaviors. For 
example, in the case of low or high permeability molecules that are selectively 
lysosomotropic, most of the molecules in the reference set are clustered at the 
high levels of pKa and high logP, whereas the simulations indicate that it should 
be possible to find molecules with lower pKa and lower logPs.  The reason for 
the limited chemical diversity of reported lysosomotropic molecules is related to 
the choice of molecules that have been tested experimentally and reported in the 
literature:  the emphasis has not been on the probing the chemical diversity of 
lysosomotropic character, but rather, in analyzing the lysosomotropic character in 
a related series of compounds (for example, studies looking at mono, bi, and tri-
substituted amines, functionalized with various aliphatic groups [9]).  In other 
cases, the emphasis has been on studying the lysosomotropic character of a 
specific type of compound developed against a specific drug target [6] (for 
example, beta-adrenergic receptor antagonists such as propranolol, atenolol, 
practolol, etc), rather than on the full chemical space occupied by lysosomotropic, 
monvalent weakly basic amines.  
Further experimental validation and testing of expected transport 
behaviors. Using lysosomal swelling, cell vacuolation and intralysosomal pH 
measurements as phenotypic read outs, it may be possible to test the model‟s 
quantitative prediction about the varying extent of lysosomal accumulation of 
monovalent weak bases as a function of the molecule‟s chemical structure or 
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physicochemical properties.  For example, our model makes quantitative 
predictions about the lysosomal concentration of molecules of varying chemical 
structure. Previous studies looking at the lysosomotropic behavior of various 
molecules have reported differences in vacuolation induction for different probes, 
at extracellular drug concentrations ranging from high millimolar to micromolar 
range [10, 13, 16].  Also, for some molecules vacuolation occurs after less than 
an hour incubation, while for other probes vacuolation occurs after twenty-four 
hour incubation, or longer [6, 9, 10, 13, 14, 16]. Combinatorial libraries of 
fluorescent molecules are available today [36, 37], offering yet another way to 
test predictions about the intracellular accumulation and distribution of probes. 
Furthermore, with organelle-selective markers and kinetic microscopic imaging 
instruments, the rate and extent of swelling of lysosomes and other organelles 
could be monitored dynamically after exposure of cells to monovalent weakly 
basic molecules [37]. For such studies, cheminformatic analysis tools are being 
developed to relate the intracellular distribution of small molecules as apparent in 
image data, with chemical structure and physicochemical features of the 
molecules, and the predicted subcellular distribution [38, 39]. Lastly, more 
quantitative assessments of model predictions can be made by directly 
monitoring the total intracellular drug mass [40, 41], as well as drug mass 
associated with the lysosomal compartment [20, 42, 43]. Recently, methods are 
being developed to rapidly isolate the lysosomes and measure intralysosomal 
drug concentrations [43].   
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To test model predictions about the lysosomotropic behavior of small 
molecules in the presence of an apical-to-basolateral concentration gradient, 
various in vitro cell culture models have been developed to assess drug intestinal 
permeability and oral absorption [44]. These are Caco-2, MDCK, LLC-PK1, 
2/4/A1, TC-7, HT-29, and IEC-18 cell models [44]. Among those models Caco-2 
(human colon adenocarcinoma) cell monolayer is the most well-established cell 
model and has been widely accepted by pharmaceutical companies and 
academic research groups interested in studying drug permeability 
characteristics [44]. In addition to Caco-2 cells, MDCK (Madin-Darby canine 
kidney) is a dog renal epithelia cell line and is another widely used cell line in 
studying cell permeability characteristics [45].  
Towards a computer-aided design of organelle-targeted molecules: 
implications for drug discovery and development. The ability to rationally 
tailor the transcellular permeability and subcellular distribution of monobasic 
amines can have important applications in medicinal chemistry efforts aimed at 
enhancing the efficacy of small molecules against specific targets, decreasing 
non-specific unwanted interactions with non-intended targets that lead to side 
effects and toxicity, as well as enhancing transcellular permeability for 
maximizing tissue penetration and oral bioavailability.  For many FDA approved 
drugs, lysosomal accumulation of the molecules would appear to be a non-
specific effect of the molecule‟s chemical structure.  For example, in the case of 
the beta-adrenergic receptor antagonists like propranolol, the drug‟s target is a 
cell surface receptor located at the plasma membrane.  Thus, lysosomal (and 
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any other intracellular) accumulation observed for this molecule is most likely an 
unintended consequence of its chemical structure [2, 6, 15, 16, 43, 46].  In 
general, due to the abundance of lysosomotropic drugs [6, 9, 10, 16], lysosomal 
accumulation seems to be tolerated, although it may not be a desirable property.  
Nevertheless, there are certain classes of therapeutic agents were 
lysosomal accumulation may be highly desirable.  For example, Toll-like receptor 
molecules are transmembrane proteins in the lysosomes of leukocytes (dendritic 
cells and macrophages). These receptors can be activated by endocytosed 
proteins, DNA and carbohydrates, and they generate inflammatory responses as 
part of the innate immune system [47, 48].  Small molecule agents that either 
block or activate Toll-like receptors are being sought to inhibit inflammatory 
reactions (associated with autoimmune diseases) or promote resistance against 
viral infections, respectively [49, 50].  A different class of molecules where 
lysosomal accumulation would be highly desirable involves agents that affect 
lysosomal enzymes involved in tissue remodeling [51]. Tissue remodeling is the 
basis of diseases like osteoporosis, which involves the loss of bone mass due to 
an imbalance in the rate of bone deposition and bone resorption.   
From the simulations, mitochondria also appear as an important site of 
accumulation of  monobasic amines – even for many molecules that have been 
previously classified as being “lysosomotropic”.  Our simulation results indicate 
that monovalent weak bases can selectively accumulate in mitochondria at very 
high levels –in fact, at much higher levels than they appear to be able to 
accumulate in lysosomes.  From a drug toxicity standpoint, unintended 
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accumulation of small molecules in mitochondria can interfere with mitochondrial 
function, leading to cellular apoptosis [52-54]. Conversely, intentional targeting of 
small molecule therapeutic agents to mitochondria can be a desirable feature for 
certain classes of drugs:  mitochondria dysfunction can cause a variety of 
diseases, so there is great interest in developing mitochondriotropic drugs [22, 
55-57].  
Nevertheless, perhaps the most important classes of subcellularly-targeted 
molecules are those that are aimed at extracellular domains of cell surface 
receptors [24].  Many „blockbuster‟ drugs in the market today target cell surface 
receptors, ion channels, and other extracellular enzymes, making extracellular 
space one of the most valuable sites-of-action for drug development [58].  
Extracellular-acting therapeutic agents include anticoagulants that interfere with 
clotting factors in the blood, agents that interfere with pro-hormone processing 
enzymes, ion channel blockers for treating heart conditions, GPCR antagonists 
for hypertension, inflammation and a variety of other different conditions, and 
many CNS-active agents that act on neurotransmitter receptors, transport and 
processing pathways. In order to target extracellular domains of blood proteins, 
cell surface receptors and ion channels, it is desirable that a molecule would 
have high transcellular permeability to facilitate absorption and tissue penetration. 
In addition, it would be desirable that the molecule would also have low 
intracellular accumulation so as to maximize extracellular concentration.  The 
simulation results indicate that indeed, finding monovalent weak bases with high 
permeability and low intracellular accumulation in both target and non-target cells 
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is possible, with several molecules in the reference set residing in this realm of 
physicochemical property space.  
To conclude, cell based molecular transport simulators constitute a 
promising cheminformatic analysis tool for analyzing the subcellular transport 
properties of small molecule drugs.  The ability to combine results from different 
models, visualize simulations representing hundreds of thousands of different 
combinations of physicochemical properties, and relate these simulation results 
to the chemical structure and phenotypic effects of specific drugs and small drug-
like molecules adds a new dimension to the existing mathematical models.  As 
related to the specific class of lysosomotropic monobasic amines analyzed in this 
study, interactive visualization of simulation results point to a richness in 
subcellular transport and distribution behavior that is otherwise difficult to 
appreciate.  We anticipate that the complexity of subcellular transport behaviors 
will ultimately be exploited in future generations of small molecule drug 
candidates “supertargeted” to their sites of action [59], be it in the extracellular 
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Table 3.1.  The reference set of ninety-nine lysosomotropic monobasic 
amines. Based on simulation results, compounds were classified by permeability 
(Peff  calculated with the R-model) and subcellular concentrations (calculated with 
the T-model) as follows: Low permeability: Peff  < 35×10
-6 cm/sec; High 
permeability: Peff ≥ 35×10
-6 cm/sec; Lyso: ClysoT > 2 mM; Mito: CmitoT > 2 mM; 
Cyto: CcytoT ≥ 2mM; Non-lyso: ClysoT < 2 mM; Non-mito: CmitoT < 2 mM; Non-
cyto: CcytoT < 2mM.  Compounds appear in gray background if they were 
reported as non-lysosomotropic in pubished research articles; in italics if they are 
calculated as selective lysosomotropic (ClysoT ≥ 2mM; ClysoT/CmitoT ≥ 2mM;  
ClysoT/CcytoT ≥ 2mM), underlined if they are calculated as selectively 














Category 1: Low Permeability, Non-lyso, Mito, Non-cyto Chemical space exists.    
Category 2: Low Permeability, Non-lyso, Non-mito, Non-cyto Chemical space exists.   
Category 3: Low Permeability, Non-lyso, Non-mito, Cyto     Chemical space does not exist.   
Category 4: Low Permeability, Non-lyso, Mito, Cyto   Chemical space exists.   
            
Category 5: Low Permeability, Lyso, Mito, Non-cyto Chemical space exists.      
Category 6: Low Permeability, Lyso, Non-mito, Non-cyto  Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT Ref. 
Lidocaine 7.2 2.71 1.16 0.15 0.06 1.74 26.67 1.87 0.81 22.26 [10] 
Category 7: Low Permeability, Lyso, Non-mito, Cyto  Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-DMAG 7.31 2.46 0.87 0.15 0.06 1.69 13.01 2.05 0.81 22.73 [60] 
β-dimethylaminoethylchloride 7.63 2.48 0.9 0.23 0.08 1.5 11.76 2.64 0.91 17.52 [21] 
Diethylaminoethyl chloride 8.16 2.71 1.16 0.53 0.24 1.36 19.93 3.83 1.72 9.87 [21] 
Triethanolamine 8.14 1.52 -0.18 0.4 0.14 1.39 0.91 3.57 1.25 12.35 [21] 
Category 8: Low Permeability, Lyso, Mito, Cyto   Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-DMAP 8.3 2.47 0.89 0.62 0.31 1.35 10.79 4.17 2.08 9.07 [60] 
2-amino-1-butanol 9.49 2.04 0.55 1.67 9.57 1.29 5.84 10.16 58.1 7.82 [21] 
2-amino-2-methyl-1,3-propanediol 9.14 1.56 0 1.44 3.32 1.3 1.58 8.01 18.52 7.22 [21] 
2-amino-2-methyl-1-propanol 9.68 1.92 0.41 1.73 14.32 1.29 4.27 10.85 89.76 8.06 [21] 
2-aminoethanol(ethanolamine) 9.22 1.75 0.22 1.51 4.42 1.29 2.66 8.62 25.18 7.36 [21] 
2-diethylaminoethanol 9.22 2.23 0.62 1.46 3.58 1.29 6.62 8.19 20.09 7.27 [21] 
2-dimethylamino-2-methyl-1-
propanol 9.25 2.17 0.55 1.47 3.76 1.29 5.65 8.31 21.23 7.3 [21] 
2-dimethylaminoethanol 8.71 2.01 0.37 0.96 0.81 1.32 3.42 5.44 4.56 7.46 [21] 
2-methylaminoethanol 9.46 1.89 0.32 1.63 7.29 1.29 3.41 9.67 43.34 7.66 [21] 
3-amino-1-propanol 9.49 1.77 0.24 1.66 8.67 1.29 2.85 9.99 52.26 7.76 [21] 
 
 
3-aminopropanal 9.14 1.77 0.24 1.46 3.6 1.29 2.76 8.17 20.17 7.25 [61] 
3-dimethylamino-1-propanol 8.83 2.03 0.39 1.08 1.13 1.31 3.66 5.98 6.25 7.23 [21] 
4-amino-1-butanol 9.55 1.92 0.41 1.69 10.52 1.29 4.24 10.34 64.43 7.88 [21] 
Ammonia 8.55 1.81 0.41 1.05 1.08 1.31 3.8 5.67 5.82 7.08 [21] 
Atenolol 9.32 2.29 0.76 1.57 5.7 1.29 9.32 9.15 33.13 7.5 [6] 
Atropine 9.02 2.67 1.23 1.44 3.36 1.3 26.87 7.98 18.66 7.18 
[10], 
[16] 
Benzylamine 9.17 2.58 1.24 1.6 6.38 1.29 28.25 9.32 37.22 7.52 [10] 
Butylamine 9.84 2.39 0.95 1.78 24.35 1.28 14.95 11.54 157.56 8.31 [21] 
Diethylamine 10.2 2.36 0.84 1.82 45 1.28 11.68 12.09 298.98 8.53 
[10], 
[21] 
Dimethylamine 10.15 2.13 0.59 1.81 38.7 1.28 6.56 11.98 255.81 8.48 [21] 
Ethylamine 9.86 2.11 0.62 1.78 22.73 1.28 6.99 11.46 146.61 8.28 [21] 





Hexylamine 9.84 2.66 1.24 1.79 25.48 1.28 29.17 11.59 165.24 8.33 [21] 
Isobutylamine 9.87 2.4 0.95 1.79 25.47 1.28 14.96 11.59 165.19 8.33 [21] 
Isopropanolamine 9.26 1.89 0.38 1.55 5.16 1.29 3.87 8.94 29.72 7.44 [21] 
Isopropylamine 10.06 2.25 0.78 1.81 37.09 1.28 10.16 11.95 244.64 8.47 [21] 
Methylamine 9.72 2 0.5 1.74 16.1 1.29 5.27 11.02 101.71 8.12 [21] 
Metoclopramide 8.73 2.56 0.99 1.05 1.06 1.31 14.48 5.81 5.82 7.22 
[14], 
[13] 
Morpholine 8.21 2.02 1.25 1.36 2.95 1.3 27.55 6.62 14.36 6.31 [10] 
N-acetylprocainamide 8.73 2.51 0.93 1.04 1.02 1.31 12.59 5.76 5.66 7.25 
[10],[
13] 
NAMA 8.72 2.38 0.79 1.02 0.97 1.31 9.09 5.68 5.36 7.29 [14] 
N,N-Dimethyl-3-chloropropylamine 8.38 2.5 0.92 0.69 0.38 1.34 11.66 4.41 2.45 8.54 [21] 
N,N-dimethyl-benzylamine 8.67 2.84 1.3 1.02 0.98 1.31 29.42 5.65 5.4 7.25 [10] 
Pentylamine 9.84 2.53 1.09 1.78 24.35 1.28 20.64 11.54 157.56 8.31 [21] 
Practolol 9.32 2.47 0.97 1.59 6.15 1.29 15.16 9.3 35.98 7.54 [6] 
Propylamine 9.85 2.27 0.8 1.78 23.26 1.28 10.58 11.49 150.19 8.29 [21] 
s-butylamine 10.07 2.4 0.95 1.81 39.59 1.28 15.03 12 261.77 8.49 [21] 
t-butylamine 10.27 2.27 0.81 1.83 59.14 1.28 10.92 12.26 395.97 8.59 [21] 




Trimethylamine 9.23 2.25 0.64 1.47 3.67 1.29 6.94 8.25 20.66 7.28 [10] 
Tris(hydroxymethyl)methylamine 8.64 1.2 -0.4 0.93 0.75 1.32 0.58 5.29 4.25 7.51 
[10],  
[21] 
Category 9: High Permeability, Non-lyso, Mito, Cyto  Chemical space does not exist. 
Category 10: High Permeability, Non-lyso, Non-mito, Cyto Chemical space does not exist.  
Category 11: High Permeability, Non-lyso, Mito, Non-cyto   Chemical space exists. 
Category 12: High Permeability, Non-lyso, Non-mito, Non-cyto Chemical space exists.  
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
3-aminoquinoline 4.63 2.65 2.00 0.73 0.73 1.12 398.87 0.82 0.82 1.25 [1] 
8-aminoquinoline 4.07 2.65 2.00 0.78 0.78 0.90 425.43 0.81 0.81 0.94 [1] 
AF-CX1325XX 1.95 2.18 0.7 0.8 0.8 0.8 148 0.81 0.81 0.81 [62] 
Aniline 4.5 2.62 1.2 0.73 0.73 1.1 372.35 0.82 0.81 1.22 [10] 
Benzocaine 2.7 2.78 1.41 0.8 0.8 0.8 588.46 0.81 0.81 0.82 [13] 
β-naphthylamine 4.12 2.95 1.57 0.77 0.77 0.93 838.56 0.81 0.81 0.98 [10] 
Pyrimidine 1.55 2.17 1.4 0.8 0.8 0.8 144.65 0.81 0.81 0.81 [10] 
Pyridine 4.95 2.44 1.88 0.69 0.69 1.3 229.69 0.82 0.82 1.56 [10] 
            
Category 13: High Permeability, Lyso, Non-mito, Non-cyto  Chemical space exists. 
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-AEP 6.59 2.56 0.99 0.14 0.09 2.43 37.31 1.17 0.80 20.89 [60] 
1-aminoisoquinoline 6.88 2.74 1.94 0.36 0.30 1.45 123.44 1.53 1.28 6.16 [1] 
1-dodecylimidazole 6.56 3.65 3.3 0.64 0.81 1.36 2615.12 1.27 1.61 2.7 [21] 
Eserine 6.46 3.03 1.51 0.15 0.11 2.51 137.8 1.09 0.81 17.74 [10] 
Harmine 5.95 2.81 2.06 0.38 0.36 1.82 265.16 0.91 0.88 4.40 [1] 
Imidazole 6.73 2.12 1.59 0.51 0.56 1.39 52.47 1.41 1.53 3.81 [21] 
Papaverine 6.07 3.1 2.39 0.37 0.35 1.72 489.43 0.94 0.91 4.42 [1] 
Pilocarpine 6.39 2.38 1.89 0.48 0.51 1.44 109.54 1.1 1.18 3.32 [10] 
s-Collidine 7.06 2.71 1.71 0.3 0.2 1.47 74.19 1.76 1.18 8.61 [21] 




Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
Cyproheptadine 7.77 3.67 2.23 0.35 0.14 1.41 235.81 3.02 1.22 12.12 [63] 
Diltiazem 7.89 3.08 1.57 0.37 0.14 1.4 51.38 3.23 1.25 12.07 [16] 
N-dodecylmorpholine 7.5 3.58 2.14 0.24 0.1 1.49 203.16 2.44 0.98 15.24 [21] 
Category 15: High Permeability, Lyso, Mito, Non-cyto   Chemical space exists.     
Category 16: High Permeability, Lyso, Mito, Cyto   Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
4-aminopyridine 8.63 2.18 1.59 1.71 11.8 1.29 64.2 9.96 68.73 7.5 [10] 
4-aminoquinaldine 8.5 2.7 1.82 1.49 4.21 1.29 104.97 7.87 22.31 6.85 [10] 
4-aminoquinoline 7.98 2.65 2.00 1.29 2.56 1.30 152.07 5.73 11.40 5.79 [1] 
4-Dimethylaminopyridine 8.47 2.53 1.98 1.67 9.26 1.29 156.25 9.28 51.49 7.16 [10] 
9-aminoacridine 8.97 3.11 2.4 1.76 18.6 1.28 419.24 10.96 115.66 7.99 [10] 
Alprenolol 9.32 3.04 1.71 1.67 9.42 1.29 84.41 10.09 56.88 7.77 [6] 
Amantadine 10.33 2.57 2.04 1.86 288.64 1.28 186.33 12.73 1973.95 8.77 [16] 
Amiodarone 8.17 4.58 3.38 0.88 0.74 1.32 3439.62 4.69 3.96 7.07 [4] 
Amitriptyline 9.41 3.7 2.27 1.67 9.14 1.29 306.28 10.07 55.23 7.78 [64] 
Biperiden 8.97 3.25 1.76 1.36 2.57 1.3 89.81 7.43 14.07 7.1 [65] 




Chlorpromazine 8.87 3.7 2.27 1.33 2.33 1.3 288.89 7.19 12.66 7.05 [16] 
Desipramine 9.66 3.4 2.01 1.76 18.13 1.29 170.9 11.17 115.25 8.17 [12] 
Dibutylamine 10.36 2.93 1.48 1.84 72.43 1.28 51.13 12.37 487.37 8.63 [21] 
Dihydroalprenolol 9.32 3.11 1.69 1.63 7.53 1.29 80.09 9.69 44.73 7.65 [7] 
Dizocilpine 8.3 3.29 1.89 0.80 0.55 1.33 110.20 4.61 3.18 7.70 [67] 
Dodecylamine 9.84 3.44 2.12 1.8 31.89 1.28 221.84 11.8 208.84 8.41 [21] 
Ephedrine 9.19 2.63 1.94 1.8 31.41 1.28 146.48 11.65 202.78 8.29 [10] 
Fluoxetine 9.45 3.58 3.01 1.84 69.46 1.28 1731.76 12.27 463.16 8.55 
[4], 
[23] 
Imipramine 8.87 3.52 2.07 1.31 2.21 1.3 181.73 7.09 11.95 7.04 [4] 
Iprindole 9.36 3.54 2.09 1.64 7.71 1.29 201.32 9.74 45.89 7.67 [66] 




Memantine 10.31 2.85 1.46 1.84 73.92 1.28 48.83 12.38 497.49 8.63 [11] 
Octylamine 9.84 2.92 1.53 1.79 27.27 1.28 56.92 11.66 177.38 8.35 [21] 
Perhexiline 10.2 3.83 3.28 1.86 244.79 1.28 3237.19 12.7 1671.65 8.76 
[4], 
[68] 
Phentermine 10.25 2.83 1.43 1.83 64.21 1.28 45.54 12.31 430.76 8.61 [66] 
Piperidine 10.03 2.37 1.64 1.85 148.62 1.28 74.09 12.6 1009.79 8.71 [10] 
Promazine 8.87 3.53 2.08 1.31 2.21 1.30 185.96 7.09 11.95 7.04 [64] 
Propranolol 9.32 3.03 1.59 1.62 7.16 1.29 63.51 9.59 42.38 7.62 [10] 
Sertraline 9.5 3.85 2.51 1.73 14.07 1.29 537.84 10.79 87.84 8.02 [64] 
Thioridazine 8.61 4.01 2.61 1.11 1.27 1.31 608.81 5.96 6.80 7.02 [64] 
Tributylamine 10.44 3.45 2.1 1.85 102.49 1.28 213.44 12.51 694.01 8.68 [10] 





Figure 3.1.  Diagrams showing the cellular pharmacokinetic phenomena 
captured by the two mathematical models used in this study: the T-Model 
of a leukocyte-like cell in suspension (A) and the R-Model an epithelial-like 
cell (B).  Key:  ap: apical compartment; bl: basolateral compartment; cyto: 
cytosol; mito: mitochondria; lyso: lysosome; R1: flux of the ionized/unionized form 
between the cytosol and the apical compartment; R2: flux of the 
ionized/unionized form between the cytosol and the basolateral compartment; R3: 
flux of the ionized/unionized form between the cytosol and the lysosome; R4: flux 
of the ionized/unionized form between the cytosol and the mitochondria; T1: flux 
of the ionized/unionized form between the cytosol and the extracellular 
compartment; T2: flux of the ionized/unionized form between the cytosol and 



















Figure 3.2.  Visualizing the simulated physicochemical property space 
occupied by lysosomotropic monobasic amines. Individual molecules in the 
reference set are indicated by yellow dots.  To discriminate between 
lysosomotropic vs. non-lysosomotropic molecules, three lysosomal concentration 
were explored as thresholds: 2 mM (A-D); 4 mM (E-H); and 8 mM (I-L). Columns 
show non-lysosomotropic molecules (A, E, I); non-lysosomotropic molecules plus 
lysosomotropic space (B, F, J); lysosomotropic molecules (C, G, K); and 




















Figure 3.3. Visualizing the simulated physicochemical property space 
occupied by selectively lysosomotropic monobasic amines.  Individual 
molecules in the reference set are indicated by yellow dots   The four graphs 
show: A) non-lysosomotropic molecules (inside blue circle) and non-selective 
lysosomotropic molecules (outside blue circle); B) selectively lysosomotropic 
molecules (inside green circle); C) physicochemical property space occupied by 
selectively lysosomotropic molecules, in relation to non-lysosomotropic 
molecules (inside blue circle) and non-selective lysosomotropic molecules 
(outside blue circle); D) selectively lysosomotropic molecules (yellow dots in  
green circle) in relation to the union of non-selective lysosomotropic and non-















Figure 3.4.  Visualizing the effect of transcellular permeability on selectively 
lysomotropic molecules. Individual molecules in the reference set are indicated 
by yellow dots   The six graphs show: A) physicochemical property space 
occupied by molecules with Peff < 1 x 10
-6 cm/s, in relation to non-selectively, 
lysosomotropic reference molecules; B) selectively lysosomotropic molecules 
with Peff < 1 x 10
-6 cm/s (yellow dots) in relation to the union of physicochemical 
property spaces occupied by non-selectively lysosomotropic, non-lysosomotropic, 
and selectively lysosomotropic molecules with Peff > 1 x 10
-6 cm/s; C) 
physicochemical property space occupied by molecules with 1 x 10-6  cm/s < Peff 
< 35 x 10-6 cm/s, in relation to non-selectively lysosomotropic molecules; D) 
selectively lysosomotropic molecules with 1 x 10-6  cm/s < Peff < 35 x 10
-6 cm/s  in 
relation to the union of physicochemical property spaces occupied by non-
selectively lysosomotropic, non-lysosomotropic, and selectively lysosomotropic 
molecules excluding those with 1 x 10-6  cm/s < Peff < 35 x 10
-6 cm/s; E) 
physicochemical property space occupied by molecules with Peff > 35 x 10
-6 cm/s, 
in relation to non-selectively, lysosomotropic molecules;  F) selectively 
lysosomotropic molecules with Peff > 35 x 10
-6 cm/s in relation to the union of 
physicochemical property spaces occupied by non-selectively lysosomotropic, 
non-lysosomotropic, and selectively lysosomotropic molecules with Peff < 35 x 10
-
6 cm/s;  Green arrow point to the general region of physicochemical property 
























Figure 3.5. Visualizing the simulated physicochemical property space 
occupied by molecules with low intracellular accumulation and high 
permeability. Individual molecules in the reference set are indicated by yellow 
dots   The three graphs show: A) reference molecules with low intracellular 
accumulation and high permeability (inside green circle); B) physicochemical 
property space occupied by molecules with calculated low intracellular 
accumulation and high permeability (green circle same as in A); C) the simulated 
physicochemical  property space occupied by molecules with high intracellular 

































Figure 3.6.  Visualizing the simulated physicochemical property space of 
various classes of non-selective, lysosomotropic molecules. Individual 
molecules in the reference set are indicated by yellow dots   The four graphs 
show: A) fifty six selectively mitochondriotropic reference molecules; B) 
seventeen lysosomotropic, reference molecules which are not selective in terms 
of lysosomal, mitochondrial or cytosolic accumulation; C) the simulated 
physicochemical property space occupied by lysosomotropic molecules that are 
also selectively mitochondriotropic; D) the simulated physicochemical property 















Figure 3.7.  Visualizing the effect of extracellular pH on physicochemical 
property space occupied by selectively-lysosomotropic molecules. 
Simulations were carried out using an apical pH of 4.5 (A-C) and 6.8 (D-F) in the 
R-Model. Yellow dots indicate the individual molecules in the reference set.  
Each row shows the physicochemical property space occupied by molecules in 
different permeability classes, as follows: A and D) Peff < 1 x 10
-6 cm/s; B and E) 
1 x 10-6  cm/s < Peff < 35 x 10
-6 cm/s, C and F) Peff > 35 x 10
-6 cm/s. 
 





The Intracellular Accumulation of Chloroquine:  




In vivo, the weakly basic, lipophilic drug chloroquine (CQ) accumulates in the 
kidney to concentrations more than thousand-fold greater than in plasma. To 
study the cellular pharmacokinetics of chloroquine in cells derived from the distal 
tubule, Madin-Darby Canine Kidney (MDCK) cells were incubated with CQ under 
various conditions. CQ progressively accumulated without exhibiting steady state 
behavior. Experiments failed to yield evidence that known active transport 
mechanisms mediated CQ uptake at the plasma membrane. CQ induced a 
phospholipidosis-like phenotype, characterized by the appearance of numerous 
multivesicular and multilamellar bodies (MLB/MVBs) within the lumen of 
expanded cytoplasmic vesicles.  Other induced phenotypic changes including 
changes in the volume and pH of acidic organelles were measured, and the 
integrated effects of all these changes were computationally modeled with a cell 
based pharmacokinetics simulator, to establish their impact on intracellular CQ 
mass accumulation. Based on CQ’s passive transport behavior, the measured 
phenotypic changes fully accounted for the continuous, non-steady state CQ 
accumulation kinetics.  Consistent with the simulation results, Raman confocal 
123 
 
microscopy of live cells confirmed that CQ became highly concentrated within 
induced, expanded cytoplasmic vesicles that contained multiple MLB/MVBs.  
Progressive CQ accumulation was increased by sucrose, a compound that 
stimulated the phospholipidosis-like phenotype, and was decreased by 
bafilomycin A1, a compound that inhibited this phenotype.  Accordingly, 
phospholipidosis-associated changes in organelle structure and intracellular 
membrane content can exert a major influence on the local bioaccumulation and 
biodistribution of drugs.  
 
Keywords: epithelial cells; biodistribution; mathematical models; organelle 
















Xenobiotics can accumulate and reach very high concentrations in specific 
sites of the body due to active transport across cellular membranes, binding and 
partitioning into cellular components, or sequestration within organelles driven by 
pH gradients and trans-membrane electrical potentials present across 
phospholipid bilayers.  For example, more than thirty years ago, DeDuve 
discovered that weakly basic molecules would accumulate within lysosomes by 
an ion trapping mechanism [1].  Ion trapping arises when a phospholipid bilayer 
separates two compartments of different pH levels. Under these conditions, basic 
membrane permeant lipophilic molecules become protonated and charged 
preferentially in the acidic compartment. Because of the lowered membrane 
permeability of the charged form of the molecule, the molecule becomes 
concentrated in the acidic compartment. Since then, many weakly basic, 
lipophilic small molecules have been reported to be sequestered within 
lysosomes or other acidic, membrane-bound intracellular compartments, through 
passive ion trapping [2-4].  
  However, detailed mass measurements have revealed that DeDuve’s 
classical ion trapping mechanism often underestimates the extent of 
sequestration of many weakly basic compounds within acidic endolysosomal 
organelles [5, 6].  In fact, intracellular accumulation of weak bases may also be 
explained by active transport mechanisms or by the many concomitant changes 
in endolysosomal organelle structure and function, including alterations in pH and 
changes in membrane traffic leading to the formation of endolysosomal 
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organelles with unique membrane characteristics [7, 8].  In some cell types, 
exposure to lipophilic weak bases induces a peculiar phenotype, 
“phospholipidosis” [9], characterized by the formation of numerous, 
phospholipids- and cholesterol-rich multivesicular and multilamellar bodies 
(MLB/MVBs). Physiologically, MLB/MVBs are late endosomal compartments that 
normally form as a result of the activation of the ubiquitin-dependent membrane 
protein sorting and degradation pathway [10-12].   
Previously, we developed a computational model of cell pharmacokinetics to 
predict the intracellular accumulation and transcellular transport properties of 
small molecules across cell monolayer [6, 13]. Using the weakly dibasic, high 
solubility drug chloroquine (CQ, pKa1 = 9.96 and pKa2 = 7.47) as a test 
compound, the model was capable of capturing the transcellular transport 
kinetics for the first four hours of drug treatment but underestimated the 
intracellular accumulation beyond the first five minutes of incubation [6]. 
Experimentally, the initial rate of transport of CQ across cell monolayer was 
directly proportional to initial concentrations in donor compartment. Also transport 
of CQ across MDCK monolayer in the presence of a transcellular concentration 
gradient was similar in both apical-to-basolateral and basolateral-to-apical 
directions. No saturation or nonlinear kinetics were observed at CQ 
concentrations < 500 M, as expected from a passive transport mechanism [6].  
Here, we present an alternative hypothesis to explain CQ accumulation: that  
drug-induced phospholipidosis corresponds to an inducible, weak base 
disposition system – a mechanism promoting CQ sequestration within cells.  We 
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performed a detailed quantitative analysis of CQ pharmacokinetics in Madin-
Darby Canine Kidney (MDCK) cells, a cell line that stably expresses the 
differentiated properties of distal tubular epithelial cells [14],  extensively 
accumulates CQ and exhibits a marked phospholipidosis-like response [15] 
corresponding to the phospholipidosis phenotype reported in the kidney cells of 
CQ-treated patients [16]. The potential involvement of active transporters and 
plasma membrane mediated uptake mechanisms was evaluated in the presence 
of extracellular pH changes, sodium-free medium, and organic cation transporter 
inhibitors. 
Although CQ concentration in plasma ranges between 10 to 250 nM [17, 18], 
cells lining the distal tubules are exposed to 10 to 300 M CQ corresponding to 
the concentrations measured in the urine of human subjects [17].  Therefore 
clinically relevant urine concentrations (0-200 M) of CQ were used to mimic the 
physiological conditions of the distal tubule, and used as input parameters in the 
cellular PK model of CQ’s transport behavior. Simulation results were compared 
to experimental measurements of intracellular CQ mass in dose-response and 
time-course experiments, under condition that enhances phospholipidosis effect 
(co-treatment with sucrose [19, 20]) or inhibits vacuolation (co-treatment with 
bafilomycin A1 [21]).  
 
Materials and Methods 
Cell Culture. Madin-Darby canine kidney (MDCK) cells were purchased 
from ATCC (CCL-34TM) and grown in Dulbecco’s modified Eagle’s medium 
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(DMEM, Gibco® 11995) containing 10% FBS (Gibco® 10082), 1X non-essential 
amino acids (Gibco® 11140) and 1% penicillin/streptomycin (Gibco® 15140), at 
37ºC in a humidified atmosphere with 5% CO2. MDCK cells were seeded at a 
density between 1×105-2×105 cells per square centimeter and were grown until 
cell monolayer was formed as suggested by visual inspection.  
Drugs and chemicals. Chloroquine diphosphate (CQ), cimetidine (Cim), 
guanidine (Gua) and tetraethylammonium (TEA) were obtained from Sigma-
Aldrich (Catalog numbers C6628, C4522, G4505 and T2265) and dissolved in 
Dulbecco’s Phosphate-Buffer Saline (DPBS, Gibco® 14190) at a concentration of 
 ℃. Bafilomycin A1 (Baf), hemicholinium-3 (HC3) and 
hydrocortisone (Sigma® B1793, H108 and H0888) were dissolved in DMSO 
(Sigma® D8418) to a final concentration of 5 M (Baf) or 50 mM (HC3 and HCor) 
for storage at -20 ºC. 3-methyladenine (3MA, Sigma® M9281) was dissolved in 
warm DMEM at a concentration of 10 mg/ml immediately before use. FITC-
dextran (FD, Sigma® FD150S) was dissolved in DPBS at a concentration of 10 
mg/ml for storage at 4 ℃. Fluorescent dyes including BCECF-AM, LysoTracker® 
Green (LTG) and Hoechst 33342 (Molecular Probes® B1150, L7526 and H3570) 
were stored according to the manufacturer’s instructions.  
Measurement of LTG fluorescence intensity, distribution and LTG-
labeled organelle volumes. MDCK cells were grown on optical bottom plate or 
chamber glass, subject to various CQ treatment, stained with 0.5 M LTG for 30 
min, and subject to microscopic analysis in situ. A Nikon TE2000S 
epifluorescence microscope with standard mercury bulb illumination, coupled to a 
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CCD camera (Roper Scientific, Tucson, AZ), with a 20X objective ((Nikon Plan 
Fluor ELWD 20x) or a 100X oil immersion objective (Nikon CFI Plan Fluor 100xH 
oil), and a triple-pass DAPI/FITC/TRITC filter set (Chroma Technology Corp. 
86013v2) was used to image the LTG-labeled cells. The 12-bit grayscale images 
were acquired with the FITC channel, and background subtracted. The LTG-
labeled expanded vesicles (or the MLB/MVBs contained within) were manually 
outlined with Circular Region tool in MetaMorph® software (Molecular Devices 
Corporation, Sunnyvale, CA). The volume and surface area of individual vesicles 
was calculated assuming a spherical shape. Fluorescence volume density was 
calculated as Integrated Intensity divided by vesicle volume. The total vesicular 
volume/surface area per cell under each treatment at each time point (0, 1, 2 or 4 
hours) was determined using 10 cells. Contrast and brightness  was adjusted to 
the same level for all figures.  
Raman confocal microscopy of CQ distribution. MDCK cells were 
seeded on cover glass until confluent. CQ-treated cells were exposed 10 M CQ 
for 12 hours, followed by 100 M CQ for 2 hours, and briefly washed in DPBS 
buffer prior to mounting on microscope slides.. The induced Raman spectrum of 
solid CQ salt, 100 mM CQ solution in DPBS, and the vesicular/cytosolic regions 
of the cells under various treatment conditions was acquired with a Renishaw 
inVia confocal Raman microscope coupled with a Nikon CFI Plan Fluor 100xH oil 
immersion objective and a CCD detector. The excitation wavelength was 514 nm. 
The exposure time was 30 sec for each measurement, with spectral resolution 
set to 1.5 cm-1, scanning from 400 cm-1 to 3200 cm-1. All spectra were 
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smoothened, baseline subtracted and normalized to the highest peak with 
ACD/UV-IR Processor (ACD/Labs, Toronto, Canada). To determine the effect of 
pH on  CQ’s Raman spectra, spectra of 100 mM CQ solution in pH 7, 6 and 5 
buffers were also acquired. 
Measurement of lysosomal, cytosolic and extracellular pH. pH 
measurements were performed using published methods [22]. To measure 
lysosomal pH, MDCK cells were incubated with 0.2 mg/ml FD in DMEM for 24 
hours in dark prior to drug treatments. FD-loaded cells were washed twice with 
warm DPBS buffer, incubated in CQ-DMEM with or without Suc or Baf for 1, 2, 3 
or 4 hours. To measure cytosolic pH, BCECF-AM was added to a final 
concentration of 2 g/ml during the last 30 min of drug treatment, in the dark. At 
the end of treatments, cells on plate were washed twice with cold buffer prior to 
ratiometric analysis of the pH-sensitive FD or BCECF-AM fluorescence signal. 
Fluorescence data was acquired with a BioTek SynergyTM 2 Microplate Reader 
using Ex.485/20-Em.528/20 filter set and Ex.450/50-Em.528/20 filter set. 
Background fluorescence was acquired with dye-free untreated cells. Standard 
curves were obtained by first preloading untreated cells with 0.2 mg/ml FD for 24 
hrs or 2 g/ml BCECF-AM for 30 min, then equilibrating with 10 µg/ml nigericin in 
different pH buffer, and finally scanning with the same filter sets as mentioned 











where F485i and F450i standard for integrated fluorescent intensity from the i
th 
well of cells under Ex.485 nm and Ex.450 nm, respectively, and the subscript bg 
indicates background fluorescence. FR values were plotted against known pH 
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values to create a standard curve, or compared with the standard curve to 
calculate pH. Extracellular pH was measured with a Corning pH meter 430 at 
designated time points. The average vesicular pH, cytosolic pH and extracellular 
pH were reported as the mean ± S.D. over a 4-hour incubation period with each 
time point measured from 3 independent experiments.  
Measurement of cell volume. Cells were detached from the tissue culture 
plates after drug treatment by incubating them with 0.25% trypisin-EDTA (Gibco® 
25200) for 15 min. The rounded, detached cells were imaged with Nikon 
TE2000S inverted microscope under brightfield illumination with a 20X objective 
(Nikon CFI Plan Fluor 20x). In the images, the perimeters of the cells were 
manually outlined with Circular Region Tool in MetaMorph® and cell volume was 
calculated from the radius of the outlined perimeter, assuming spherical shape. 
For each treatment, 10 bright field images (more than 100 cells) were collected 
after 1, 2, 3 or 4 hours. The average cell volume was reported as the mean ± S.D. 
over 4 hour treatment.  
Measurement of the cellular partition coefficient of CQ. MDCK cells 
were grown on tissue culture dishes, treated with 50 M CQ for 4 hours to induce 
vacuolar expansion and MLB/MVBs.  After this induction period, the cells were 
permeabilized with 0.1% saponin in DPBS buffer for 30 min to extract soluble 
cellular components while leaving lipids, DNA, and associated, insoluble 
cytoskeletal components.  Permeabilized cells were then incubated with 100 M 
CQ for 1 hour, washed twice and centrifuged. Cellular lipids and associated 
molecules were extracted from the pellet with 1% Triton X-100 in DPBS for 1 
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hour. Nuclei and other insoluble debris were spun down, and the amount of 
extracted CQ in the supernatants was determined by measuring absorbance at 
343 nm using Microplate Reader. Based on electron micrographs, we estimated 
a Triton-extractable, 5% lipid volume fraction in the cell. CQ concentration 
partitioned into the cellular lipid structures was calculated as bound CQ amount 
divided by the estimated lipid volume for the cells.  The lipid partition coefficient 
was calculated as the logarithm of the lipid:buffer CQ concentration ratio.   
Probing the mechanism of CQ uptake with transport inhibitors. To 
study the effect of active cation transporters on CQ uptake, MDCK cells on 24-
well tissue culture plates (Costar® 3526 or NuncTM 165305) were incubated with 
50 M CQ in 0.5 mL bicarbonate-free transport buffer (sodium chloride 140 mM, 
potassium chloride 5.4 mM, calcium chloride 1.8 mM, magnesium chloride 0.8 
mM, d-glucose 25 mM, HEPES 10 mM, pH 5.5, 6.5, 7.4 and 8.5) or  sodium-free, 
choline-based transport buffer (substitute sodium chloride with choline chloride in 
the above transport buffer), at 37 ℃. To study the effect of autophagy, energy 
supply, vacuolar-ATPase, organic cation transporters (OCTs) and pre-expanded 
lysosomal volume on CQ uptake, MDCK cells were incubated in 0.5 mL DMEM 
containing 50 M CQ in the presence or the absence of 10 mg/ml 3MA 
(autophagy inhibitor); 5 M FCCP (mitochondrial uncoupling agent that disrupts 
ATP synthesis and cellular metabolism);  10 nM Baf (vacuolar H+/ATPase 
inhibitor that disrupts endolysosomal pH gradients); 500 M Cim (OCT inhibitor); 
500 M Gua (OCT inhibitor); 500 M HC3 (OCT inhibitor); 500 M TEA (OCT 
substrate/inhibitor); 20 M HCor (a hormone that stimulates OCT expression); or, 
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0.1 M Suc (a treatment that  enhances the phospholipidosis phenotype without 
competing with CQ uptake). Cells co-treated with CQ and sucrose (Suc) or 
hydrocortisone (HCor) were pre-incubated with 0.1 M sucrose  or 20 M 
hydrocortisone in DMEM for 24 hours or 48 hours, respectively, before the 
experiments. CQ uptake was measured 0.5, 5, 15, 30, 60, 120, 180 or 240 min 
after beginning of incubation with CQ, with or without Suc or Baf. CQ uptake was 
measured 30 min and 240 min after the beginning of incubation. For CQ uptake 
measurements, three of the four replicates under the same treatment were briefly 
washed with cold buffer and lyzed in 1% Triton X-100 for 1 hour. The lysates 
were centrifuged at 15,000 rpm for 10 minutes and the supernatant was collected 
for CQ measurement by reading absorbance at 343 nm using Microplate Reader. 
Intracellular CQ mass was normalized by the number of cells per well as 
evaluated by counting cells in the fourth replicate well. Background signal from 0 
M CQ treatment was subtracted and CQ mass was calculated with the aid of a 
standard curve. The results were expressed as mean ± S.E.M from 3 
independent experiments for each time point.  
Measurement of MLB/MVB morphology.  For transmission electron 
microscopy, MDCK cells were grown on tissue culture dish (BD FalconTM 
-free 
DMEM, fixed with 2.5% glutaraldehyde in 0.1 M Sorensen’s buffer at pH 7.4 at 
37 ℃, and washed with 0.1 M Sorensen’s buffer  three times, 5 min each. Cells 
were fixed with 1% osmium tetroxide in 0.1 Sorensen’s buffer for 15 min at room 
temperature and washed three times with double-distilled water. Cells were 
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incubated with 8% uranyl acetate in double-distilled water for 1 hour at room 
temperature, dehydrated in a graded ethanol:water series (50, 70, 90 and 100%, 
5 min each), infiltrated in Epon resin and polymerized at 60 ℃ overnight. Cells 
were sectioned and photographed with a Phillips CM-100 transmission electron 
microscope at magnifications from 2,600 to 96,000X. More than 5 cells were 
photographed for control and treated cells under each condition. Quantitative 
morphological analysis of EM images was performed with MetaMorph® software 
(Molecular Devices, Inc.)  
Mathematical Modeling of CQ Uptake. A multi-compartment, constant-field, 
fixed-parameter mathematical model [23] was adapted to predict the passive, 
membrane potential and pH-dependent ion trapping behavior of CQ in MDCK 
cells. The original model was modified to incorporate the gradual volume 
expansion of the endolysosomal compartment induced by CQ, coupled to 
changes in extracellular concentration accompanying pronounced, intracellular 
CQ sequestration. Briefly, the total change in CQ mass with time in each 
compartment was expressed by equations 1-4: 
   
  
              (1) 
   
  
                                  (2) 
   
  
            (3) 
 
   
  
                                                      (4) 
where, M stands for the total mass, J indicates the flux, A and V indicate the 
membrane surface area and volume, respectively, of the specific subcellular 
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compartments as indicated by the subscripts e, c, m, and l: extracellular 
compartment, cytosol, mitochondria and (acidic) lysosomes compartment. Ac 
indicates the cell’s plasma membrane area. The comma between two subscripts 
means “to” (e.g. “Jc,m” represents the flux from cytosol to mitochondria). With 
extracellular volume, cell volume and mitochondria volume constant and 
lysosomal volume change, the concentration change in each compartment was 
expressed by equations 5-8: 
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For CQ, the total flux is contributed by a neutral form and two ionized forms 
with one or two positive charges [6]. The total flux across membrane as 
contributed by three species can be calculated with Fick’s equation and Nernst-
Planck equation: 
                          
   
      
                
        
   
      
         
        
                   (9) 
where, subscripts o and i indicate outer- and inner-compartment, n, d1, and 
d2 indicate neutral form, ionized form with one charge, and ionized form with two 
charges, respectively. P is the permeability across the bilayer membranes and it 
was estimated based on the logarithm of CQ’s octanol/water partition coefficient 
(logPo/w) calculated with ChemAxon® MarvinSkecth 5.1.4 
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(http://www.chemaxon.com) as                         [23]. f represents the 
ratio of the activities (an, ad1 and ad2) and the total concentration. It can be 
calculated from lipid fraction and ionic strength in each compartment and the 
sorption coefficient for each species as estimated from logPo/w [13, 23] or the 
measured cellular partition coefficient [6]. In equation 4, N = zEF/(RT), where z = 
+1 for Nd1 (ionized base with one charge), and z = +2 for Nd2 (ionized base with 
two charges); E, F, R, and T are membrane potential, Faraday constant, 
universal gas constant, and absolute temperature, respectively. The rate of 
change in vesicular volume was derived by fitting volume measurement at each 
time point with a linear model. When simulating CQ binding to MLB/MVBs, the 
measured cellular partition coefficient of CQ was used to estimate f. The ordinary 
differential equations were numerically solved with MATLAB® ODE15s solver 
using the average value of each parameter to plot a kinetic curve of CQ 
intracellular accumulation. Model validation/consistency check was performed by 
summing CQ mass in all compartments during the simulation, confirming that 
total CQ mass in the system stays constant (mass balance).  
Parameter Sensitivity and Error Propagation Analysis. To determine 
whether variations in individual parameters would lead to a large variation in 
prediction, sensitivity analysis was performed by systemically changing one 
parameter at a time and plotting predictions against parameter values. In addition, 
Monte Carlo simulations were performed to assess the distribution CQ 
accumulation values that would be consistent with uncertainties or experimental 
error of the input parameters. Parameter ranges were obtained based on the 
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error of experimental measurements or variations in the published literature 
reports. MATLAB® ODE15s solver was employed to run 10,000 simulations 
during which simulation parameters were randomly sampled from uniform 
distributions within the range of parameter values (Table 4.2 and Appendix L). 




CQ-treated MDCK cells undergo marked changes in organelle structure 
and membrane organization. Electron microscopy was performed to study the 
effects of CQ on the membrane and organelle structure of MDCK cells during the 
course of a 4 hour incubation period. Most strikingly, CQ induced the formation of 
numerous MLB/MVBs within the lumen of expanded cytoplasmic vesicles (Figure 
4.1).  The expanded vesicles were approximately 1.50 ± 0.34 m (n = 20) in 
diameter.  Within these expanded vesicles there were often many MLBs of 0.42 ± 
0.025 m (n = 10) in diameter and MVBs of 0.39 ± 0.03 m (n = 10) in diameter.  
For MLBs, the spacing between membrane layers ranged from 24.0 to 29.2 nm 
(25.7 ± 2.2 nm) and the apparent thickness of each layer varied from 22.5 to 24.0 
nm (23.2 ± 0.7 nm).  For MVBs, the internal vesicles varied in size between 50 to 
100 nm in diameter. It was generally the case that in the presence of CQ, each 
expanded vesicle contained several MLB/MVBs.  Without CQ treatment, control 
cells completely lacked these features (data not shown).  
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Induced MLB/MVBs sequester weakly basic lipophilic molecules. LTG 
is a weakly basic fluorescent probe that labels acidic organelles within cells by 
the ion trapping mechanism.  Fluorescence micrographs of CQ-treated cells 
incubated with LTG showed LTG fluorescence accumulation in enlarged vesicles 
ranging 1-2 m in diameter. Most remarkably, at high magnification, LTG 
distribution within each one of the expanded vesicles was clearly associated with 
intralumenal MLB/MVBs (Figure 4.2A). In many of these vesicles, LTG was 
clearly localized to multiple internal vesicles of about 0.34 ± 0.06 m (n=20) in 
diameter, consistent with the numbers and diameters of the MLB/MVBs 
previously observed by electron microscopy.  Based on quantitative image 
analysis, we calculated accumulation of LTG fluorescence bound to the 
MLB/MVBs was at least 4.7 ± 0.5 (n=20) –fold greater than its accumulation in 
the lumen of the expanded vesicle. LTG-labeled MLB/MVBs appeared to move 
by Brownian motion, within the confines of the outer membrane bounding the 
expanded vesicles (Figure 4.2A, a-f). Increasing CQ concentrations did not inhibit 
LTG fluorescence accumulation. Instead, the accumulation of LTG fluorescence 
in the vacuoles was directly dependent on the concentration of CQ used for 
treatment showing no evidence of competition or saturation (Figure 4.2B). 
CQ accumulates within induced, expanded vesicles. The MLB/MVB 
containing, LTG-labeled vesicles induced by CQ corresponded to large, clear 
vacuoles apparent by brightfield transmitted light microscopy (Figure 4.3A). 
Confocal Raman microscopic imaging was performed in CQ-treated (Figure 4.3B, 
a) and -untreated (Figure 4.3B, b) cells. The signature Raman signal of CQ 
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(Figure 4.3B, spectrum 1, arrows, 1370 and 1560 cm-1) was present in the 
vacuoles observed by brightfield transmitted light microscopy (Figure 4.3B, 
spectrum 2), yet CQ signal was mostly undetectable in the vesicle-free regions of 
the same cells (Figure 4.3B, spectrum 3). In control experiments, the signal 
intensity of the Raman vibrational peaks of CQ at 1370 and 1560 cm-1 were 
constant between pH 7 and 5 (data not shown), so differences in the pH of 
intracellular compartments cannot explain the observed, spectral differences in 
Raman signal.  Furthermore, CQ signal was completely absent from untreated 
cells (Figure 4.3B, 4 and 5). Given their small volume, the presence of Raman 
signal within the vacuoles of CQ-treated cells confirmed that CQ is highly 
concentrated within these vesicles.  
CQ uptake is coupled to induction of phospholipidosis-like phenotype 
and cannot be inhibited by OCT inhibitors.  Consistent with the neutral, 
membrane-permeant form of CQ being mostly responsible for its passive cellular 
uptake, CQ uptake within the first 30 minutes was significantly reduced in by 
lowering extracellular pH (Figure 4.4A) but not significantly affected by the 
presence of OCT inhibitors and a stimulator (Cim, Gua, HC3, TEA or HCor) nor 
by the substitution of sodium with chloride in the transport buffer (Figure 4.4B). 
Incubation at 4 ℃ reduced CQ uptake in the first 30 min, consistent with inhibited 
passive diffusion at low temperature, while pre-incubation with 0.1 M sucrose-
DMEM, a treatment that induced lysosomal volume expansion, stimulated CQ 
uptake by 32% during this time (Figure 4.4B). Bafilomycin A1, a vesicular-
ATPase inhibitor which hampers the acidification of lysosomes, reduced CQ 
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uptake by 21% within the first 30 min of CQ incubation, while the autophagy 
inhibitor 3MA did not (Figure 4.4B). After 4h treatment, a close correlation 
between CQ uptake (Figure 4.4C) and lysosomal volume expansion (Figure 4.4D) 
was observed: in cells treated with Baf and FCCP, CQ-induced vesicular 
expansion was significantly suppressed, and so was the cellular uptake; in cells 
treated with transporter inhibitors, sucrose or 3MA, no significant reduction in 
vesicular expansion nor cellular uptake were observed, as compared with CQ 
treatment alone.  In the presence of Suc, 3MA, or other OCT inhibitors we also 
observed LTG fluorescence accumulated in association with the MLB/MVBs 
present within the induced, expanded vacuoles, as was observed in cells treated 
with CQ alone.   
CQ affected organelle volume and pH.  LTG-positive (acidic) organelle 
volume and pH, as well as cell volume and cytosolic pH, were measured at 
various time points, during a 4 hour CQ incubation period (Table 4.1). 
Experiments were also performed in the presence of 0.1 M Suc, a treatment that 
perturbs endolysosomal membrane traffic and promotes a phospholipidosis-like 
phenotype [20]. CQ uptake measurements were also performed in the presence 
of 10 nM Baf, a treatment that inhibits the phospholipidosis effect.  CQ-induced 
vacuolation was greater in the presence of sucrose compared to cells treated 
with CQ alone, and was inhibited by Baf (Table 4.1). Total cell volume 
significantly expanded in Suc but not in CQ or CQ/Baf. (Table 4.1). CQ (with or 
without Suc or Baf) increased vesicular pH during 4-hour incubation period, but 
cytosolic pH was not significantly perturbed (Table 4.1). The extent of CQ 
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induced vesicular pH increase was highest in the presence of Suc, intermediate 
with Baf and least with CQ alone. At 200 µM CQ, CQ toxicity became apparent, 
with several of the observed trends becoming reversed (Table 4.1). Consistent 
with the large buffering capacity of the extracellular medium, measurements 
confirmed that CQ treatments with or without Suc or Baf did not alter the 
extracellular pH (Table 4.1). 
Organelle volume and pH also affect CQ uptake.  The effects of Suc and 
Baf on the pharmacokinetics of CQ were measured in dose-response and time-
course experiments.  Upon prolonged incubation, CQ exhibited a time-dependent, 
gradual accumulation over the 4h incubation period (Figure 4.5). Suc treatment 
prior to CQ incubation led to the most pronounced intracellular accumulation of 
CQ (Figure 4.5A).  Baf inhibited the gradual accumulation of CQ, with cells 
showing a rapid uptake during the first five minutes, followed by a low, steady 
state level during the next four hours (Figure 4.5A).  At 50 and 100 µM CQ, CQ 
accumulation over the 4h period appears almost linear in Suc-treated cells as 
well as in cells that were incubated with CQ alone (Figure 4.5A).  
Simulations of CQ cellular pharmacokinetics. Computational simulations 
of CQ uptake with a mathematical model that incorporates volume expansion of 
acidic organelles, protonated CQ binding to MLB/MVBs, and using the measured 
parameter values as input yielded CQ dose-response and time-course traces 
that were consistent with the experimentally measured values (Figure 4.5A) and 
well within the simulated margins of error based on physiologically-relevant 
ranges of input parameters (Figure 4.5B).  The effects of Suc and Baf on CQ 
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uptake paralleled the experimental measurements (Figure 4.5A) for 25, 50 and 
100 M CQ treatments. Simulation results for 200 M treatments tended to over-
predict CQ uptake (Figure 4.5A), which we ascribe to the toxic effects that were 
apparent at this higher dose. Overall, the accuracy of predicted cellular uptake 
was good for a wide range of different CQ concentrations, in the presence or 
absence of Suc or Baf at 8 time points, with 70% of the predicted values within a 
factor of 2 or 86% within a factor of 3 of the measured cellular uptake values 
(Figure 4.6). Except for 200 M treatments during which cellular uptake were 
possibly reduced by toxic effect, most other discrepancies were observed 
between predictions and measurements for the first time points when the amount 
of cellular CQ uptake was close to the detection limit of the instrument. 
For comparison, the simulated intracellular CQ mass at the end of a 4-hour 
incubation period was calculated under three different conditions (1) in the 
presence of ion trapping but without expanding organelle volumes nor binding of 
protonated CQ species to MLB/MVBs (Figure 4.5B, green); (2) in the presence of 
ion trapping within expanding acidic organelles but without binding of protonated 
CQ species to MLB/MVBs (Figure 4.5B, blue); and (3) in the presence of ion 
trapping in expanding acidic organelles, with binding of protonated CQ species to 
MLB/MVBs (Figure 4.5B, black). Parameter sensitivity analysis [24] showed that 
molecular properties including pKa and logP for the neutral forms or ionized forms, 
pH and volume in the extracellular compartment, volume in the cytosol, pH, 
volume, membrane potential, ionic strength and lipid fraction in the lysosomes 
were important factors (caused a >20% change with parameters randomly 
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sampled from physiologically-relevant ranges) for CQ uptake. Consequently, 
Monte Carlo simulations were performed to calculate a distribution of predicted 
CQ accumulation values based on a range of these input parameters, in cells 
incubated with CQ alone, or in combination with Suc or Baf.  
The impact of CQ induced phenotypic effects on the predicted cellular 
accumulation of CQ was consistent with most of the intracellular CQ 
accumulation occurring within the expanding acidic (LTG-positive) vesicles.  
Based on the simulations,  the volume increase of acidic organelles led to a > 5 
fold increase in the predicted intracellular mass (Figure 4.5B, green vs. blue), 
while adding an MLB/MVB binding component led to an additional 2-fold increase 
in intracellular CQ mass (Figure 4.5B, blue vs. black). Simulation results 
incorporating vesicular expansion and CQ binding to MLB/MVBs corresponded to 
the range of measured values (Figure 4.5B, black vs. red lines). 
The greatest discrepancy between simulation results and experimental 
measurements was observed in Baf-treated cells.  This discrepancy can be 
ascribed to measurement errors: In Baf, LTG uptake is much reduced and the 
diameter of acidic vesicles was close to the optical resolution limit of the 
microscope, so the organelle volume measurements were less precise as 
compared to the other conditions.  Also, the accuracy and precision of CQ mass 
measurement in the presence of Baf was considerably lower than in the other 




In this study, we used MDCK cells exposed to 0 to 200 M CQ as a 
physiologically-relevant in vitro experimental model to analyze CQ 
pharmacokinetics in cells of the distal renal tubule. We present quantitative 
evidence that the phospholipidosis-like phenotypic effect induced by CQ may be 
responsible for the observed, non-steady state intracellular accumulation of CQ. 
In the process, we elaborated a computational in silico model for simulating how 
phospholipidosis affects the cellular pharmacokinetics of small molecule drugs. 
As a physiologically-relevant transport probe, CQ is a weak base drug for 
treatments of malaria, arthritis, viral infection and cancer [25, 26].  Despite of its 
high solubility, CQ has slow clearance, accumulates in kidney (and other 
organs) >1000-fold relative to plasma concentrations, and has  highly variable 
pharmacokinetics with the elimination half-life ranging from 20-60 days [27]. 
Significant variability in CQ pharmacokinetics have been ascribed to differences 
in protein binding, but functional differences in renal filtration could also be 
involved as the drug is mostly cleared by the kidney [28].  
Previous studies have established that CQ reached high concentrations 
inside cells with particularly high levels in the lysosomes [29], presumably by the 
action of a carrier-mediated active transport mechanism. However, while CQ may 
be a substrate of multiple drug resistance 1 protein [30] and organic cation 
transporter-like 2 protein [31], both of these are involved in the excretion of drugs 
from cytosol to the extracellular medium.  No active transporter mechanisms 
have been found to play a role in CQ cellular uptake. The organic cation 
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transporter 2 (OCT2) plays important roles in the uptake of cationic compounds 
in the kidney, but chloroquine does not appear to interact with OCT2 [32].  In fact, 
unlike other organic cations which are substrates of an active transporter (i.e., 
plasma membrane monoamine transporter or PMAT) [33], the cellular uptake of 
CQ did not depend on sodium concentration in the extracellular medium (Figure 
4B and 4C). Also, while low pH in the extracellular medium has been found to 
stimulate the uptake of PMAT substrates, we found it significantly inhibited CQ 
uptake. Lastly, PMAT and OCTs are not extensively expressed in normal, distal 
tubular cells [34, 35]. Therefore, all available evidence supports the role of 
passive diffusion in CQ crossing biological membranes of MDCK cells (Figure 
4A). We found that many pharmacological OCTs inhibitors did not affect cellular 
uptake of CQ (Figure 4A, 4B and 4C), while all treatments that directly affected 
the cellular vacuolation response did affect CQ uptake.  
Microscopically, the appearance of MLB/MVBs in MDCK cells treated with 
CQ corresponds to the morphology of kidney cells of CQ-treated patients, as well 
as that of other cells following exposure to weakly basic, lipophilic drugs [16, 36, 
37]. The sizes of the expanded vesicles and the internal vesicles as measured by 
fluorescence microscopy and TEM were comparable (Figure 1 and 2). The 
discrepancy between the absolute values of these two measurements can be 
ascribed to differences in sample preparation as well as the resolution of these 
two instruments. In fluorescence microscopy the samples are fresh and 
immersed in living cell environment, while in EM the samples are dehydrated. 
Secondly, for TEM sample preparation, cells are sliced with a ultramicrotome so 
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the diameter of the vesicles in TEM micrographs might not be the actual 
equatorial diameter. As a result, the measured size of the expanded vesicles in 
TEM images seemed smaller than measurements from fluorescent images. 
When comparing the measured sized of internal vesicles in MLB/MVB, the 
discrepancy in measured sizes was not significant considering the relatively low 
resolution of the fluorescence microscopy (1 pixel = 0.047 m in this study).  
Meanwhile a close relation between CQ-induced volume expansion of LTG-
positive vesicles and CQ uptake was observed (Figure 4B and 4C). Accordingly, 
we sought to measure the cellular pharmacokinetics of CQ in dose-response and 
time-course experiments. In turn, these measurements were compared to 
simulation results obtained by modeling intracellular CQ mass accumulation 
under three different scenarios: (1) in the absence of CQ-induced phenotypic 
effects; (2) in the presence of expanding acidic organelles; and (3) in the 
presence of expanding acidic organelles coupled to binding to intralumenal 
MLB/MVBs. We found that the latter condition yielded results that were largely 
consistent with the measured absolute CQ levels as well as the relative changes 
of intracellular CQ mass under several different conditions.  
Supporting a role for MLB/MVBs in the sequestration of CQ, LTG (a weakly 
basic fluorescent probe that accumulates in acidic organelles due to ion trapping) 
was visibly concentrated within MLB/MVBs in the lumen of expanded cytoplasmic 
vesicles induced by CQ.  The inability of 3MA to inhibit the phenotypic effects 
induced by CQ suggests that the phospholipidosis effects of CQ are not due to 
an induced, autophagocytic mechanism. Experiments and simulations of CQ 
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uptake in combination with Suc provided evidence that stimulating the 
phospholipidosis-like phenotype facilitates CQ accumulation. Experiments and 
simulations of CQ uptake in combination with Baf provided evidence that 
inhibiting the phospholipidosis-like phenotype decreases CQ accumulation. 
Lastly, Raman confocal microscopy confirms that intracellular CQ accumulates 
within the expanded, CQ-induced cytoplasmic vesicles with intralumenal 
MLB/MVBs, as predicted by the model.  Phospholipids such as 
phosphatidylcholine have very high affinity for protonated CQ [38], consistent 
with most of the protonated CQ within the expanded vesicles being bound to the 
membranes of intralumenal MLB/MVBs.  
It is also noteworthy that intracellular transformation into a less membrane 
permeant CQ metabolite cannot account for the continuous chloroquine 
accumulation in MDCK cells. With MDCK cell monolayers on porous membrane 
supports, we have previously demonstrated that intracellular CQ in MDCK cells is 
mostly present in intact form.  While passive diffusion coupled to ion trapping and 
phospholipid binding can explain the observed transport behaviors, we also 
searched for evidence that CQ accumulated by an active transport mechanism. 
However, the effects of bafilomycin and sucrose, the lack of effect of active 
transport inhibitors, and the good correlation between vacuolar expansion and 
the level of CQ, the insensitivity to extracellular sodium, the pH sensitivity of CQ 
uptake, and the linear concentration dependence of CQ uptake all made it very 
difficult to relate CQ’s behavior to candidate active transport mechanisms. 
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To conclude, our results indicate that the phospholipidosis effects of CQ 
may underlie an inducible, highly effective, intracellular weak base sequestration 
system. To our knowledge, this is the first study to evaluate the potential effects 
of phospholipidosis on the cellular pharmacokinetic behavior of a weakly basic 
molecule. Our simulations and experimental results converge to provide 
evidence those changes in organelle structure and membrane organization 
induced by CQ can profoundly alter the intracellular bioaccumulation and 
distribution of CQ according to its passive transport properties, leading to the 
non-steady state accumulation behavior.  Considering that these morphological 
changes have been reported in other weak base drugs that accumulate 
intracellularly such as procainamide and amiodarone [21], our results indicate 
that phenotypic changes associated  phospholipidosis warrant consideration as 
candidate, mechanistic determinants of the local (and systemic) distribution and 
disposition of weakly basic lipophilic molecules in the tissues and organs of the 
body, especially in cells exposed to high local concentrations of the drug. 
Passive transport models have been successfully used for developing predictive 
physiologically-based pharmacokinetic models of bioaccumulation and 
biodistribution of neutral or ionized organic compounds in tissues and organs [39-
41].   For weakly basic molecules, incorporating the cellular pharmacokinetic 
effects of phospholipidosis may considerably improve physiologically-based 
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Table 4.1. Cellular parameters obtained during 4-hour incubation with different concentrations of CQ. pH measurements 
and cell volume correspond to the average over the 4-hour incubation period; data was presented as mean ± S.D., n = 4. 
Vesicle volume corresponds to the volume at the end of the fourth hour treatment; data was presented as mean ± S.D., n 


















Untreated 5.03±0.15 21±8 219±74 7.4±0.2 1.64±0.41 7.45±0.04 
25 M 
CQ 
Suc 5.91±0.23 602±145 2130±349 7.37±0.02 3.00±0.14 7.48±0.03 
/ 5.36±0.28 304±76 1159±47 7.36±0.04 1.66±0.12 7.48±0.03 
Baf 5.55±0.17 18±5 189±55 7.38±0.03 1.74±0.14 7.47±0.03 
50 M 
CQ 
Suc 6.08±0.20 843±176 2795±491 7.36±0.01 3.05±0.28 7.47±0.03 
/ 5.51±0.34 587±126 2207±1050 7.36±0.01 1.84±0.05 7.47±0.03 
Baf 5.69±0.37 19±4 204±24 7.35±0.02 1.70±0.15 7.47±0.03 
100 M 
CQ 
Suc 6.45±0.21 1121±343 2995±385 7.37±0.02 2.95±0.33 7.50±0.02 
/ 5.81±0.21 294±53 1219±234 7.35±0.04 1.83±0.12 7.50±0.02 
Baf 5.88±0.14 17±3 178±28 7.34±0.03 1.77±0.14 7.50±0.02 
200 M 
CQ 
Suc 6.73±0.28 565±140 1468±351 7.37±0.02 3.27±0.37 7.50±0.02 
/ 5.98±0.45 204±47 785±193 7.30±0.02 1.62±0.17 7.50±0.02 
Baf 6.26±0.45 17±4 186±32 7.17±0.04 1.78±0.09 7.50±0.02 
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Table 4.2. Parameter ranges for Monte Carlo simulations. pH, E, A, V, L and Is indicate pH, membrane potential 
relative to the cytosol, surface area, volume, lipid fraction and ionic strength in each compartment, while the subscripts a, 
c, l, and m indicate the apical/extracellular, cytosolic, lysosomal and mitochondrial compartment. pH_a, pH_l, V_l, V_c, 
A_l, rate of change in surface area or volume and cellular partition coefficient (logPn,d1,d2_cell) were measurement as 
described in the manuscript. pKa1, pKa2, logPn, logPd1 and logPd2 were calculated by ChemAxon® based on weighted 
method prediction with 0.5 log units variant. Temperature (T) is set to 310.15 K during uptake experiment. Ionic strength 
and membrane potential values were based on literature report [13, 23, 42]. 
 
  
CQ CQ/Suc. CQ/Baf. 
  
25 50 100 200 25 50 100 200 25 50 100 200 
pH_c 2, 4 
a 7.29 7.34 7.28 7.27 7.34 7.34 7.34 7.32 7.33 7.32 7.29 7.10 
b 7.43 7.38 7.42 7.33 7.40 7.38 7.40 7.38 7.43 7.38 7.39 7.24 
pH_l 2 
a 4.88 5.22 5.45 5.20 5.51 6.03 6.09 6.25 5.26 5.05 5.64 5.48 
b 5.84 5.80 6.17 6.76 6.31 6.73 6.81 7.21 5.84 6.33 6.12 7.04 
V_c (m3) 2 
a 1452 1752 1616 1314 2761 2572 2391 2630 1491 1437 1512 1608 
b 1874 1922 2042 1916 3250 3535 3516 3904 1989 1961 2022 1945 
V_l_initial 2  
(m3) 
a 8.8 8.8 8.8 8.8 54.9 54.9 54.9 54.9 8.8 8.8 8.8 8.8 
b 32.4 32.4 32.4 32.4 128.0 128.0 128.0 128.0 32.4 32.4 32.4 32.4 
A_l_initial 2, 4 
a 111.5 111.5 111.5 111.5 517.5 517.5 517.5 517.5 111.5 111.5 111.5 111.5 
b 335.0 335.0 335.0 335.0 899.7 899.7 899.7 899.7 335.0 335.0 335.0 335.0 
rate of change   
A: m2/hr 3, 4 
V: m3/hr 3 
A 239.3 466.3 247.9 163.0 339.0 549.9 624.2 206.2 0.0 0.0 0.0 0.0 
V 68.7 106.9 66.0 45.1 121.4 227.2 266.3 127.3 0.0 0.0 0.0 0.0 
T (K) 310.15 
logPn
 (3.68, 4.18)  
logPd1 (0.18, 0.68)  
logPd2 (-1.16, -0.66)  
logPn,d1,d2_cell (1.70, 1.83) 
pKa1 (9.71, 10.21) 
pKa2 (7.22, 7.72) 
E_a (mV) 4 -10  
 E_l (mV) (5, 15) 
E_m (mV) -160 
pH_a (7.4, 7.5) 
pH_m 4 8 
cellNo (/well) (50, 70) × 104 
V_a (m3) 0.5×10
12/cellNo 
V_m (m3) 16.35 
A_a (m2) 4 100 
A_m (m2) 4 196.35 
L_c 4 0.05  
L_l (0.025, 0.075) 
L_m 4 0.05 
Is_c 4 0.3 
Is_l (0.2, 0.4) 
Is_m 4 0.3 
 
1 The center points for each range were used to simulate the typical kinetic curves under specific each treatment, as 
shown in Figure 3.6.  









b a  , (S2) where the mean values were reported in the above 
table, and the variance was calculated as the squared s.d.. 
3  Rate of changes of vesicular volume and surface area were obtained by fitting measurements at 1-4 hour time points 
with a linear model using the initial values as intercepts. The slope of vesicular volume and surface area under CQ 
treatments with bafilomycin A1 were essentially 0 after statistical analysis.   







Figure 4.1. CQ induces a phospholipidosis-like phenotype characterized by 
the formation of many MLB/MVBs in MDCK cells. MDCK cells were treated 
with 50 M CQ for 4 hours followed by transmission electron microscopy analysis. 
A. (Magnification 7900X), B. and C. (Magnification 34000X), and D. 
(Magnification 13600X) illustrate MDCK cells with enlarged vesicular 
compartments, or MLB/MVBs, comprised of intralumenal MLBs (single arrows) or 

























Figure 4.2. CQ-induced non-uniform distribution (A) and dose-dependent 
accumulation (B) of LTG within the LTG-positive vesicles in MDCK cells. A. 
At the end of 4-hour incubation with 50 M CQ, LTG fluorescence within 
individual vesicles was concentrated within small particles of 0.3 – 0.4 m in 
diameter, which underwent Brownian motion within the confines of the enlarged 
vesicles. These particles corresponded in shape and size to MLB/MVBs 
observed by EM (see Figure 4.1). Image a to f was taken at 4 second intervals to 
show the Brownian movement of the bright MLB/MVB particles within the lumen 
of the expanded vesicles. Scale bar: 2 m. B. After 4-hour incubation with 
different amount of CQ, the fluorescence volume intensity per vesicle increased 
as CQ treatment. 5 cells (more than 300 vesicles) were measured under the 




























Figure 4.3. CQ accumulates within enlarged MLB/MVB-positive vesicles. 
MDCK cells were treated with 10 M CQ for 12 hours, which primes them for 
vacuolar expansion and MLB/MVB formation, followed by 100 M CQ for 2 hours 
prior to imaging. For fluorescence microscopy, cells were incubated with 0.5 M 
LTG for 30 min immediately prior to imaging. A. LTG fluorescence (top) and the 
corresponding brightfield image (middle) of a representative CQ-treated cell was 
merged (bottom) showing the highly heterogenous LTG fluorescence associated 
with MLB/MVBs within the expanded cytoplasmic vesicles. Scale bar: 4 m. B. 
Analysis of intracellular CQ distribution by confocal Raman microscopy. (upper) 
Brightfield image showing a 100 M CQ-treated (a)  and untreated (b) cells from 
which spectra were acquired. Scale bar: 5 m. (lower) Spectrum 1 was acquired 
from 100 mM CQ solution in buffer, as reference. Spectrum 2 and 3 were 
acquired from the vesicles and cytosol of treated cells, respectively; spectrum 4 
and 5 were acquired from the vesicles and cytosol of untreated cells.  In these 
spectra, CQ-specific Raman vibrational peaks (around wavenumbers 1370 and 
1560) were identified based on Spectrum 1.  CQ-specific Raman signal was 























Figure 4.4. Temperature- and pH-dependent CQ uptake parallels the 
induced phospholipidosis effect, and is insensitive to pharmacological 
inhibitors of organic cation transport.  (A) Within 30 min CQ uptake (50 M) 
into MDCK cells was significantly reduced by lowering extracellular pH and 
lowering the temperature. Uptake experiments were performed in transport buffer. 
Control experiments were performed at pH 7.4 and 37 ℃. (B) Within 30 min of 
incubation, CQ uptake (50 M) and cellular vacuolation were not significantly 
perturbed by inhibitors of autophagy or active transport. Pre-incubation with 0.1 
M sucrose in DMEM increased CQ uptake within 30 min, while co-treatment with 
bafilomycin A1 inhibited CQ uptake, but the difference was not significant. 
Uptake experiments were performed in choline-based transport buffer (Cho) and 
DMEM (all the other conditions). (C) and (D) At the end of 4-hour incubation, CQ 
uptake and LTG-positive vesicular expansion was partially inhibited by FCCP, 
significantly suppressed by bafilomycin A1 but not reduced by OCT 
inhibitor/stimulator, the autophagy inhibitor 3MA or the sodium-free extracellular 
buffer..  Con.: control, 50 M CQ only; Cho: 50 M CQ in choline-based transport 
buffer; Cim: 500 M cimetidine; HC3, 500 M hemicholinium-3; Gua: 500 M 
guanidine; TEA: 500 M tetraethylammonium; HCor: 20 M hydrocortisone; 
FCCP: 5 M FCCP; 3MA: 10 mg/mL 3-methyladenine; Suc: 0.1 M sucrose; Baf: 
10 nM bafilomycin A1. Data were presented as mean ± S.E.M from 3 
experiments. Asterisks indicate significant difference from control using unpaired 

























Figure 4.5. Quantitative analysis and mechanism-based, predictive 
pharmacokinetic modeling of CQ uptake in MDCK cells. A. Measured uptake 
kinetics during 1) 25, 50, 100 and 200 M CQ treatments, in previously untreated 
cells (CQ/); 2) Suc pre-treated cells during co-treatment with CQ and sucrose 
(CQ/Suc); and 3) co-treatment with CQ and Baf in previously untreated cells 
(CQ/Baf). Data points correspond to mean ± S.E.M. (n = 3). B. Histograms of 
Monte Carlo simulations of intracellular CQ accumulation in relation to 
experimental CQ mass accumulation. A total of 10,000 simulations were 
performed with parameters randomly selected from a range (Table 4.2). Red 
solid lines correspond to the measured, average CQ mass per cell at the end of a 
4-hour incubation with 25, 50, 100 and 200 M CQ (red dashed lines represent ± 
S.E.M). Green: simulation results in the absence of phenotypic changes. Blue: 
simulation results incorporating volume changes of organelles but without 
partitioning to MLB/MVBs. Black: simulation results incorporating volume 












Figure 4.6. Assessing the performance of the cellular pharmacokinetic 
model. The predicted intracellular mass was plotted against the measured 
values at 8 time points for 4 levels of CQ treatment with (or without) sucrose or 
bafilomycin A1. The solid line represents the unity line and the dashed lines 
represent a factor of 2 on both side of the unity. The dotted line represents the 
best fit with the equation displayed. (A) All the 96 data points were plotted. The 
solid circles represent data from 25, 50 and 100 M CQ treatments; the open 
circles represent data from 200 M CQ treatments. (B) The fitted line for data 































Simulation-Driven Analysis for Assessing the  
Lateral Inter-Cellular Transport of Small Molecules  




Studies on the inter-cellular transport between cells in a monolayer have been 
limited to small amounts of hydrophilic fluorescent molecules microinjected into 
single cells.  Here, we proposed a novel design, utilizing impermeable polyester 
membranes perforated by single 3 m diameter pore or geometric pore arrays, to 
probe the intracellular and intercellular transport pathways of small hydrophobic 
molecules within and between cells in a monolayer.  In experimental 
demonstrations, Madin-Darby Canine Kidney epithelial cells were inoculated into 
inserts holders with patterned, transparent polyester membrane supports. The 
small, cell permeant dyes, Hoechst 33342, MitoTracker Red and BCECF-AM 
were added into the basolateral compartment of the transwell system. Lateral 
transport of the dye within cell monolayer was tracked by fluorescence 
microscopy. The time course of probe uptake and the distribution of probe within 
individual cells were analyzed with quantitative imaging software. We observed 
that single pores feed only into cells in the immediate vicinity and lateral diffusion 
between cells was highly constrained and occurred slowly, leading to geometric 
labeling patterns controlled by the area and pattern of the pores and the transport 
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properties of the cells. A cell-based mathematic model was developed to guide 
the analysis of observed standing gradient in between neighboring cells. Despite 
of its simplicity, geometrically patterned, micro-fabricated pore arrays provide an 
experimental system to quantitatively studying the cellular transport pathways of 
various hydrophobic small compounds. 
 




















Lateral transport between neighboring cells is critical to the maintaining of 
spatial and functional organizations in different tissue and organs. Depending on 
cell types, the lateral transport of xenobiotic and/or endoergic signaling 
molecules plays pivotal roles ranging from maintaining the cell homeostasis, to 
establishing the electrical propagation, and to conducting regulating the 
differential and developmental fates in adjacent cells [1-4]. It can be generated by 
many local stimuli including but not limiting to neuronal cell transmission, calcium 
waves in myocytes or liver endothelial cell monolayers, coupled cellular 
contraction in cardiac muscle and signal transduction during developmental 
processes. Improper regulation of lateral intercellular transport has been 
associated with a series of disease progressions including cardiac arrythmia, 
epileptic seizures, and anticancer drug resistance phenomenon [5-8].  
For small molecules there are two major routes for lateral intercellular 
transport: the gap-junction mediated lateral transport and the passive diffusion 
across plasma membranes. The concept of gap junctions, clusters of connexin 
protein channels that connect adjacent cells, was introduced more than fifty 
years ago, as the fundamentals of impulse transmission and metabolite 
exchange between neighboring cells [9-11]. By coupling immune-histology with 
electro-physiological studies or fluorescence-based imaging techniques, 
researchers have revealed an urgent need to screening for biological and genetic 
factors (e.g. the structure, distribution, and composition of connexin proteins) on 
the selectivity and permeability of gap junctions to hydrophilic compounds or 
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charged ions [12]. Nevertheless, traditional fluorescence-based methods, which 
initiate with the microinjection and scrape loading of fluorescent dyes into a 
single cell within a cell monolayer or cluster, are very time consuming and could 
not be escalated for high throughput screening assays in lateral diffusion studies 
[13]. Fluorescence recovery after photobleaching (FRAP) assays have also been 
developed in monitoring the diffusion of fluorescent dyes, but similar to the 
traditional loading methods, FRAP is intrusive to cell viability [14].  
For hydrophobic compounds that get transported across cell boundaries 
mainly by passive diffusion, even less knowledge has been collected on their 
lateral transport properties. One of the reasons is that the loading of hydrophobic 
compounds in the source cell requires higher efficiency as these compounds 
might escape from the apical membrane to the extracellular environment even 
before the monitoring starts. Thus a design that provides constant source to the 
center cell would be highly desirable in the lateral transport studies of 
hydrophobic compounds.  
In this paper we presented a trans-well insert system that could provide a 
constant supply of small compounds to the cell in a non-intrusive manner as well 
as a mechanism-based computational model that simulate the lateral diffusion 
properties of small molecules. By seeding Madin-Darby Canine Kidney (MDCK) 
epithelial cells (a cell lines that does not have functional gap junctions at 
confluency [15, 16]) on non-permeant polyester membrane supports with 
patterned pore arrays and adding hydrophobic fluorescent compounds in the 
basolateral side of cell monolayer, the time course dye uptake in the cells sitting 
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above the pores and the kinetics of lateral transport between neighboring cells of 
could be visualized spontaneously with a fluorescence microscopy. Furthermore, 
when a hydrophobic pro-drug of a hydrophilic gap junction substrate was 
administered, gap junction mediated dye transfer could also be analyzed for the 
quantitatively evaluation of gap junction functions. We demonstrated that this 
insert system serves as a platform for comprehensive studies on the lateral 
transport phenomenon through both passive diffusing route and gap junction 
mediated route. 
 
Materials and Methods. 
Design of point-source insert system. We designed an insert system with 
fabricated polyester membranes to support cell growth and to provide point 
source for compound administration (Figure 5.1).  Non-porous, transparent, 
polyester membranes were perforated with focused-ion-beam techniques to 
create patterned pore arrays. These arrays features 3 m pore size, arranged 20 
m apart in a 5-by-5 array, or 40, 80 and 160 m apart in 3-by-3 arrays. The 
patterned membranes were glued (Krazy® Glue) to the bottom of hollow 
Transwell® holder (Costar 3462 or 3460) to create permeable support for cell 
growth.  
Cell culture. Madin-Darby canine kidney (MDCK) cells were purchased from 
ATCC (CCL-34TM) and grown in Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco 11995) containing 10% FBS (Gibco 10082), 1X non-essential amino acids 
(Gibco 11140) and 1% penicillin/streptomycin (Gibco 15140), at 37ºC in a 
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humidified atmosphere with 5% CO2. MDCK cells were seeded at a density 
between 1×105-2×105 cells per square centimeter and were grown until cell 
monolayer was formed.  
Chemicals. Organelle targeting fluorescent dyes, Hoechst 33342 (Hoe) 
(Molecular Probes H3570) was stored by manufacturer instruction. Fluorescent 
dye BCECF-AM and MitoTracker Red (MTR) (Molecular Probes® B1170 and 
M7512) were stored according to the manufacturer’s instructions and was 
dissolved in DMSO to final concentrations of 2 mg/ml before use. Trypan Blue 
(Sigma T6146) was dissolved in HBSS buffer (Gibco 14025) to a final 
concentration of 5 mM and stored in room temperature. 
Characterization of the insert system. The integrity of insert system was 
tested by adding 5 mM Trypan Blue into the insert wells. The inserts was 
considered intact if there will be no sign of Trypan Blue leakage from the edge of 
the insert membranes. In this situation, the transport of test chemicals from the 
basolateral to the apical compartment only occurred through the pore arrays. To 
evaluate the effect of pore arrays on cell growth, MDCK cells were washed and 
incubated in transport buffer (HBSS buffer supplemented with 25 mM D-glucose, 
pH 7.4) for 30 min, and subjected to transepithelial electrical resistance (TEER) 
measurement using Millipore Millicell ERS. Cell monolayers were considered 
intact if the background subtracted TEER values were higher than 100 Ω·cm2. 
Fluorescence imaging and image analysis. Fluorescent dyes were added 
into the basolateral compartment of the transwell system at time 0. A Nikon 
TE2000S epifluorescence microscope with standard mercury bulb illumination, 
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coupled to a CCD camera (Roper Scientific, Tucson, AZ), with a 10X objective 
((Nikon Plan Fluor ELWD 10x) or a 20X objective ((Nikon Plan Fluor ELWD 20x). 
A triple-pass DAPI/FITC/TRITC filter set (Chroma Technology Corp. 86013v2) 
was used to image the dynamic staining pattern in the cells. The 12-bit grayscale 
images were acquired and background subtracted. Individual cells or nucleus 
were manually outlined with Region tool in MetaMorph software (Molecular 
Devices Corporation, Sunnyvale, CA). The average and standard deviation of 
cellular or nucleus fluorescence intensity was captured with MetaMorph. The rate 
of staining of Hoe in the nucleus was measured as the slope of fluorescence 
increase normalized by the slope of increase in the first nucleus (closest to the 
pore).  
Estimation of intercellular diffusivity of cell permeant hydrophobic 
dyes. The distance (L) between the pore and the furthest stained object (the 
nucleus or the mitochondria) in between 2 to 3 hours were measured with 
MetaMorph. The equivalent lateral diffusion coefficient (D) assuming free 
diffusion was calculated according to the equation: D = L2/(4*t), where t is the 
time lapse after the addition of the dye into the basolateral compartment. The 
theoretical lateral diffusion coefficient assuming free diffusion in solution was 
estimated using the Einstein–Stokes equation:    
    
    
, where kB  is the 
Boltzmann's constant, T is the absolute temperature,  is the viscosity of the 
solution, and r is the Radius of the particle could be calculated with MarvinSketch 
at www.chemaxon.com.  
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Mathematical Modeling of the Intercellular gradient of Hoe. A multi-
compartment, constant-field, fixed-parameter mathematical model [17] was 
adapted to predict the passive diffusion of Hoe from the first cell on top of a 
single pore to its neighboring cells within MDCK cell monolayer (Figure 5.2). 
Briefly, the cell monolayer was modeled as five layers of hexagon cells. Only the 
nucleus compartment was included in the model. The total change in Hoe mass 
with time in each compartment was expressed by equations 1-5: 
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where, M stands for the total mass, J indicates the flux, A and V indicate the 
membrane surface area and volume, respectively, of the specific subcellular 
compartments as indicated by the subscripts a, b, c, n, and i: apical, basolateral 
compartment, cytosol, nucleus and intercellular space between two neighboring 
layers of cells. x indicates the cell layer number, ranging from 1 to 5 for the 
cytosol and nucleus compartment and 1 to 4 for the intercellular space. Aix,x is the 
surface area facing the xth layer and Aix,x+1 is facing the x+1
th layer of cells. Ai0 
and Ji0,c1 (when x = 1) are the same as Ab and Jb,c1. When x = 5, the terms 
regarding the 5th intercellular space are removed. The comma between two 
subscripts in the flux means “to” (e.g. “Jc,m” represents the flux from cytosol to 
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mitochondria). With all and surface area terms constant, the concentration 
change in each compartment was expressed by equations 6-10: 
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For Hoe, the total flux is contributed by a neutral form and three ionized 
forms with one to three positive charges. The total flux across membrane as 
contributed by three species can be calculated with Fick’s equation and Nernst-
Planck equation [18] : 
                          
   
      
                
        
   
      
         
        
        
   
      
                 
                                                           (11) 
where, subscripts o and i indicate outer- and inner-compartment, n, d1, and 
d2 indicate neutral form, ionized form with one charge, and ionized form with two 
charges, respectively. P is the permeability across the bilayer membranes and it 
was estimated based on the logarithm of Hoe’s octanol/water partition coefficient 
(logPo/w) calculated with ChemAxon® MarvinSkecth 5.1.4 
(http://www.chemaxon.com) as                         [17]. f represents the 
ratio of the activities (an, ad1 and ad2) and the total concentration. It can be 
calculated from lipid fraction and ionic strength in each compartment and the 
sorption coefficient for each species as estimated from logPo/w [17, 19]. When 
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estimating Hoe binding to DNA in the nucleus, sorption coefficient in the nucleus 
was estimated by 2*10-14 M of binding sites / Hoe in 5 m3 radius sphere-shape 
nucleus in the presence of 10 M Hoe in the extracellular medium [20]. In 
equation 4, N = zEF/(RT), where z = +1, +2 and +3 for Nd1, Nd2 and Nd3 (ionized 
base with one, two and three charges); E, F, R, and T are membrane potential, 
Faraday constant, universal gas constant, and absolute temperature, 
respectively. The ordinary differential equations were numerically solved with 
MATLAB® ODE15s solver to plot a kinetic curve of nucleus concentration of Hoe. 
Model validation/consistency check was performed by summing Hoe mass in all 
compartments during the simulation, confirming that total Hoe mass in the 
system stays constant (mass balance). 
The intercellular gradient between neighboring cells was modeled as the 
difference in the rate of staining over a 2 hour period. Monte Carlo simulations 
were performed to assess the distribution of staining rate in neighboring layers of 
cells. MATLAB® ODE15s solver was employed to run 1,000 simulations during 
which simulation parameters were randomly sampled from uniform distributions 
within the range of parameter values.  
 
Results 
The design of membrane support insert system of pattern pore arrays. 
The inserts with impermeable polyester membranes (with fabricated pore arrays) 
were placed in a 12-well plate (Figure 5.1A). MDCK cells were inoculated in the 
insert and let grown to confluence (Figure 5.1B) in 0.5 ml fully supplemented 
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DMEM medium. Before transport experiments, cells were washed and incubated 
in 0.5 ml dye-free transport buffer for 30 min. After equilibrium, 1.5 ml transport 
buffer containing appropriate dyes were added into the basolateral compartment.  
Fluorescence microscopy could be applied to capture the staining of MDCK cell 
monolayer at designated time points.  
The effect of pore arrays on cell growth. The morphology of cell 
monolayer exhibited no visual differences between membranes with various pore 
array patterns (Figure 5.1B). No cell migration through the pores was observed 
for all membrane types. The TEER values of MDCK cell monolayer and the 
number of cells per insert well were similar regardless of different membrane 
types (Table 5.1). Cell counts on patterned membranes were comparable to 
previous reports on commercialized, porous insert with 0.4 m pores and similar 
cell supporting membrane area [21]. The TEER value was significantly higher on 
the patterned membranes than the porous membrane, indicating the formation of 
tighter intercellular junctions in the presence of less scattered pore area [21].  
Lateral transport of small hydrophobic dye occurred at limited rate 
around the pores. Using Hoechst 33342 as a fluorescent probe, the kinetics of 
dye staining within MDCK cell monolayer was tracked with fluorescence 
microscopy at room temperature (Figure 5.3). Within 3 hrs, only cells that lied 
within close vicinity was stained (Figure 5.3), indicating that the cells formed a 
tight seal with the pores such that each pore fed almost exclusively into cells that 
were in immediate contact with the pores. A geometric labeling pattern was 
observed as controlled by the area and pattern of the pores and the transport 
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properties of the cells (Figure 5.4). These results suggested that the pores 
served as point sources of sustained dye supply to the adjacent cells. Therefore, 
for cells grown on membranes with 3×3, 80 m or 160 m-apart pore arrays, 
each pore could be considered as the single point source of dye molecules. 
Also consistent with this limited lateral diffusion rate statement, while each 
nucleus accumulated more dye with time, Hoe staining was not saturated over 3-
hour period (Figure 5.5). Similar geometric label patterns were also observed for 
other small hydrophobic, cell permeant dyes MitoTracker Red (Figure 5.6) and 
LysoTracker Green (data not shown). 
The application of fabricated insert system to study different lateral 
transport behavior of small molecules.  Within MDCK cell monolayer stained 
with Hoe, a standing gradient was observed in neighboring cells with various 
distant to the pore (Figure 5.5 and 5.6). Fluorescence intensity decreases 
dramatically as the number of layers to the pore increases (Figure 5.5). The 
same staining gradient was observed for other cell permeant dyes including MTR 
(Figure 5.6). After 2-hours staining from the basolateral compartment, the 
normalized fluorescence intensity in the third layer of cell from the pore was 
significantly higher for MTR than Hoe (Figure 5.6D). Not surprisingly, the 
measured equivalent lateral diffusivity assuming free diffusion within live cell 
monolayer was higher for MTR than for Hoe (5.88 ± 1.33 E-14 m2/sec for MTR 
and 3.12 ± 1.12 E-14 m2/sec for Hoe, n = 6). In a separate study, MDCK cells 
were pre-treated with 1% Triton 100 for 10 min before the addition of Hoe in the 
basolateral compartment. The number of cells stained within 2 hours was 
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significantly larger than under the live cell condition (Figure 5.7). The measured 
intercellular lateral diffusivity assuming free diffusion in the membrane extracted 
environment was 1.18 ± 0.434 E-13 m2/sec.  
When stained with BCECF-AM from the basolateral compartment with 
BCECF-AM, green fluorescence of the hydrophobic hydrolysis product, BCECF, 
was only observed in the first layers of cells that are in direct contact with the 
pores (Figure 5.8). 
Simulation of the gradient in neighboring cells from single point 
source. The rate of change in the average fluorescence intensity against time 
was measured and normalized to the closest cell to the pore on a 3-by-3, 160 m 
apart pore array (Figure 5.9A). The rate of change in nucleus concentration 
against time was also simulated and normalized with MatLab® for 1000 cells 
using randomly selected cellular parameters within reasonable range (Figure 
5.9B). In both the measurement and the simulation results, a gradient in the rate 
of staining (the measured slope of fluorescence increment and the calculated 
rate of change of Hoe) was observed in neighboring cell layers. The difference in 
the rate of staining in neighboring cells could be described with exponential 
decay y = Ae-x. The measured exponent was significantly less than that derived 
from model simulations (0.966 ± 0.313, n = 9 vs. 2.043 ± 0.294, n = 957), and the 
higher variation in measured exponents reflected a huge heterogeneity in the 





In this study we presented a practical method to trace the real time lateral 
transport of various chemical agents with distinguished properties. The insert 
system with patterned pore arrays provides the flexibility to study the rapid flux of 
molecules to different regions under various experimental conditions. It takes 
common materials to build this insert system. Once coupled with appropriate 
imaging instrument, this system could be easily adjusted for high content 
screening purposes in search for molecules with specific diffusion properties. 
The choice of the cell lines in this experiment is the wild type MDCK cells, a 
cell line that stably expresses the differentiated properties of distal tubular 
epithelial cells [22], forms intact cell monolayer quickly in vitro and  not 
extensively expresses active transporters [23-25]. Therefore, although Hoe is a 
substrate of many multidrug resistance transporters, the transport behavior of 
Hoe in wild type MDCK cell should be driven by passive diffusion [26]. It has also 
been well established that MDCK does not form functional gap junctions when 
reaching confluency [15, 16], thus, it can be used a negative control in selecting 
molecules that are restrict gap junction substrate.    
With this design, we studied the lateral transport behavior of Hoe, a 
hydrophobic cell permeant fluorescent dye. We found that lateral transport of 
Hoe occurred at limited rate around the pores. For a spherical particle with a 
similar molecular weight as Hoe, the Einstein–Stokes equation predicts the 
diffusion coefficient in water and blood to be around 1E-10 m2/sec. The 
measured lateral intercellular diffusivities in live cells was less than one third of 
that in membrane extracted, dead cells, and the later was barely comparable to 
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diffusivities measured from FRAP studies for similar molecular weight fluorescent 
compounds (<5E-13 m2/sec) [27, 28]. We consider this low, measured diffusion 
coefficient of Hoe was due to DNA binding that attenuate chemical potential at 
cell boundaries and the crowding effect as present in the cellular environment, 
the latter of which is known to slow the diffusion of solutes [29]. When cell 
membrane was removed, the crowding effect as introduced by the cytoplasmic 
organelles and membrane structures were reduced  [29], but the DNA binding 
effect still remains to hamper the free diffusion of Hoe. It also comes to our notice 
that, the basolateral staining of Hoe in cell monolayer sitting on top of 
commercialized membrane support (with more densely and randomly distributed 
3 m pores) would reach steady state within 3 hours (data not shown). This 
implies that the pattern of point sources has impact on way the dye interacts with 
its molecular target. 
The application of mathematic modeling has seen general success in 
quantitative prediction of intercellular concentration gradient.  However, the 
model predicted a more homogeneous distribution in the second and third layers 
of cells. These discrepancies between the simulation and observation indicates 
alternative hypothesis (in addition to the passive diffusion, instantaneous 
intracellular mixing and instant binding to DNA) in Hoe staining in the MDCK cells.    
One disadvantage of the current design system is the limited resolution in 
acquired images. Unlike the optical glass based chip designs [28, 30, 31], the 
polyester membrane support is not suitable for high resolution confocal analysis. 
In the PARTCELL system as proposed by Takayama et al., subpopulations of the 
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cells that grow on cover glasses could be selectively labeled with fluorescent 
dyes as delivered by multiple laminar fluid streams [31]. The cells could be 
analyzed with high resolution and high precision confocal microscopy to visualize 
the 3D distribution of xenobiotic agents. The spatial distribution of xenobiotic 
agents will provide valuable information in understanding the intracellular 
diffusion and mixing process.   
 
Conclusions. 
In this study we presented a simple geometrically patterned pore arrays as a 
useful tool for quantitatively studying small molecule transport between epithelial 
cells within a monolayer, at a single cell level. Compared with traditional 
fluorescence based methods, e.g. microinjection, scalpel loading and FRAP, this 
insert system represent a cell-friendlier, faster, more flexible and more 
quantitative alternative that is suitable for a more diverse group of chemical 
agents. Future efforts in improving current design with micro-fabricated pore 
arrays will be focused on elucidating the spatial distribution and intracellular 
diffusion process with more desirable membrane materials which are suitable for 
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(× 105 / well) 
Patterned 
membrane 
5 × 5, 20 m 
458 ± 69 4.9 ± 0.5 
Patterned 
membrane 
3 × 3, 40 m 
379 ± 76 5.2 ± 0.4 
Patterned 
membrane 
3 × 3, 80 m 
388 ± 106 5.2 ± 0.3 
Patterned 
membrane 
3 × 3, 160 m 





Figure 5.1. The design of insert system with patterned pore arrays on 
membrane support.  (A) Insert design and imaging strategy. (B) Light scattering 
images of a 5×5, 20 m apart pore array. (C) MDCK cell monolayer above a 





































Figure 5.3. Time course and differential uptake of Hoechst 33342 in cell 
monolayer on 5×5, 20 m apart pore arrays. Images (A-F) were taken 25, 45, 
55, 70, 85 and 115 min after the addition of Hoe in the basolateral compartment. 
























Figure 5.4. Fluorescent images of cell monolayer stained between 2.5-3 
hours after the addition of Hoechst 33342 in the basolateral compartment. 
Cells were grown and imaged on a (A) 5×5, 20 m apart, (B)  a 3×3, 40 m apart, 
(C) 3×3, 80 m apart and (D) 3×3, 160 m apart  pore array membranes. Red 























Figure 5.5. Fluorescent images of cell monolayer stained 3 hours after the 
addition of Hoechst 33342 in the basolateral compartment (A) and the 
kinetics of differential fluorescence intensity incensement in neighboring 
cells (B). MDCK cells were grown on a 3×3, 160 m apart pore array 
membranes. Cell numbers indicates vicinity to the closet pore. Red spots indicate 
the location of pores. Normalized fluorescence intensity was presented in mean ± 






























Figure 5.6. Fluorescent images of cell monolayer stained 2 hours after the 
addition of Hoechst 33342 and MitoTracker Red in the basolateral 
compartment and the gradient of staining in neighboring cells. MDCK cells 
were grown on a 3×3, 160 m apart pore array membranes. Cell numbers 
indicates vicinity to the closet pore. (A) The staining of the nucleus with Hoechst 
33342; (B) the staining of mitochondria with MitoTracker Red; (C) Overlay image 
of cells stained with both dyes. White spots indicate the location of pores. 
Normalized fluorescence intensity was presented in mean ± s.d. of 6 sets of cells. 
Asterisk indicates significant difference using Student’s T-test (p<0.05). Scale bar: 













Figure 5.7. Fluorescent images of live cell monolayer (A) and Triton 
extracted cell monolayer (B) between 2.5-3 hours after the addition of 
Hoechst 33342 in the basolateral compartment. Cells were grown and imaged 
on 3×3, 80 m apart pore array membranes. Red spots indicate the location of 



































Figure 5.8. Fluorescent images of cell monolayer stained 2 hours after the 
addition of Hoechst 33342 and BCECF-AM in the basolateral compartment. 
MDCK cells were grown on a 3×3, 40 m apart pore array membranes. (A) The 
staining of the nucleus with Hoechst 33342; (B) the staining of cytosol with 
BCECF-AM; (C) Overlay image of cells stained with both dyes. Red spots 


































Figure 5.9. Normalized rate of change of Hoechst concentration. (A) The 
rate of change in the average fluorescence intensity against time was measured 
for individual nucleus on a 3-by-3, 160 m apart pore array. This number was 
divided by the maximum rate of all nucleuses and plotted against the distance as 
the xth nucleus to the pore. (B) The rate of change in nucleus concentration 
against time was simulated with MatLab® for 1000 cells using randomly selected 
cellular parameters within reasonable range. This number was divided by the 
medium rate of all nucleuses and those equal or smaller than the medium was 












In this project the current knowledge of organelle targeting features of small 
molecules were evaluated in terms of its relevance to developing computational 
tool for subcellular pharmacokinetics behavior. A mechanism-based 
computational model [1] that has been successful in predicting the trans-cellular 
permeability of highly permeable molecules [2] was further applied to study 1) the 
relationship between the physicochemical properties and the associated cellular 
distribution profiles of small molecules; 2) the effect of drug-induced cellular 
response on non-steady state, continuous subcellular transport and accumulation; 
and 3) the slower-than-expected intercellular lateral diffusion rate of small 
hydrophobic cell permeant fluorescent dyes. These studies exemplify the 
usefulness of a mechanistic cell-based model to advance subcellular transport 
knowledge of passively diffusing molecules, guide experiments aiming at 
elucidating subcellular pharmacokinetics, and to serve as a step stone toward 
building a physiologically-based pharmacokinetic model to facilitate the analysis 
of drug distribution and efficacy in human bodies.  
This study also pointed out many opportunities to advance effective 
screening for drug candidates with desirable distribution and transport behavior 
at a subcellular and systemic level. In the following sections we will be discussing 
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several opportunities that the cheminformatic and mechanistic study of drug 
distribution / transport could benefit from. 
 
The development of quantitative experimental platform for the real time 
tracking and analysis of non-fluorescent molecules in multiple subcellular 
compartments  
The advantages and limitations of experimental methods used in subcellular 
pharmacokinetics studies have been shaping and re-shaping our understanding 
of small molecule distribution / transport behavior and generating evidences that 
would affect our judgment on emerging approaches in the field. In Chapter I, we 
have reviewed the progress of subcellular distribution research in the past half 
century. We realized that current knowledge of small molecule subcellular 
distribution and intracellular transport is biased towards fluorescent compounds, 
with either intrinsic fluorescence or fluorescent molecular tags. Therefore, the 
development of experimental platform that are applicable to non-fluorescent, 
non-targeted molecules will be very beneficial to expand our current 
understanding of the subcellular distribution properties of small molecules.  
In Chapter V we have proposed an insert system with geometrically 
patterned pore arrays for quantitative, real time tracking of the intracellular and 
intercellular transport of small fluorescent molecules. Similar with the multiple 
laminar fluid streams design as proposed by Takayama et al. [3], this system 
could be used to track the pharmacological effect of non-fluorescent molecules 
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within cell monolayer. We envision this novel insert design would be a useful tool 
in testing hypothesis of drug subcellular transport behavior.  
 
Elaboration of hypothesis-driven, mechanistic modeling technique 
The success of mechanism-based modeling replied on a thorough 
understanding of the biological phenomenon of the interest. When discrepancies 
between model estimation and observation are observed, the researcher is 
encouraged to search for mechanisms that are left out in the model. For example, 
the earliest cell-based transport simulator [1] was build based upon mass 
balance, Fick‟s law of diffusion, Nernst–Planck equation. The input parameters of 
the models, including the physiological properties of the cellular environment 
were considered constant throughout drug treatment. While this basic model well 
predicted the lysosomotropic phenomenon [4] and the trans-cellular permeability 
of highly permeable molecules [2], its performance in  analyzing the intracellular 
accumulation of chloroquine was compromised  [2]. In Chapter IV, because 
chloroquine is observed to induce phospholipidosis like response, the modified 
model was proposed to incorporate the lysosomal swelling mechanism as 
modeled by increasing volume in the acidic compartment, and the binding 
mechanism as represented by higher sorption efficient. This updated model well 
captured the kinetics of chloroquine inside cells [5]. More mechanisms that are 
often encountered during subcellular distribution and transport studies include 
the metabolism, active transport and reverse binding to cellular components [6]. 
195 
 
Other factors that may contribute to improved model performances include 
the better estimation of molecule diffusivity in the cellular environment. In 
Chapter V we have shown that measured intercellular diffusivities of Hoechst 
33342, a fluorescent nucleus stain, are different in live and dead cellular 
environment, both of which were significantly lower than the theoretical estimate 
based on the Einstein-Stoke equation. This discrepancy in the measured and 
theoretically predicted diffusivities was observed for similar molecular weight 
compounds [7, 8]. The crowding effect has been proposed to account for this 
slow diffusion of solutes in the cellular environment, possibly due to the 
electrostatic interaction between ionic species and charged cellular components 
(e.g. negatively charged DNA and phospholipids, mitochondria with negative 
membrane potentials) [9, 10]. A quantitative characterization of the molecular 
size effect and the crowding effect in the model should be able to facilitate 
model-guided experimental design and analysis. 
 
Promotion of simulation-guided experimental design 
The application of mechanism-based computational models function as a 
cost-effective „in silico laboratory‟ in which every aspect of knowledge about 
molecules can be applied, sorted and analyzed according to their relevance to 
the desired property [11-13]. This strategy cuts down the number of candidates 
for detailed studies by focusing on the most promising candidate molecules as 
well as the key parameters for experiment control. The cell-based passive 
transport model has been successfully used to develop predictive physiologically-
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based pharmacokinetic models for absorption, distribution and clearance in 
tissues and organs [14-19]. However, the development and application of these 
physiologically-based models have been restricted to a much smaller number of 
scientific research groups than it could have been potentially useful.  The 
adaption of these Matlab® or Perl based models to window-based, programming-
free and more user-friendly software would be highly desirable to promote the 
application of simulation-guided experimental design. 
 
Incorporation of synthetic biology concepts into pharmacokinetics studies 
In Chapter IV, we found that chloroquine continuously accumulated inside 
cells, by forming complexes with multilamellar bodies that appeared de novo 
within the lysosomes [5]. Similarly, in our laboratory, we found that chronic 
administration of clofazimine, a very lipophilic antibiotic, resulted in the formation 
of autophagosome-like drug inclusions (“aldis”), a new organelle that is derived 
from mitochondria ([20], under review in Molecular Pharmaceutics). These 
synthetic organelles may play an important role in determining the 
pharmacokinetics behavior and subcellular delivery pathways. In the future, we 
envision that the development of new drug delivery strategies and therapeutic 
modalities will greatly benefit from a better understanding the formation of new 
organelles in response to drug therapy, deeper insights into the role of 
chemically-synthetic organelles as intracellular drug depots, and the capability of 





1. X. Zhang, K. Shedden, and G.R. Rosania. A cell-based molecular 
transport simulator for pharmacokinetic prediction and cheminformatic 
exploration. Mol Pharmaceutics. 3:704-716 (2006). 
2. X. Zhang, N. Zheng, P. Zou, H. Zhu, J.P. Hinestroza, and G.R. Rosania. 
Cells on Pores: A Simulation-Driven Analysis of Transcellular Small 
Molecule Transport. Mol Pharm. 7:456-467 (2010). 
3. S. Takayama, E. Ostuni, P. LeDuc, K. Naruse, D.E. Ingber, and G.M. 
Whitesides. Selective chemical treatment of cellular microdomains using 
multiple laminar streams. Chem Biol. 10:123-130 (2003). 
4. X. Zhang, N. Zheng, and G.R. Rosania. Simulation-based cheminformatic 
analysis of organelle-targeted molecules: lysosomotropic monobasic 
amines. J Comput Aided Mol Des. 22:629-645 (2008). 
5. N. Zheng, X. Zhang, and G.R. Rosania. The Effect of Phospholipidosis on 
the Cellular Pharmacokinetics of Chloroquine. J Pharmacol Exp Ther 
(2011). 
6. T. Watanabe, H. Kusuhara, K. Maeda, Y. Shitara, and Y. Sugiyama. 
Physiologically based pharmacokinetic modeling to predict transporter-
mediated clearance and distribution of pravastatin in humans. J 
Pharmacol Exp Ther. 328:652-662 (2009). 
7. C.W. Cunningham, A. Mukhopadhyay, G.H. Lushington, B.S. Blagg, T.E. 
Prisinzano, and J.P. Krise. Uptake, distribution and diffusivity of reactive 
fluorophores in cells: implications toward target identification. Mol Pharm. 
7:1301-1310 (2010). 
8. S. Chen and L.P. Lee. Non-invasive microfluidic gap junction assay. Integr 
Biol (Camb). 2:130-138 (2010). 
9. J.A. Dix and A.S. Verkman. Crowding effects on diffusion in solutions and 
cells. Annu Rev Biophys. 37:247-263 (2008). 
10. H.M. Jones, N. Parrott, K. Jorga, and T. Lave. A novel strategy for 
physiologically based predictions of human pharmacokinetics. Clin 
Pharmacokinet. 45:511-542 (2006). 
11. C. Lipinski and A. Hopkins. Navigating chemical space for biology and 
medicine. Nature. 432:855-861 (2004). 
12. C.M. Dobson. Chemical space and biology. Nature. 432:824-828 (2004). 
13. A.C. Anderson. The process of structure-based drug design. Chem Biol. 
10:787-797 (2003). 
14. K.S. Pang. Modeling of intestinal drug absorption: roles of transporters 
and metabolic enzymes (for the Gillette Review Series). Drug Metab 
Dispos. 31:1507-1519 (2003). 
198 
 
15. D. Tam, H. Sun, and K.S. Pang. Influence of P-glycoprotein, transfer 
clearances, and drug binding on intestinal metabolism in Caco-2 cell 
monolayers or membrane preparations: a theoretical analysis. Drug Metab 
Dispos. 31:1214-1226 (2003). 
16. L. Yan, S. Sheihk-Bahaei, S. Park, G.E. Ropella, and C.A. Hunt. 
Predictions of hepatic disposition properties using a mechanistically 
realistic, physiologically based model. Drug Metab Dispos. 36:759-768 
(2008). 
17. W. Fu, A. Franco, and S. Trapp. Methods for estimating the 
bioconcentration factor of ionizable organic chemicals. Environ Toxicol 
Chem. 28:1372-1379 (2009). 
18. J.Y. Yu and G.R. Rosania. Cell-based multiscale computational modeling 
of small molecule absorption and retention in the lungs. Pharm Res. 
27:457-467 (2010). 
19. S. Trapp, A. Franco, and D. Mackay. Activity-based concept for transport 
and partitioning of ionizing organics. Environ Sci Technol. 44:6123-6129 
(2010). 
20. J. Baik and G.R. Rosania. molecular Imaging of Intracellular Drug-









The chemical compounds with reported subcellular localization site in the 
endo-lysosomes. References information is available in Appendix H. Structure 
is presented as the Simplified Molecular Input Line Entry Specification string of 
the major microspecies at pH 7.4, as calculated by ChemAxon.  
 
Name: Ammonia 















































Method: Pharmacological Effect 




















































































































































Method: Pharmacological Effect 




Method: Pharmacological Effect 




Method: Pharmacological Effect 




















Method: Pharmacological Effect 






Method: Pharmacological Effect 






Method: Pharmacological Effect 






Method: Pharmacological Effect 





Method: Pharmacological Effect 













Method: Pharmacological Effect 












Name: N3246; Neutral red 







Method: Pharmacological Effect 






Method: Pharmacological Effect 













Method: Fluorescence Microscopy 

































L7534; LysoTracker® Green 
DND-153 







































Method: Pharmacological Effect 






L7533; LysoTracker® Blue 
DND-167  








Method: Fluorescence Microscopy 



























L7535; LysoTracker® Green 
DND-189 







L7526; LysoTracker® Green 
DND-26 
Method: Fluorescence Microscopy 









L7528; LysoTracker® Red 
DND-99 







Name: Mepacrine; Quinacrine 
Method: Fluorescence Microscopy 














Method: Cell Fractionation 









Method: Fluorescence Microscopy 















Method: Pharmacological Effect 































Name: F7030; FUN® 1 





















Method: Cell Fractionation 






Method: Pharmacological Effect 





























































































Name: Vitamin A 






Name: Uroporphyrin I 













Method: Pharmacological Effect 






Method: Pharmacological Effect 

























Method: Pharmacological Effect 





Name: Serine Dodecylamide; SDA 











Name: Dansylamylamine; MDH 
















PPC; Pyridinium Zn (II) 
phthalocyanine 










TSPC; Tetrasulfonated Zn(II) 
phthalocyanine 
































































Name: Cyamemazine; CMZ 






Name: PCI-0123; Lutetium Texapyrin 


















































































































































Method: Fluorescence Microscopy 










Name: AR-L 115 BS; Sulmazole 






Name: HX-CH 44 BS 







Name: SX-AB 1316 SE 







Name: AF-CX 1325 XX 

























































































































































Name: Methotrexate Polyglutamate 
















































































































































Phthalocyanine Derivative 10 














Phthalocyanine Derivative 11 




















Phthalocyanine Derivative 12 
















Phthalocyanine Derivative 13 

















Phthalocyanine Derivative 14 

















Phthalocyanine Derivative 15 














































































































































































Phthalocyanine Derivative 5a 




















































































































































































































































Name: Saponin Derivative 1a 











Name: Saponin Derivative 1b 













Name: Saponin Derivative 2 










Name: Saponin Derivative 3 










Name: Iejimalide Derivative 8 








Phthalocyanine Derivative 3 























































Porphyrin-Bile Acid Conjugate 
1 





















Porphyrin-Bile Acid Conjugate 
2 























Porphyrin-Bile Acid Conjugate 
3 





















Porphyrin-Bile Acid Conjugate 
4 










































































































































































































































































The chemical compounds with reported subcellular localization site in the 
mitochondrion. References information is available in Appendix H. Structure is 
presented as the Simplified Molecular Input Line Entry Specification string of the 
major microspecies at pH 7.4, as calculated by ChemAxon.  
 
Name: Valproic acid 
Method: Uptake/Binding 




Method: Pharmacological Effect 
















Method: Pharmacological Effect 
References: 4, 717 
Structure: Clc1cccc(NN=C(C#N)C#N)c1 
  
Name: Clofibric acid 


















Name: Nalidixic acid 































Method: Fluorescence Microscopy 












Name: Trichlorophenoxyacetic acid 






























Method: Cell Fractionation 




















Method: Pharmacological Effect 












Name: Nitroxinil; Nitroxynil 












Name: Pyronine; Pyronin Y 
Method: Fluorescence Microscopy 






























Name: Safranin O 








































Method: Pharmacological Effect 


























Name: D632; dihydrorhodamine 123 
Method: Fluorescence Microscopy 





Name: Phosphate diethylstilbesterol 






















Name: Malachite green 
Method: Uptake/Binding 













































Name: Crystal violet 
Method: Uptake/Binding 







Method: Pharmacological Effect 
















M7511; MitoTracker® Orange 
CM-H2TMRos 
Method: Fluorescence Microscopy 





























Name: Perfluorooctanoic acid 

















M7510; MitoTracker® Orange 
CMTMRos; 
Tetramethylrosamine 















Method: Fluorescence Microscopy 






R14060; RedoxSensor™ Red 
CC-1 








Method: Pharmacological Effect 






Name: Rhodamine 6G 
Method: Fluorescence Microscopy 






Name: D633; Dihydrorhodamine 6G 
Method: Fluorescence Microscopy 






Name: Cyhalothrine; Cyhalothrin 




















Method: Fluorescence Microscopy 






Name: Betulinic acid 







Name: Victoria blue 







Name: Rhodamine B  
Method: Fluorescence Microscopy 















M7513; MitoTracker® Red 
CM-H2XRos 









methyl ester, perchlorate; 
TMRM 


















Name: Janus green B 








Name: Perfluorodecanoic acid 










ethyl ester, perchlorate; 
TMRE 








M7512; MitoTracker® Red 
CMXRos 
Method: Fluorescence Microscopy 







M22426; MitoTracker® Deep 
Red 633 







Name: Protoporphyrin IX 
Method: Uptake/Binding 









Name: Xanthomegnin  































cyanine iodide; JC-1; 
CBIC2(3) 








M7514; MitoTracker® Green 
FM 




























M22425; MitoTracker® Red 
580 








Name: Rhodopinal glucoside; RPA 



















Name: Rhodamine 123 







Name: Methylene Blue 












































Method: Cell Fractionation 












Method: Cell Fractionation 







































































Method: Fluorescence Microscopy 


















































































































































































Name: Rhodamine 110; Rh 110 










orange 10-hexyl bromide  









acridine orange 10-methyl 
iodide 









acridine orange 10-nonyl 
bromide 















Name: Rhodamine 3B; R3B 

















































Name: Photofrin  








Name: Aminolevulinic Acid 














Name: Mesochlorin; Mce6 















































Name: Porphyrin Derivative 4 










Name: Chlorin 30 











Name: Bacteriochlorin 31 











Name: 6-Aminoquinoline Derivative 2 







Name: 6-Aminoquinoline Derivative 3 


















































































































Name: XF 70 








Name: XF 73 











Silicon (IV) Phthalocyanine; 
SIPc[C3H5(NMe2)2O](OMe)  
Method: Fluorescence Microscopy 










Method: Fluorescence Microscopy 











Method: Fluorescence Microscopy 








































































































Name: Bacteriochlorin Derivative 16 









Name: Bacteriochlorin Derivative 17 









Name: Bacteriochlorin Derivative 18 









Name: Bacteriochlorin Derivative 19 









Name: Bacteriochlorin Derivative 20 



































































Name: Cyanine Dye Conjugate 4b 






Name: Cyanine Dye Conjugate 6b 








Name: Cyanine Dye Conjugate 7b 







Name: Cyanine Dye Conjugate 4c 










Name: Cyanine Dye Conjugate 6c 










Name: Cyanine Dye Conjugate 7c 
























Name: Fusaric Acid 









































Name: Aflatoxin B1 






Name: Rubratoxin B 





































































































Name: Methylene Blue Derivative 

































































Name: Coenzyme Q9 









Name: Conenzyme Q10 














































































Name: DMSP-Coumarin Derivative 4 







Name: DMSP-Coumarin Derivative 5 















































































































































































































































































Name: Porphyrazine 16⁰ 





















































































Name: Hexadecanedioic Acid 







Name: PBR Fluorescent Derivative 4 



















Name: Toluidine blue O  
Method: Distr.others  













The chemical compounds with reported subcellular localization site in the 
nucleus. References information is available in Appendix H. Structure is 
presented as the Simplified Molecular Input Line Entry Specification string of the 
major microspecies at pH 7.4, as calculated by ChemAxon.  
 
Name: DAPI  







Name: Ethidium bromide 
Method: Fluorescence Microscopy  







E1374; Ethidium monoazide 
bromide; EMA  
Method: Fluorescence Microscopy  






Name: L7595; LDS 751  
Method: Fluorescence Microscopy  








Method: Fluorescence Microscopy  







benzimide); Hoechst 33258 







Name: H21486; Hoechst 34580 










trihydrate; Hoechst 33342 









P3581; PO-PRO™ 1 iodide 
(435/455) 







N21485; Hoechst S769121, 
trihydrochloride, trihydrate; 
Nuclear yellow 


















Y3603; YO-PRO®-1 iodide 
(491/509) 










T3602; TO-PRO®-1 iodide 
(515/531) 








Y3607; YO-PRO®-3 iodide 
(612/631) 







Name: P1304MP; Propidium Iodide 








T3605; TO-PRO®-3 iodide 
(642/661) 









9-acridinyl) spermine; Acridine 
homodimer  



















E1169; Ethidium homodimer-1; 
EthD-1 





















B3586; BOBO™3 iodide 
(570/602) 






































Y3601; YOYO®-1 iodide 
(491/509) 











E3599; Ethidium homodimer-2; 
EthD-2 











T3600; TOTO®-1 iodide 
(514/533) 






















T3604; TOTO®-3 iodide 
(642/660) 










































Name: Chromomycin A3 











Name: SYBR Green I 











































































































Name: Polyamide 1 














Name: Polyamide 3 














Name: Polyamide 5 














Name: Polyamide 6 
















Name: Polyamide 11 














Name: Polyamide 12 














Name: Polyamide 13 














Name: Polyamide 14 














Name: Polyamide 22 
























Name: Flunitrazepam  






Name: BODIPY-labeled Polyamide 2  















Name: Uracil Mustard 






































Name: Mitoxantrone  
















Name: Cascade Blue Derivative 2  








Name: Cascade Blue Derivative 3 







Name: Cascade Blue Derivative 4 








Name: Cascade Blue Derivative 10 







Name: Cascade Blue Derivative 11 







Name: Cascade Blue Derivative 14 








Name: Cascade Blue Derivative 15 









Name: Cascade Blue Derivative 16 










Name: Cascade Blue Derivative 19 









Name: Cascade Blue Derivative 20 




























Name: Daunorubicin Analogue 1 

















Name: BBR 3422 











Name: DB75; Furamidine 


















































































Name: Zinc Benzochlorin 































Name: ß-Carboline Derivative A 






Name: ß-Carboline Derivative B 






Name: ß-Carboline Derivative C 






Name: ß-Carboline Derivative D 







Name: ß-Carboline Derivative E 








Name: Sanguinarine  


























































































Name: Hoechst 33377 (H1)  







Name: Hoechst 33342 (H20) 























Name: BNIPSpd  






























Conjugate 50a  
































Name: Polyamide-FITC Conjugate 1  














Name: Polyamide-FITC Conjugate 2 

































































The chemical compounds with reported subcellular localization site in the 
plasma membrane. References information is available in Appendix H. 
Structure is presented as the Simplified Molecular Input Line Entry Specification 





Method: Fluorescence Microscopy 

























Name: P36005; Cis-parinaric acid 
Method: Fluorescence Microscopy 





























BODIPY® FL C5 









sulfonic acid, sodium salt; 2,6-
TNS 



































Name: P96;1-pyrenedodecanoic acid 
248 
 



















3-nonanoic acid; BODIPY® 
500/510 C4, C9 
Method: Fluorescence Microscopy 









3-dodecanoic acid; BODIPY® 
500/510 C1, C12 










3-pentanoic acid; BODIPY® 
500/510 C8, C5 











BODIPY® FL C11 





































BODIPY® FL C16 























undecanoic acid; BODIPY® 
581/591 C11 






































































phosphate, diammonium salt; 



























phosphocholine; NBD C6-HPC 





























BODIPY® FL C12 












methylpyridinium iodide; DiA 















BODIPY® FL C5-HPC 





















































































phosphocholine ; BODIPY® FL 
C12-sphingomyelin 













perchlorate; FAST DiO™ solid; 










































BODIPY® 500/510 C12-HPC 















BODIPY® FL C12-HPC 















DiA™ solid; DiDelta9,12- 
C18ASP, CBS 














BODIPY® 530/550 C5-HPC 

























perchlorate; FAST DiI™ oil; 
DiIDelta9,12- C18(3), ClO4 












perchlorate; DiI'; DiIC18(3) 
Method: Fluorescence Microscopy 































Method: Fluorescence Microscopy 











perchlorate; DiD' oil; DiIC18(5) 
oil 









P22652; Pacific Blue™ 1,2-
ditetradecanoyl-sn-glycero-3- 
phosphoethanolamine, 











































iodid; DiR; DiIC18(7) 





























































Name: C7000; CellTracker™ CM-DiI 










O12650; Oregon Green® 488 
1,2-dihexadecanoyl-sn-glycero-
3- phosphoethanolamine; 















oxacarbocyanine, sodium salt; 
SP-DiOC18(3) 


































































triethylammonium salt; TRITC 
DHPE 














Name: Hostalux SN 






Name: Uvitex EBF 






Name: Blancophor DCR 






Name: MPPT  
























































Name: Cytochalasin D 




















Name: CIBC Derivative 2 










CICD Derivative 5; 13,15-N-
cycloimide Derivatives of 
Chlorin p10 


















Name: Evans Blue 










Name: SnNT2H2 (Cl2) 








Name: EBCS  
















Name: JPW-3028; Di-1-ANEPEQ 






Name: JPW-3080; Di-1-APEFEQPQ 







Name: JPW-600; Di-4-ANBDQPQ 







Name: JPW-4090; Di-2-ANBDQPQ 







Name: PY-1261; Di-2-BTEPPTEA 







Name: PY-1268; Di-2-TTEPPTEA 







Name: PY-1286; Di-3-BTEPPTEA 







Name: PY-1266; Di-4-BTEPPTEA 
















































































































































































































Name: JPW5037; di-8-ANEPPS 
Method: Fluorescence Microscopy 















































































































































Name: C6ABz PC 



















Name: C8ABz PC 









Name: C8ABzC4 PC 









Name: 1-Pyrene Butyric Acid; PBA 







Name: Lepidine Dye 









Name: Indolenine Dye 








Name: Benzthiazole Dye 







Name: Sulfindolenine Dye 








Name: Benzoxazole Dye 







Name: Sulfoindolenme Dye 








Name: Methoxyquinaldine Dye 







Name: Methoxylepidine Dye 








Name: Amethyst Violet 















































































Name: RH237  




















Fluorophore Derivative 22 












Fluorophore Derivative 23:::::: 








































The chemical compounds with reported subcellular localization site in the 
endoplasmic reticulum and Golgi apparatus. References information is 
available in Appendix H. Structure is presented as the Simplified Molecular Input 
Line Entry Specification string of the major microspecies at pH 7.4, as calculated 
by ChemAxon.  
 
Name: B7450; Brefeldin A 
Method: Fluorescence Microscopy 

















B7447; Brefeldin A, BODIPY® 
FL conjugate; gBFA I 












e; NBD C6-ceramide 






















BODIPY® FL C5-ceramide 









B7449; Brefeldin A, BODIPY®  
558/568 conjugate; rBFA 













; BODIPY® TR ceramide 














phosphocholine ; BODIPY® 
FL C5-sphingomyelin 












E34251; ER-Tracker™ Green; 




























E34250; ER-Tracker™ Red; 
BODIPY® TR glibenclamide 










































Name: gBFA II 


































Name: CIBC Derivative 1  









Name: CIBC Derivative 5 
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Name: CIBC Derivative 10 






























Name: Okadaic Acid 











Conjugate 13  








Name: Vitamin K 





























Derivative 5  














































Name: SNAFR-6  















Name: Hypericin Derivatives 2 








Name: Hypericin Derivatives 3 








Name: Hypericin Derivatives 4 








Name: Hypericin Derivatives 5 









Method: Fluorescence Microscopy 










Method: Fluorescence Microscopy 





























The chemical compounds with reported subcellular localization site in the 
cytosol. References information is available in Appendix H. Structure is 
presented as the Simplified Molecular Input Line Entry Specification string of the 
major microspecies at pH 7.4, as calculated by ChemAxon.  
 
Name: Gentamicin 
Method: Cell Fractionation 








L7525; LysoTracker® Blue 
DND-22  






















PBD Derivative 5; 7-
Diethylaminocoumarin 
pyrrolobenzodiazepine 
derivative 5  































Name: 6-Aminoquinoline Derivative 1 






































Name: Aclacinomycin A  









Name: Rose Bengal Acetate  











yl)porphyrin tri-iodide  









Name: Photolabeled BBR 3422 







Name: 4-DCB; 4,4'-dichlorobiphenyl 





















Name: 2-Chloroaniline  














Name: ZnPcS3C2  













































Name: Ergocalciferol; Vitamin D2 







Name: Cholecalciferol; Vitamin D3 









Phthalocyanine Derivative 4  












Phthalocyanine Derivative 5 












Phthalocyanine Derivative 8 












Name: DCHQ Derivative 1 






Name: Porphyrazine A4 Derivative 5  













Name: Porphyrazine A4 Derivative 8 














Porphyrazine A3B Derivative 
6 













Porphyrazine A3B Derivative 
9 















Porphyrazine A2B2 Derivative 
7 












Porphyrazine A2B2 Derivative 
10 












Pentaphyrin Derivative 1; 
isopentaphyrin  










Pentaphyrin Derivative 2; 
pentaphyrin 






















































Name: Iejimalide Derivative 7b 









































Phthalocyanine Derivative 9 
















Phthalocyanine Derivative 17 











Phthalocyanine Derivative 19 















































































aminoacridine Derivative 1 







aminoacridine Derivative 2 






aminoacridine Derivative 3 

















































































The chemical compounds with multiple reported subcellular localization 
sites. Localization 1: endo-lysosomes; 2: mitochondria; 3: nucleus; 4: plasma 
membrane; 5: endoplasmic reticulum and Golgi apparatus; and 6: cytosol. 
References information is available in Appendix H. Structure is presented as the 
Simplified Molecular Input Line Entry Specification string of the major 
microspecies at pH 7.4, as calculated by ChemAxon.  
 
Name: A1301; Acridine orange 
Localization: 1, 3 








Method: Pharmacological Effect 








Localization: 2, 3 






Name: N1142; Nile red 
Localization: 1, 3, 4 
















Name: Trifluoperazine (TFP) 
Localization: 1, 2 











Localization: 1, 4 






Name: H7593; Hexidium iodide 





















R648MP; rhodamine B, hexyl 
ester, perchlorate (R6) 
Localization: 2, 6 














D-lactoside; BODIPY® FL C5-
lactosylceramide 











Localization: 1, 3 







Localization: 1, 3 






Name: Acridine orange R 
Localization: 1, 3 







Localization: 2, 4 



















acridine orange 10-hexadecyl 
bromide 
Localization: 2, 6 










Localization: 1, 3 












Name: Merocyanine 540 
Localization: 1, 2, 4 








Localization: 1, 2 









Localization: 3, 4 







Localization: 4, 5 







Name: Toluidine Blue 
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Localization: 4, 5 







Localization: 2, 3 






Name: BODIPY-labeled Polyamide 1 
Localization: 1, 5 















Localization: 3, 6 






Name: Motexafin Gadolinium 
Localization: 1, 2, 5 











Name: HB; Hypocrellin B 
Localization: 1, 4 











Localization: 1, 4 








Name: HBBA-R2; Butylaminated HB 
Localization: 4, 5 









Localization: 2, 3 









Name: Guanidine Porphyrin 
Localization: 1, 2, 5 









Name: Biguanidine Porphyrin 
Localization: 1, 2 










Localization: 2, 5 
















Localization: 2, 5 









Localization: 1, 5, 6 








Name: CIBC Derivative 3 
Localization: 4, 5 









Name: CIBC Derivative 4 
Localization: 4, 5 









Name: CIBC Derivative 6 
Localization: 4, 5 









Name: CIBC Derivative 8 
Localization: 4, 5 









Name: CIBC Derivative 9 
Localization: 4, 5 









Name: CIBC Derivative 11 
Localization: 4, 5 










CICD Derivative 1; 13,15-N-
cycloimide Derivatives of 
Chlorin p6 
Localization: 2, 5 










CICD Derivative 2; 13,15-N-
cycloimide Derivatives of 
Chlorin p7 
Localization: 2, 5 












CICD Derivative 3; 13,15-N-
cycloimide Derivatives of 
Chlorin p8 
Localization: 2, 5 










CICD Derivative 4; 13,15-N-
cycloimide Derivatives of 
Chlorin p9 
Localization: 2, 5 












Localization: 1, 2 












Localization: 1, 2 












Localization: 1, 2 












Localization: 1, 2, 3, 5 









CAME (Chlorin e6 
triacetoxymethyl ester) 
(Lysosomes) 
Localization: 1, 2 










Localization: 4, 6 








Localization: 1, 3 







Localization: 1, 5 









Localization: 3, 4  








Name: Distamycin Analogue 10 
Localization: 2, 6 











Localization: 1, 5 











Localization: 3, 6 















Localization: 3, 6 








Localization: 2, 3 








Localization: 1, 3 











Localization: 1, 2 














Localization: 4, 5 






















Localization: 4, 5 

























Localization: 1, 3 






Name: RP 38422 
Localization: 1, 3 








Name: RP 21080 
Localization: 1, 3 








Localization: 1, 4 











Localization: 1, 5 
















Localization: 1, 5 
















Localization: 1, 5 
































Localization: 4, 6 
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Localization: 1, 2, 5 










TPP Conjugate 6 
Localization: 2, 5 













TPP Conjugate 7 
Localization: 2, 5 















TPP Conjugate 8 
Localization: 1, 2 

















TPP Conjugate 9 
Localization: 1, 2 


















Localization: 2, 3, 5 







Localization: 4, 6 










Localization: 4, 6 










Localization: 2, 3, 6 
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Localization: 1, 3 








Localization: 1, 4 








Localization: 1, 5 








Localization: 1, 6 








Localization: 1, 3 








Localization: 1, 3 







aminoacridine Derivative 13 
Localization: 3, 6 









Localization: 3, 6 
















Localization: 3, 6 

















Localization: 3, 6 

















Localization: 2, 3 








Name: Org 6368 
Localization: 2, 3 








Localization: 1, 2 








Name: Ageladine A 
Localization: 1, 4 







Localization: 2, 3 






Name: Chlorin 1 
Localization: 1, 2, 5 









Name: Chlorin 3 
Localization: 1, 2 









Name: Chlorin 4 
Localization: 1, 2 










Localization: 2, 6 
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Chemical structures of the random dataset from DrugBank representing 
molecules with drug properties. Structure is presented as the Simplified 
Molecular Input Line Entry Specification string of the major microspecies at pH 
7.4, as calculated by ChemAxon. 
 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chemical structures of the random sample from PubChem database 
representing small organic compounds without drug related properties and 
without subcellular localization information. Structure is presented as the 
Simplified Molecular Input Line Entry Specification string of the major 
microspecies at pH 7.4, as calculated by ChemAxon. 
 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Matlab code for cellular parameters used in T and R models for studying lysosomotropic behavior.  This also is the Matlab 
code of numerical solution for coupled ordinary differential equation.  All explanations come after the symbol „%'. 
 
% The R-Model 
 




T = 310.15;                           % temperature (37centigrade) 
R = 8.314;                            % universal gas constant 
F = 96484.56;                        % faraday constant 
La = 0;                               % lipid fraction in apical compartment 
Lc = 0;                               % lipid fraction in cytosol 
Lm = 0;                               % lipid fraction in mitochondria 
Ll = 0;                               % lipid fraction in lysosomes 
Lb = 0;                               % lipid fraction in basolateral compartment 
Wa = 1-La;                           % water fraction in apical compartment 
Wc = 1-Lc;                           % water fraction in cytosol 
Wm = 1-Lm;                           % water fraction in mitochondria  
Wl = 1-Ll;                           % water fraction in lysosomes 
Wb = 1-Lb;                           % water fraction in basolateral compartment 
gamma_na = 1;              % activity coefficient of neutral molecules in apical compartment 
gamma_da = 1;              % activity coefficient of ionic molecules in apical compartment 
gamma_nc = 1.23026877;        % activity coefficient of neutral molecules in cytosol 
gamma_dc = 0.73799822;        % activity coefficient of ionic molecules in cytosol 
gamma_nm = 1.23026877;        % activity coefficient of neutral molecules in mitochondria 
gamma_dm = 0.73799822;        % activity coefficient of ionic molecules in mitochondria 
gamma_nl = 1.23026877;         % activity coefficient of neutral molecules in lysosomes 
gamma_dl = 0.73799822;         % activity coefficient of ionic molecules in lysosomes    
gamma_nb = 1;                         % activity coefficient of neutral molecules in basolateral  
gamma_db = 1;                         % activity coefficient of ionic molecules in basolateral  
 351 
 
Ca = 1 ;                              % apical initical drug concentration (mM) 
 
% areas and volumes (m^2, m^3) 
% epithelium is considered as a square with the lengh of 10^(-5)m.  
% mitochondria and lysosomes are considered as spheres with the diameter of 10^(-6)m 
Aa = 50*10^(-10) ;                  % the apical membrane surface area 
Aaa = 20*10^(-10) ;                 % the monolayer area 
Am = 100*3.14*10^(-12);          % the mitochondrial membrane surface area  
Al = 100*3.14*10^(-12);          % the lysosomal membrane surface area 
Ab = 10^(-10);                       % the basolateral membrane surface area 
Vc = 10*10^(-15);                    % the cytosolic volume 
Vm = 100*5.24*10^(-19);             % the mitochondrial volume, 100 mitochondria 
Vl = 100*5.24*10^(-19);              % the lysosomal volume, 100 lysosomes 
Vb = 4.7*10^(-3);                   % the volume of basolateral compartment 
 
% Membrane potential (units in 'Voltage') 
Ea = -0.0093 ;                       % apical membrane potential 
Em = -0.15 ;                         % mitochondrial membrane potential 
El = 0.01 ;                          % lysosomal membrane potential 
Eb = 0.0119 ;                        % basolateral membrane potential 
 
% pH values 
pHa = 5.5 ;                          % pH value in apical compartment 
pHc = 7.0 ;                          % pH value in cytosol 
pHm = 8.0 ;                          % pH value in mitochondria 
pHl = 5.0 ;                          % pH value in lysosomes 
pHb = 7.4 ;                          % pH value in basolateral compartment 
       
% read drug properties from files 
[DrugName,pKaall,logPnall,logPdall, ZNall] = textread('Molecules.txt', 
'%s %f %f %f %f','commentstyle','matlab'); 
 
% The calculated results are saved in this file 'MoleculesR.dat' 
 352 
len = length(pKaall) ; 
fid1 = fopen('MoleculesR.dat','w'); 
str1 = ' Name --------------- pKa ----- logP_n ---logP_d---Cc(mM)-----Cm(mM)-------Clyso(mM)------
-Peff(cm/sec) ' ; 
fprintf(fid1,'%s\n',str1) ; 
 
% liposomal approximation for logP_n and logP_d 
for n = 1:len 
    if ( abs(ZNall(n)-1) <= 10^(-6) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.37*logPdall(n)+2 ; 
    end 
    if ( abs(ZNall(n)+1) <= 10^(-6) )  
        logP_nlipT(n) = 0.37*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.6 ; 
    end 
    if ( abs(ZNall(n)-0) <= 10^(-5) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.2 ; 
    end 
end 
 
% Get the first two decimals. 
logP_nlip = round(logP_nlipT*100)/100 ; 
logP_dlip = round(logP_dlipT*100)/100 ; 
 
% solve differential equations 
 
for n = 1:len 
    pKa = pKaall(n); 
    logP_n = logP_nlip(n) ; 
    logP_d = logP_dlip(n) ;     
    z = ZNall(n) ;  
    i = -sign(z) ; 
 353 
    Na = ((z)*(Ea)*F)/(R*T); 
    Nm = ((z)*(Em)*F)/(R*T); 
    Nl = ((z)*(El)*F)/(R*T); 
    Nb = ((z)*(-Eb)*F)/(R*T);   
     
    Pn = 10^(logP_n-6.7); 
    Pd = 10^(logP_d-6.7); 
    Kn_a = La*1.22*10^(logP_n); 
    Kd_a = La*1.22*10^(logP_d); 
    Kn_c = Lc*1.22*10^(logP_n); 
    Kd_c = Lc*1.22*10^(logP_d); 
    Kn_m = Lm*1.22*10^(logP_n); 
    Kd_m = Lm*1.22*10^(logP_d); 
    Kn_l = Ll*1.22*10^(logP_n); 
    Kd_l = Ll*1.22*10^(logP_d); 
    Kn_b = Lb*1.22*10^(logP_n); 
    Kd_b = Lb*1.22*10^(logP_d);   
     
    fn_a = 1/(Wa/gamma_na+Kn_a/gamma_na+Wa*10^(i*(pHa-pKa))/gamma_da... 
           +Kd_a*10^(i*(pHa-pKa))/gamma_da); 
    fd_a = fn_a*10^(i*(pHa-pKa)); 
    fn_c = 1/(Wc/gamma_nc+Kn_c/gamma_nc+Wc*10^(i*(pHc-pKa))/gamma_dc... 
           +Kd_c*10^(i*(pHc-pKa))/gamma_dc); 
    fd_c = fn_c*10^(i*(pHc-pKa)); 
    fn_m = 1/(Wm/gamma_nm+Kn_m/gamma_nm+Wm*10^(i*(pHm-pKa))/gamma_dm... 
           +Kd_m*10^(i*(pHm-pKa))/gamma_dm); 
    fd_m = fn_m*10^(i*(pHm-pKa)); 
    fn_l = 1/(Wl/gamma_nl+Kn_l/gamma_nl+Wl*10^(i*(pHl-pKa))/gamma_dl... 
           +Kd_l*10^(i*(pHl-pKa))/gamma_dl); 
    fd_l = fn_l*10^(i*(pHl-pKa)); 
    fn_b = 1/(Wb/gamma_nb+Kn_b/gamma_nb+Wb*10^(i*(pHb-pKa))/gamma_db... 
            +Kd_b*10^(i*(pHb-pKa))/gamma_db); 
    fd_b = fn_b*10^(i*(pHb-pKa)); 
 
 354 
    k11 = -(Aa/Vc)*Pn*fn_c-(Aa/Vc)*Pd*Na*fd_c*exp(Na)/(exp(Na)-1)... 
           -(Am/Vc)*Pn*fn_c-(Am/Vc)*Pd*Nm*fd_c/(exp(Nm)-1)... 
           -(Al/Vc)*Pn*fn_c-(Al/Vc)*Pd*Nl*fd_c/(exp(Nl)-1)... 
           -(Ab/Vc)*Pn*fn_c-(Ab/Vc)*Pd*Nb*fd_c/(exp(Nb)-1) ; 
 
    k12 = (Am/Vc)*Pn*fn_m+(Am/Vc)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k13 = (Al/Vc)*Pn*fn_l+(Al/Vc)*Pd*Nl*fd_l*exp(Nl)/(exp(Nl)-1) ;  
    k14 = (Ab/Vc)*Pn*fn_b+(Ab/Vc)*Pd*Nb*fd_b*exp(Nb)/(exp(Nb)-1) ; 
    S1 = (Aa/Vc)*Ca*(Pn*fn_a+Pd*Na*fd_a/(exp(Na)-1)) ; 
 
    k21 = (Am/Vm)*Pn*fn_c+(Am/Vm)*Pd*Nm*fd_c/(exp(Nm)-1) ; 
    k22 = -(Am/Vm)*Pn*fn_m-(Am/Vm)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k23 = 0 ; 
    k24 = 0 ; 
    S2 = 0 ; 
 
    k31 = (Al/Vl)*Pn*fn_c+(Al/Vl)*Pd*Nl*fd_c/(exp(Nl)-1) ; 
    k32 = 0 ;  
    k33 = -(Al/Vl)*Pn*fn_l-(Al/Vl)*Pd*Nl*fd_l*exp(Nl)/(exp(Nl)-1) ; 
    k34 = 0 ; 
    S3 = 0 ; 
     
    k41 = (Ab/Vb)*Pn*fn_c+(Ab/Vb)*Pd*Nb*fd_c/(exp(Nb)-1) ; 
    k42 = 0 ; 
    k43 = 0 ; 
    k44 = -(Ab/Vb)*Pn*fn_b-(Ab/Vb)*Pd*Nb*fd_b*exp(Nb)/(exp(Nb)-1) ; 
    S4 = 0 ; 
 
    A = [k11, k12, k13, k14; k21, k22, k23, k24; k31, k32, k33, k34; k41, k42, k43, k44] ; 
    G = [S1, S2, S3, S4]' ; 
    RR = [0,0,0,0]' ;       % initial conditions: at t = 0, Ccyto=0; Cmito=0; Clyso=0; Cbaso=0 
  t = 10^6 ;              % the time point at which intracellular / subcellular … 
                          %concentrations were calculated 
 
 355 
    % Solve the system. 
    [V,E] = eig(A); 
    E = diag(E); 
    H = inv(V)*G; 
    B = V \ RR; 
    C = B + H./E; 
    Z = -(H./E) + exp(t * E).*C ; 
    Y = real(V * Z); 
    Y = Y'; 
    Peff = Y(4)*Vb*10^8/(t*Aaa*Ca); 
    NA = [pKa, logP_n, logP_d, Y(1),Y(2),Y(3), Peff]; 
    str = DrugName{n}; 
    fprintf(fid1,'%s\t %12.2f %12.2f %12.2f %12.4f %12.4f  %12.4f %12.4f\n',str, NA') ;   
end 
    fclose(fid1); 
  
     
     




T = 310.15 ;                         % Temperature 
R = 8.314 ;                          % Universal gas constant 
F = 96484.56 ;                       % Faraday constant 
Lo = 0 ;                              % Lipid fraction in apical compartment 
Lc = 0 ;                              % Lipid fraction in cytosol 
Lm = 0 ;                              % Lipid fraction in mitochondria 
Ll = 0 ;                              % Lipid fraction in lysosomes 
Wo = 1-Lo ;                          % Water fraction in apical compartment 
Wc = 1-Lc ;                          % Water fraction in cytosol 
Wm = 1-Lm ;                          % Water fraction in mitochondria  
Wl = 1-Ll ;                          % Water fraction in lysosomes  
gamma_no = 1;                      % activity coefficient of neutral molecules out of the cells 
 356 
gamma_do = 1;                      % activity coefficient of ionic molecules out of the cells 
gamma_nc = 1.23026877;         % activity coefficient of neutral molecules in cytosol 
gamma_dc = 0.73799822;         % activity coefficient of ionic molecules in cytosol 
gamma_nm = 1.23026877;         % activity coefficient of neutral molecules in mitochondria 
gamma_dm = 0.73799822;         % activity coefficient of ionic molecules in mitochondria 
gamma_nl = 1.23026877;         % activity coefficient of neutral molecules in lysosomes 
gamma_dl = 0.73799822;         % activity coefficient of ionic molecules in lysosomes    
 
% areas and volumes (units in m^2 and m^3 respectively) 
Ac = 3.14*10^(-10) ;           % the suface area of a floating-cell, 10 um (10^-5m) diameter 
Vc = 5.24*10^(-16) ;           % the cytosolic volume 
Am = 30*4*pi*(1*10^(-6))^2 ;              % the mitochondrial membrane surface area 
Vm = 30*(4/3)*pi*(1*10^(-6))^3 ;        % the mitochondrial volume 
Al = 20*4*pi*(0.5*10^(-6))^2 ;            % the lysosomal membrane surface area 
Vl = 20*(4/3)*pi*(0.5*10^(-6))^3 ;        % the lysosomal volume, 20 lysosomes 
 
% membrane potential (units in 'Voltage') 
Ec = -0.06 ;                         % the plasma membrane potential 
Em = -0.15 ;                         % the mitochondrial membrane potential 
El = 0.01 ;                          % the lysosomal membrane potential 
    
% pH values 
pHo = 7.4 ;                          % the extracellular pH value 
pHc = 7 ;                            % the cytosolic pH 
pHm = 8 ;                            % the mitochondrial pH  
pHl = 5 ;                            % the lysosomal pH 
 
Co = 1 ;                             % the extracellular drug concentration, unit in mM 
 
% Read drug properties from files 
[DrugName,pKaall,logPnall,logPdall, ZNall] = textread('Molecules.txt', 
'%s %f %f %f %f','commentstyle','matlab'); 
 
% The calculated results are saved in this file 'MoleculesT.dat' 
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len = length(pKaall) ; 
fid1 = fopen('MoleculesT.dat','w'); 
str1 = ' Name --------------- pKa ----- logP_n ---logP_d---Cc(mM)-----Cm(mM)-------Clyso(mM) ' ; 
fprintf(fid1,'%s\n',str1) ; 
 
% liposomal approximation for logP_n and logP_d 
for n = 1:len 
    if ( abs(ZNall(n)-1) <= 10^(-6) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.37*logPdall(n)+2 ; 
    end 
    if ( abs(ZNall(n)+1) <= 10^(-6) )  
        logP_nlipT(n) = 0.37*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.6 ; 
    end 
    if ( abs(ZNall(n)-0) <= 10^(-5) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.2 ; 
    end 
end 
 
% Get the first two decimals 
logP_nlip = round(logP_nlipT*100)/100 ; 
logP_dlip = round(logP_dlipT*100)/100 ; 
 
% solve differential equations 
for n = 1:len 
    pKa = pKaall(n); 
    logP_n = logP_nlip(n) ; 
    logP_d = logP_dlip(n) ; 
    z = ZNall(n) ;  
    i = -sign(z) ; 
    Nc = ((z)*(Ec)*F)/(R*T); 
    Nm = ((z)*(Em)*F)/(R*T); 
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    Nl = ((z)*(El)*F)/(R*T); 
     
    Pn = 10^(logP_n-6.7) ; 
    Pd = 10^(logP_d-6.7) ; 
    Kn_o = Lo*1.22*10^(logP_n) ; 
    Kd_o = Lo*1.22*10^(logP_d) ; 
    Kn_c = Lc*1.22*10^(logP_n) ; 
    Kd_c = Lc*1.22*10^(logP_d) ; 
    Kn_m = Lm*1.22*10^(logP_n) ; 
    Kd_m = Lm*1.22*10^(logP_d) ;  
    Kn_l = Ll*1.22*10^(logP_n) ; 
    Kd_l = Ll*1.22*10^(logP_d) ; 
         
    fn_o = 1/(Wo/gamma_no+Kn_o/gamma_no+Wo*10^(i*(pHo-pKa))/gamma_do... 
           +Kd_o*10^(i*(pHo-pKa))/gamma_do) ; 
    fd_o = fn_o*10^(i*(pHo-pKa)) ; 
    fn_c = 1/(Wc/gamma_nc+Kn_c/gamma_nc+Wc*10^(i*(pHc-pKa))/gamma_dc... 
           +Kd_c*10^(i*(pHc-pKa))/gamma_dc) ; 
    fd_c = fn_c*10^(i*(pHc-pKa)) ; 
    fn_m = 1/(Wm/gamma_nm+Kn_m/gamma_nm+Wm*10^(i*(pHm-pKa))/gamma_dm... 
           +Kd_m*10^(i*(pHm-pKa))/gamma_dm) ; 
    fd_m = fn_m*10^(i*(pHm-pKa)) ; 
    fn_l = 1/(Wl/gamma_nl+Kn_l/gamma_nl+Wl*10^(i*(pHl-pKa))/gamma_dl... 
           +Kd_l*10^(i*(pHl-pKa))/gamma_dl) ; 
    fd_l = fn_l*10^(i*(pHl-pKa)) ; 
       
    k11 = -(Ac/Vc)*Pn*fn_c-(Ac/Vc)*Pd*Nc*fd_c*exp(Nc)/(exp(Nc)-1)... 
           -(Am/Vc)*Pn*fn_c-(Am/Vc)*Pd*Nm*fd_c/(exp(Nm)-1)... 
           -(Al/Vc)*Pn*fn_c-(Al/Vc)*Pd*Nl*fd_c/(exp(Nl)-1); 
            
    k12 = (Am/Vc)*Pn*fn_m+(Am/Vc)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k13 = (Al/Vc)*Pn*fn_l+(Al/Vc)*Pd*Nl*fd_l*exp(Nl)/(exp(Nl)-1) ; 
    S1 = (Ac/Vc)*Co*(Pn*fn_o+Pd*Nc*fd_o/(exp(Nc)-1)) ; 
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    k21 = (Am/Vm)*Pn*fn_c+(Am/Vm)*Pd*Nm*fd_c/(exp(Nm)-1) ; 
    k22 = -(Am/Vm)*Pn*fn_m-(Am/Vm)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k23 = 0 ; 
    S2 = 0 ; 
 
    k31 = (Al/Vl)*Pn*fn_c+(Al/Vl)*Pd*Nl*fd_c/(exp(Nl)-1) ; 
    k32 = 0 ; 
    k33 = -(Al/Vl)*Pn*fn_l-(Al/Vl)*Pd*Nl*fd_l*exp(Nl)/(exp(Nl)-1) ;  
    S3 = 0; 
 
    A = [k11, k12, k13; k21, k22, k23; k31, k32, k33]; 
    G = [S1, S2, S3]' ; 
    RR = [0,0,0]' ; 
    t = 1000000 ;   
     
    [V,E] = eig(A) ; 
    E = diag(E) ; 
    H = inv(V)*G ; 
    B = V \ RR ; 
    C = B + H./E ; 
    Z = -(H./E) + exp(t * E).*C ; 
    Y = real(V * Z) ; 
    Y = Y' ; 
    NA = [pKa, logP_n, logP_d, Y] ; 
     
    str = DrugName{n}; 






MATLAB® code and R code for the Monte Carlos simulation of phospholipidosis effect on chloroquine 
intracellular accumulation. To simulate CQ uptake in MDCK cells with the assumption of lysosomal swelling and CQ 
binding to cellular lipid fractions, save Code_S1 and Code_S2 as .m files. To simulate CQ uptake in without binding, in 
Code_S1, use logPn,d1,d2 instead of logPn,d1,d2_cell in calculated sorption coefficients (Kn,d1,d2) in each compartment. To 
simulate CQ uptake without volume expansion, in Code_S2, substitute A_slope_Gr and V_slope_Gr (rate of change in 
lysosomal area or volume) to an array of 0s. MATLAB® R2009b was used to code the programs; higher versions 
MATLAB® should be able to run the files. Code_S3.txt was copied into R 2.8.1 program to plot Monte Carlos simulation of 
CQ uptake. To generate green or blue histograms when simulating uptake without binding or swelling, substitute code 
“col="black"” or “col="white"” to “col="green"” or “col="blue"” in the “hist” and “lines” command. 
 
1) Code _S1. m 
% The following section is to simulate the intracellular 
% concentration of CQ in MDCK cells with volume expansion in acidic 
% compartment and binding of CQ to cellular membrane structures.  
% Smiles: CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O 
% MDCK cells on 24well plates, 2cm^2 bottom, assuming 60*10^4 cell/well 
  




global V_l_initial A_l_initial V_c_initial A_a V_m A_m V_a i  
global Pn Pd1 Pd2  
global Nd1_a Nd1_m Nd1_l Nd2_a Nd2_m Nd2_l 
global fn_a fn_c fn_l fn_m  
global fd1_a fd1_c fd1_l fd1_m  
global fd2_a fd2_c fd2_l fd2_m   
  
% Constant 
T = 310.15 ;                % temperature 
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R = 8.314 ;                 % Universal gas constant 
F = 96484.56 ;              % Faraday constant 
  
% Group conditions: 1-4, CQ treatments (25, 50, 100, 200 uM); 5-8, CQ/Suc. 
% treatments (25, 50, 100, 200 uM); and 9-12, CQ/Baf. treatments (25, 50, 
% 100, 200 uM). 
  
C_aGr = [0.025, 0.050, 0.100, 0.200, 0.025, 0.050, 0.100, 0.200, 0.025,... 
    0.050, 0.100, 0.200] ;         % Apical initial drug concentration (mM) 
V_cGr_a = [1452, 1752, 1616, 1314, 2761, 2572, 2391, 2630, 1491, 1437,... 
    1512, 1608] ;                  % cell volume, lower bound (um^3) 
V_cGr_b = [1874, 1922, 2042, 1916, 3250, 3535, 3516, 3904, 1989, 1961,... 
    2022, 1945] ;                  % cell volume, upper bound (um^3) 
pH_lGr_a = [4.88, 5.22, 5.45, 5.20, 5.51, 5.73, 6.09, 6.25, 5.26, 5.05,... 
    5.64, 5.48] ;                  % pH in lysosome, lower bound 
pH_lGr_b = [5.84, 5.80, 6.17, 6.76, 6.31, 6.43, 6.81, 7.21, 5.84, 6.33,... 
    6.12, 7.04] ;                  % pH in lysosome, upper bound 
pH_cGr_a = [7.29, 7.34, 7.28, 7.27, 7.34, 7.34, 7.34, 7.32, 7.33, 7.32,... 
    7.29, 7.10] ;                  % cytosolic pH, lower bound 
pH_cGr_b = [7.43, 7.38, 7.42, 7.33, 7.40, 7.38, 7.40, 7.38, 7.43, 7.38,... 
    7.39, 7.24] ;                  % cytosolic pH, upper bound 
A_l_initial_Gr_a = [111.5, 111.5, 111.5, 111.5, 517.5, 517.5, 517.5,... 
    517.5, 111.5, 111.5, 111.5, 111.5] ;  
    % initial lysosomal membrane area, lower bound 
A_l_initial_Gr_b = [335.0, 335.0, 335.0, 335.0, 899.7, 899.7, 899.7,... 
    899.7, 335.0, 335.0, 335.0, 335.0] ; 
    % initial lysosomal membrane area, upper bound 
V_l_initial_Gr_a = [8.8, 8.8, 8.8, 8.8, 54.9, 54.9, 54.9, 54.9, 8.8,... 
    8.8, 8.8, 8.8] ; % initial lysosomal volume, lower bound 
V_l_initial_Gr_b = [32.4, 32.4, 32.4, 32.4, 128.0, 128.0, 128.0, 128.0,... 





for i = 1:1:12 
    for round = 1:1:10000 
  
C_a = C_aGr(i);                              % extracellular concentration 
cellNo = (50+20*rand())*10^4;                % cell number per well 
         
% Drug information -- ChemAxon calculation including logPn, pKa1, and pKa2 
pKa1 = 9.96+0.25-0.5*rand() ;  % higher pKa 
pKa2 = 7.47+0.25-0.5*rand() ;  % lower pKa 
z1 = 1 ;                       % electric charge 
z2 = 2 ;                       % electric charge 
i1 = sign(z1) ; 
i2 = sign(z2) ; 
logPn = 3.93+0.25-0.5*rand() ;  
    % logarithm of octanol/water partition coefficient for neutral species 
logPd1 = 0.43+0.25-0.5*rand() ; 
    % logarithm of octanol/water partition coefficient for +1 ion species 
logPd2 = -0.91+0.25-0.5*rand() ; 
    % logarithm of octanol/water partition coefficient for +2 ion species 
  
logPn_cell = 1.70+rand()*(1.83-1.70) ; 
logPd1_cell = 1.70+rand()*(1.83-1.70) ; 
logPd2_cell = 1.70+rand()*(1.83-1.70) ; 
    % logarithm of cellular partition coefficient for all three species 
     
Pn = 10^(logPn-6.7) ;          % membrane permeability for neutral species        
Pd1 = 10^(logPd1-6.7) ;        % membrane permeability for +1 ion species 
Pd2 = 10^(logPd2-6.7) ;        % membrane permeability for +2 ion species 
     
% pH values 
pH_a = 7.4+0.1*rand() ;                         % pH in apical compartment 
pH_c = pH_cGr_a(i)+(pH_cGr_b(i)-pH_cGr_a(i))*rand() ; % pH in cytosol 
pH_l = pH_lGr_a(i)+(pH_lGr_b(i)-pH_lGr_a(i))*rand() ; % pH in lysosomes 
pH_m = 8.0;                                           % pH in mitochondria 
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% lipid fractions 
L_l = 0.025+0.05*rand() ;           % lipid fraction in lysosomes 
L_c = 0.05 ;           % lipid fraction in cytosol 
L_m = 0.05 ;                        % lipid fraction in mitochondria 
  
% Areas and volumes (units in m^2 and m^3) 
A_a = 100*10^(-10) ;                 % apical membrane surface area 
A_l_initial = 10^(-12)*(A_l_initial_Gr_a(i)+(A_l_initial_Gr_b(i)... 
    -A_l_initial_Gr_a(i))*rand()) ;  % lysosomal membrane surface area 
A_m = 250*7.85*10^(-13) ;            % mitochondrial membrane surface area 
V_a = 0.5*10^(-6)/cellNo ;           % extracellular drug solution volume 
V_c_initial = 10^(-18)*(V_cGr_a(i)+(V_cGr_b(i)-V_cGr_a(i))*rand()) ; 
                                     % initial cytosolic volume 
V_l_initial = 10^(-18)*(V_l_initial_Gr_a(i)+(V_l_initial_Gr_b(i)... 
    -V_l_initial_Gr_a(i))*rand()) ;  % lysosomal volume 
V_m = 250*6.55*10^(-20);             % mitochondrial volume 
  
% Membrane potential (units in 'Voltage') 
E_a = -0.009 ;                   % membrane potential of apical membrane 
E_l = +0.01-0.005+0.01*rand() ;  % membrane potential of lysosomal membrane 
E_m = -0.16 ;                % membrane potential of mitochondrial membrane 
  
% Apical Compartment 
fn_a = 1/(1+10^(i1*(pKa1-pH_a))+10^(i1*(pKa1-pH_a)+i2*(pKa2-pH_a))) ; 
% ratio of the activity of neutral species and  
% total molecular concentration in apical compartment 
fd2_a = fn_a*10^(i1*(pKa1-pH_a)+i2*(pKa2-pH_a)) ; 
% ratio of the activity of +1 ion species and  
% total molecular concentration in apical compartment 
fd1_a = fn_a*10^(i1*(pKa1-pH_a)) ; 
% ratio of the activity of +2 ion species and  
% total molecular concentration in apical compartment 
Nd2_a = z2*E_a*F/(R*T) ; 
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Nd1_a = z1*E_a*F/(R*T) ; 
  
% Cytoplasm 
W_c = 1-L_c ;        % water fraction in cytosol 
Is_c = 0.3 ;         % ionic strength in cytosol (mol) 
gamman_c = 10^(0.3*Is_c) ;  
                     % activity coefficient of neutral molecules in cytosol 
gammad1_c = 10^(-0.5*z1*z1*(sqrt(Is_c)/(1+sqrt(Is_c))-0.3*Is_c)) ;   
                     % activity coefficient of monovalent base in cytosol 
gammad2_c = 10^(-0.5*z2*z2*(sqrt(Is_c)/(1+sqrt(Is_c))-0.3*Is_c)) ;   
                     % activity coefficient of bivalent base in cytosol 
Kn_c = L_c*1.22*10^(logPn_cell) ;  
                     % sorption coefficient for neutral species in cytosol 
Kd1_c = L_c*1.22*10^(logPd1_cell) ; 
                     % sorption coefficient for +1 ion species in cytosol 
Kd2_c = L_c*1.22*10^(logPd2_cell) ; 
                     % sorption coefficient for +2 ion species in cytosol 
an_c = 1/(1+10^(i1*(pKa1-pH_c))+10^(i1*(pKa1-pH_c)+i2*(pKa2-pH_c))) ; 
                     % activity of neutral species in cytosol 
ad2_c = an_c*10^(i1*(pKa1-pH_c)+i2*(pKa2-pH_c)) ; 
                     % activity of +1 ion species in cytosol 
ad1_c = an_c*10^(i1*(pKa1-pH_c)) ; 
                     % activity of +2 ion species in cytosol 
Dd2_c = ad2_c/an_c ; 
Dd1_c = ad1_c/an_c ; 
fn_c = 1/(W_c/gamman_c+Kn_c/gamman_c+Dd2_c*W_c/gammad2_c... 
    +Dd2_c*Kd2_c/gammad2_c+Dd1_c*W_c/gammad1_c+Dd1_c*Kd1_c/gammad1_c) ; 
% ratio of the activity of neutral species and  
% total molecular concentration in cytosol 
fd2_c = fn_c*Dd2_c ; 
% ratio of the activity of +1 ion species and  
% total molecular concentration in cytosol 
fd1_c = fn_c*Dd1_c ; 
% ratio of the activity of +2 ion species and  
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% total molecular concentration in cytosol 
  
% Mitochondria 
W_m = 1-L_m ;        % water fraction in mitochondria       
Is_m = 0.3 ;         % ionic strength in mitochondria (mol)       
Nd2_m = z2*E_m*F/(R*T) ; 
Nd1_m = z1*E_m*F/(R*T) ; 
gamman_m = 10^(0.3*Is_m) ;   
                % activity coefficient of neutral molecules in mitochondria 
gammad1_m = 10^(-0.5*z1*z1*(sqrt(Is_m)/(1+sqrt(Is_m))-0.3*Is_m)) ; 
                % activity coefficient of +1 ion molecules in mitochondria 
gammad2_m = 10^(-0.5*z2*z2*(sqrt(Is_m)/(1+sqrt(Is_m))-0.3*Is_m)) ; 
                % activity coefficient of +2 ion molecules in mitochondria 
Kn_m = L_m*1.22*10^(logPn_cell) ; 
                % sorption coefficient for neutral species in mitochondria 
Kd1_m = L_m*1.22*10^(logPd1_cell) ; 
                % sorption coefficient for +1 ion species in mitochondria 
Kd2_m = L_m*1.22*10^(logPd2_cell) ; 
                % sorption coefficient for +2 ion species in mitochondria 
an_m = 1/(1+10^(i1*(pKa1-pH_m))+10^(i1*(pKa1-pH_m)+i2*(pKa2-pH_m))) ; 
                % activity of neutral species in mitochondria 
ad2_m = an_m*10^(i1*(pKa1-pH_m)+i2*(pKa2-pH_m)) ; 
                % activity of +1 ion species in mitochondria 
ad1_m = an_m*10^(i1*(pKa1-pH_m)) ; 
                % activity of +2 ion species in mitochondria 
Dd2_m = ad2_m/an_m ; 
Dd1_m = ad1_m/an_m ; 
fn_m = 1/(W_m/gamman_m+Kn_m/gamman_m+Dd2_m*W_m/gammad2_m... 
    +Dd2_m*Kd2_m/gammad2_m+Dd1_m*W_m/gammad1_m+Dd1_m*Kd1_m/gammad1_m ) ; 
% ratio of the activity of neutral species and  
% total molecular concentration in mitochondria 
fd2_m = fn_m*Dd2_m ; 
% ratio of the activity of +1 ion species and  
% total molecular concentration in mitochondria 
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fd1_m = fn_m*Dd1_m ; 
% ratio of the activity of +2 ion species and  
% total molecular concentration in mitochondria 
  
% lysosomes 
W_l = 1-L_l ;                  % water fraction in lysosomes 
Is_l = 0.2 + 0.2 * rand() ;    % ionic strength in lysosomes (mol)  
Nd2_l = z2*E_l*F/(R*T) ; 
Nd1_l = z1*E_l*F/(R*T) ; 
gamman_l = 10^(0.3*Is_l) ;  
                   % activity coefficient of neutral molecules in lysosomes 
gammad1_l = 10^(-0.5*z1*z1*(sqrt(Is_l)/(1+sqrt(Is_l))-0.3*Is_l));   
                   % activity coefficient of +1 ion molecules in lysosomes 
gammad2_l = 10^(-0.5*z2*z2*(sqrt(Is_l)/(1+sqrt(Is_l))-0.3*Is_l)); 
                   % activity coefficient of +2 ion molecules in lysosomes 
Kn_l = L_l*1.22*10^(logPn_cell) ; 
                   % sorption coefficient for neutral species in lysosomes 
Kd1_l = L_l*1.22*10^(logPd1_cell) ; 
                   % sorption coefficient for +1 ion species in lysosomes 
Kd2_l = L_l*1.22*10^(logPd2_cell) ; 
                   % sorption coefficient for +2 ion species in lysosomes 
an_l = 1/(1+10^(i1*(pKa1-pH_l))+10^(i1*(pKa1-pH_l)+i2*(pKa2-pH_l))) ; 
                   % activity of neutral species in lysosomes 
ad2_l = an_l*10^(i1*(pKa1-pH_l)+i2*(pKa2-pH_l)) ; 
                   % activity of +1 ion species in lysosomes 
ad1_l = an_l*10^(i1*(pKa1-pH_l)) ;  
                   % activity of +2 ion species in lysosomes 
Dd2_l = ad2_l/an_l ; 
Dd1_l = ad1_l/an_l ; 
fn_l = 1/(W_l/gamman_l+Kn_l/gamman_l+Dd2_l*W_l/gammad2_l... 
    +Dd2_l*Kd2_l/gammad2_l+Dd1_l*W_l/gammad1_l+Dd1_l*Kd1_l/gammad1_l ) ; 
% ratio of the activity of neutral species and  
% total molecular concentration in lysosomes 
fd2_l = fn_l*Dd2_l ; 
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% ratio of the activity of +1 ion species and  
% total molecular concentration in lysosomes 
fd1_l = fn_l*Dd1_l ; 
% ratio of the activity of +2 ion species and  
% total molecular concentration in lysosomes 
  
  
% Solve the differential equation system: 
% Given a system of linear ODE's expressed in matrix form: 
% Y' = AY+G with initial conditions Y(0) = [0 0 0 1 1 C_a]' 
  
time = 14400; 
Y0 = [0 0 0 1 1 C_a]'; 
[TI,Y] = ode15s(@Code_S2,[0,time],Y0); 
[a,b]=size(Y); 
Mass_cell = Y(a,1)*(V_c_initial-V_l_initial*Y(a,4))*10^12+... 
    (Y(a,2)*V_m+Y(a,3)*V_l_initial*Y(a,4))*10^12 ;   
    % intracellular mass (pmol/cell) 
Mass_all = Y(a,1)*(V_c_initial-V_l_initial*Y(a,4))*cellNo*10^9+... 
    (Y(a,2)*V_m+Y(a,3)*V_l_initial*Y(a,4)+Y(a,6)*V_a)*cellNo*10^9 ;  
    % total mass (nmol) 
N = [i, round, C_a, Y(a,1), Y(a,2), Y(a,3), Y(a,4), Y(a,5), Y(a,6),... 
    Mass_cell, Mass_all]; 
if mod(i,4)==1 
    fid = fopen('Monte25.dat','a'); 
elseif mod(i,4)==2 
    fid = fopen('Monte50.dat','a'); 
elseif mod(i,4)==3 
    fid = fopen('Monte100.dat','a'); 
else fid = fopen('Monte200.dat','a'); 
end 




clear Y TI; 
  
    end 
end 
 
2)  Code_S2.  
 
% The following section is the function called by Code_S1.m to simulate 
% intracellular concentration of CQ in MDCK cells with volume expansion in 
% acidic compartment and binding of CQ to cellular membrane structures.  
  
function [dCR] = Code_S2(t,CR)  
  
global V_l_initial A_l_initial V_c_initial A_a V_m A_m V_a i  
global Pn Pd1 Pd2  
global Nd1_a Nd1_m Nd1_l Nd2_a Nd2_m Nd2_l 
global fn_a fn_c fn_l fn_m  
global fd1_a fd1_c fd1_l fd1_m  
global fd2_a fd2_c fd2_l fd2_m   
  
% Solve the differential equation system for each drug: 
% Given a system of linear ODE's expressed in matrix form: 
% Y' = AY+G with initial conditions Y(0) = [0 0 0 1 1 C_a]' 
  
A_slope_Gr = [237.75, 464.69, 246.37, 161.42, 339.03, 549.90, 624.23,... 
    206.23, 0.00, 0.00, 0.00, 0.00] ; % rate of change in lyso surface area 
V_slope_Gr = [68.77, 106.88, 66.07, 45.08, 121.37, 227.24, 266.29,... 
    127.33, 0.00, 0.00, 0.00, 0.00] ; % rate of change in lyso volume 
V_slope_base = [20.6, 20.6, 20.6, 20.6, 91.42, 91.42, 91.42, 91.42,... 
    20.6, 20.6, 20.6, 20.6] ; % initial lysosomal volume (um^3) 
A_slope_base = [223.26, 223.26, 223.26, 223.26, 708.61, 708.61, 708.61,... 
    708.61, 223.26, 223.26, 223.26, 223.26] ; 
    % initial lysosomal surface area (um^2) 
  
 369 
V_l = V_l_initial*CR(4) ; 
A_l = A_l_initial*CR(5) ; 
V_c = V_c_initial-V_l ; 
  
k11 = -(A_a/V_c)*Pn*fn_c... 
       -(A_a/V_c)*Pd1*Nd1_a*fd1_c*exp(Nd1_a)/(exp(Nd1_a)-1)... 
       -(A_a/V_c)*Pd2*Nd2_a*fd2_c*exp(Nd2_a)/(exp(Nd2_a)-1)... 
       -(A_m/V_c)*Pn*fn_c-(A_m/V_c)*Pd1*Nd1_m*fd1_c/(exp(Nd1_m)-1)... 
       -(A_m/V_c)*Pd2*Nd2_m*fd2_c/(exp(Nd2_m)-1)... 
       -(A_l/V_c)*Pn*fn_c-(A_l/V_c)*Pd1*Nd1_l*fd1_c/(exp(Nd1_l)-1)... 
       -(A_l/V_c)*Pd2*Nd2_l*fd2_c/(exp(Nd2_l)-1) ; 
k12 = (A_m/V_c)*Pn*fn_m+(A_m/V_c)*Pd1*Nd1_m*fd1_m*exp(Nd1_m)/... 
    (exp(Nd1_m)-1)+(A_m/V_c)*Pd2*Nd2_m*fd2_m*exp(Nd2_m)/(exp(Nd2_m)-1) ;  
k13 = (A_l/V_c)*Pn*fn_l+(A_l/V_c)*Pd1*Nd1_l*fd1_l*exp(Nd1_l)/... 
    (exp(Nd1_l)-1)+(A_l/V_c)*Pd2*Nd2_l*fd2_l*exp(Nd2_l)/(exp(Nd2_l)-1) ;    
k16 = (A_a/V_c)*Pn*fn_a+(A_a/V_c)*Pd1*Nd1_a*fd1_a/... 
    (exp(Nd1_a)-1)+(A_a/V_c)*Pd2*Nd2_a*fd2_a/(exp(Nd2_a)-1) ; 
  
k21 = (A_m/V_m)*Pn*fn_c+(A_m/V_m)*Pd1*Nd1_m*fd1_c/(exp(Nd1_m)-1)... 
       +(A_m/V_m)*Pd2*Nd2_m*fd2_c/(exp(Nd2_m)-1) ; 
k22 = -(A_m/V_m)*Pn*fn_m-(A_m/V_m)*Pd1*Nd1_m*fd1_m*exp(Nd1_m)/... 
    (exp(Nd1_m)-1)-(A_m/V_m)*Pd2*Nd2_m*fd2_m*exp(Nd2_m)/(exp(Nd2_m)-1) ;  
  
S4 = V_slope_Gr(i)/V_slope_base(i)/3600 ;  
S5 = A_slope_Gr(i)/A_slope_base(i)/3600 ;                                 
  
k31 = (A_l/V_l)*Pn*fn_c+(A_l/V_l)*Pd1*Nd1_l*fd1_c/(exp(Nd1_l)-1)... 
       +(A_l/V_l)*Pd2*Nd2_l*fd2_c/(exp(Nd2_l)-1) ; 
k33 = -(A_l/V_l)*Pn*fn_l-(A_l/V_l)*Pd1*Nd1_l*fd1_l*exp(Nd1_l)/... 
    (exp(Nd1_l)-1)-(A_l/V_l)*Pd2*Nd2_l*fd2_l*exp(Nd2_l)/(exp(Nd2_l)-1)... 
    -S4/CR(4) ; 
  
k61 = (A_a/V_a)*Pn*fn_c+(A_a/V_a)*Pd1*Nd1_a*fd1_c*exp(Nd1_a)... 
    /(exp(Nd1_a)-1)+(A_a/V_a)*Pd2*Nd2_a*fd2_c*exp(Nd2_a)/(exp(Nd2_a)-1) ; 
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k66 = -(A_a/V_a)*Pn*fn_a-(A_a/V_a)*Pd1*Nd1_a*fd1_a/... 
    (exp(Nd1_a)-1)-(A_a/V_a)*Pd2*Nd2_a*fd2_a/(exp(Nd2_a)-1) ; 
  
% CR = [0,0,0,1,1, C_a]; 
dCR(1) = k11*CR(1)+k12*CR(2)+k13*CR(3)+ k16*CR(6); 
dCR(2) = k21*CR(1)+k22*CR(2); 
dCR(3) = k31*CR(1)+k33*CR(3); 
dCR(4) = S4; 
dCR(5) = S5; 
dCR(6) = k61*CR(1)+k66*CR(6);  
  






#---Remove extra top margin: 
par(mar=c(3,3,1,1))  # Trim margin around plot [b,l,t,r] 
par(tcl=0.35)  # Switch tick marks to insides of axes 
par(mgp=c(1.5,0.2,0))  # Set margin lines; default c(3,1,0) [title,labels,line] 







IntraMass_exp_std = 0.0015 
IntraMass_expS = 0.0062 
IntraMass_exp_stdS = 0.001 
IntraMass_expB = 0.0020 
IntraMass_exp_stdB = 0.0014 
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file <- "Monte25.dat" 
Data <- read.table(file,header=F) 
 
Data.IntraMass <- log(Data[1:10000,10], base=10) 
Data.IntraMassS <- log(Data[10001:20000,10], base=10) 
Data.IntraMassB <- log(Data[20001:30000,10], base=10) 
 
Histo <- hist(Data.IntraMass, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")  
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_exp), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_exp+IntraMass_exp_std), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_exp-IntraMass_exp_std), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassS, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expS), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expS+IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_expS-IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassB, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 




axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expB), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expB+IntraMass_exp_stdB), col="red", lty=2, lwd=3) 





IntraMass_exp_std = 0.0004 
IntraMass_expS = 0.0170 
IntraMass_exp_stdS = 0.0044 
IntraMass_expB= 0.0034 
IntraMass_exp_stdB = 0.0012 
 
file <- "Monte50.dat" 
Data <- read.table(file,header=F) 
 
Data.IntraMass <- log(Data[1:10000,10], base=10) 
Data.IntraMassS <- log(Data[10001:20001,10], base=10) 
Data.IntraMassB <- log(Data[20001:30000,10], base=10) 
 
Histo <- hist(Data.IntraMass, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")  
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_exp), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_exp+IntraMass_exp_std), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_exp-IntraMass_exp_std), col="red", lty=2, lwd=3) 
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Histo <- hist(Data.IntraMassS, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expS), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expS+IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_expS-IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassB, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expB), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expB+IntraMass_exp_stdB), col="red", lty=2, lwd=3) 





IntraMass_exp_std = 0.0019 
IntraMass_expS = 0.0216 
IntraMass_exp_stdS = 0.0057 
IntraMass_expB= 0.0048 
IntraMass_exp_stdB = 0.0012 
 
file <- "Monte100.dat" 
Data <- read.table(file,header=F) 
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Data.IntraMass <- log(Data[1:10000,10], base=10) 
Data.IntraMassS <- log(Data[10001:20000,10], base=10) 
Data.IntraMassB <- log(Data[20001:30000,10], base=10) 
 
Histo <- hist(Data.IntraMass, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")  
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_exp), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_exp+IntraMass_exp_std), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_exp-IntraMass_exp_std), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassS, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expS), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expS+IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_expS-IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassB, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expB), col="red", lty=1, lwd=3) 
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abline(v=log10(IntraMass_expB+IntraMass_exp_stdB), col="red", lty=2, lwd=3) 





IntraMass_exp_std = 0.0013 
IntraMass_expS = 0.0191 
IntraMass_exp_stdS = 0.0047 
IntraMass_expB= 0.0056 
IntraMass_exp_stdB = 0.0003 
 
file <- "Monte200.dat" 
Data <- read.table(file,header=F) 
 
Data.IntraMass <- log(Data[1:10000,10], base=10) 
Data.IntraMassS <- log(Data[10001:20000,10], base=10) 
Data.IntraMassB <- log(Data[20001:30000,10], base=10) 
 




axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_exp), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_exp+IntraMass_exp_std), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_exp-IntraMass_exp_std), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassS, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 




axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expS), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expS+IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_expS-IntraMass_exp_stdS), col="red", lty=2, lwd=3) 
 
Histo <- hist(Data.IntraMassB, freq=T, breaks=c(-125:0)/25, axes=TRUE, main="", xlim=c(-4,-1), 
ylim=c(0,1500), col="white")   
axTicks(1) 
axTicks(2) 
axis(1, lwd = 4.5) 
axis(2, lwd = 4.5) 
lines(Histo$mids, Histo$counts, lwd=4.5, col="black") 
abline(v=log10(IntraMass_expB), col="red", lty=1, lwd=3) 
abline(v=log10(IntraMass_expB+IntraMass_exp_stdB), col="red", lty=2, lwd=3) 
abline(v=log10(IntraMass_expB-IntraMass_exp_stdB), col="red", lty=2, lwd=3) 
